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Abstract 
Type 2 diabetes is a heterogeneous condition, but evidence gaps exist with respect to 
risks and outcomes for sub-populations.  The tenet of this thesis is that routinely 
collected clinical data captured within the eHR can be utilised for diabetes research; the 
eHR can provide new information with specific regard to further characterising diabetes 
sub-populations, which can meaningfully inform patient care.  
Clinical data captured in the course of usual patient care for over 20,000 patients held 
within the longstanding RPAH Diabetes Centre eMR was studied.  Data linkage was 
undertaken with the National Death Index to ascertain the survival status.  Studies were 
undertaken to examine 1) the heterogeneity of survival outcomes for 7 different ethnic 
groups, 2) the survival of young onset type 2 diabetes compared with type 1 diabetes 
and usual onset type 2 diabetes, 3) how systematically collected retinopathy data could 
be used  to inform public health decisions and 4) the comprehensiveness and degree of 
standardisation in the reporting of retinopathy sourced from optometrists and 
ophthalmologists.   
Significant differences in diabetes complications and mortality were observed amongst 
ethnic groups; for Chinese, Indian, Arab and Mediterranean groups survival was better 
than the Anglo-Celtic reference group.  In contrast, Indigenous Australians had the 
highest adjusted hazard for death.  
We also found that young onset type 2 diabetes had a twofold greater mortality than 
type 1 diabetes, with deaths occurring at a significantly younger age.  Furthermore, in 
comparison to older onset type 2 diabetes, we found the greatest mortality impact in 
                                                                                                             16   
 
younger onset type 2 diabetes.  Taken together these results newly highlighted the 
aggressive nature of early onset type 2 diabetes.  
We demonstrated the potential utility of cross-sectional retinopathy data  1)  in the 
prediction of the future retinopathy burden for different sub-groups and 2)  to provide an 
index of past glycaemic exposure for subgroups to identify those most at risk.   Finally, 
we identified a lack of standardisation in the reporting of retinopathy amongst providers.    
Overall, this body of work demonstrated the wide-ranging utility of the routinely 
collected eHR, to further characterise heterogeneity in type 2 diabetes and to 
meaningfully inform future diabetes research and care. 
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Saeed· Connie Luo· Ted Wu· Stephen M. Twigg· Dennis K. Yue· Jencia Wong  
ABSTRACT: To evaluate long-term clinical outcomes and survival in young-onset type 
2 diabetes (T2DM) compared with type 1 diabetes (T1DM) with a similar age of onset. 
Records from the Royal Prince Alfred Hospital Diabetes Clinical Database, established 
in 1986, were matched with the Australian National Death Index to establish mortality 
outcomes for all subjects until June 2011.  Clinical and mortality outcomes in 354 
patients with T2DM, age of onset between 15 and 30 years (T2DM15-30), were 
compared with T1DM in several ways but primarily with 470 patients with T1DM with a 
similar age of onset (T1DM15-30) to minimise the confounding effect of age on 
outcome.  For a median observation period of 21.4 (interquartile range 14-30.7) and 
23.4 (15.7-32.4) years for the T2DM and T1DM cohorts, respectively, 71 of 824 patients 
(8.6%) died.  A significant mortality excess was noted in T2DM15-30 (11 vs. 6.8%, P = 
0.03), with an increased hazard for death (hazard ratio 2.0 [95% CI 1.2-3.2], P = 0.003). 
Death for T2DM15-30 occurred after a significantly shorter disease duration (26.9 [18.1-
36.0] vs. 36.5 [24.4-45.4] years, P = 0.01) and at a relatively young age.  There were 
more cardiovascular deaths in T2DM15-30 (50 vs. 30%, P < 0.05).  Despite equivalent 
glycaemic control and shorter disease duration, the prevalence of albuminuria and less 
favourable cardiovascular risk factors were greater in the T2DM15-30 cohort, even 
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soon after diabetes onset.  Neuropathy scores and macrovascular complications were 
also increased in T2DM15-30 (P < 0.0001).  Young-onset T2DM is the more lethal 
phenotype of diabetes and associated with a greater mortality, more diabetes 
complications and unfavourable cardiovascular disease risk factors than T1DM.  
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Ethnic specific differences in survival of patients with type 2 diabetes: Analysis 
of data collected from an Australian multi-ethnic cohort over a 25 year period (2) 
Turki J. Alharbi · Maria I. Constantino · Lynda Molyneaux · Ted Wu · Stephen M. Twigg 
· Dennis K. Yue · Jencia Wong  
ABSTRACT: Aims To examine the survival of patients with type 2 diabetes from 7 
ethnic groups, living in the shared environment of an Australian city.  Methods Hazard 
Ratio of death (HR) after diagnosis of diabetes was compared between Anglo-Celtic (n 
= 5433), Indigenous Australian (n = 439), Pacific Islander (n = 354), Mediterranean (n = 
3138), Arabic (n = 768), Indian (n = 702) and Chinese (n = 1632) patients who live in 
metropolitan Sydney.  Mortality was ascertained by data linkage with the Australian 
National Death Index.  The modulating effects of glycaemic control, diabetes/vascular 
complications and risk factors, year of diabetes diagnosis and duration of diabetes on 
ethnic differences were analysed by Cox regression.  Socio-economic status and 
competence in English were also examined.  Results There were significant differences 
in survival between the ethnic groups; the Indigenous Australians had the highest HR 
for death (2.3, 95% CI 1.7–3.0) and the Chinese the lowest (0.4, 95% CI 0.4–0.5).  The 
survival of the Anglo-Celtics (HR 1) was surprisingly poorer than for Indian (0.6, 95% CI 
0.5–0.8), Arab (0.7, 95% CI 0.6–0.8) and Mediterranean groups (0.8, 95% CI 0.7–0.9).  
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Prevalence of smoking and albuminuria were strongly associated with HR.  The better 
survival of Chinese and Arab and the worse survival of Indigenous Australians 
remained after adjustment for risk factors.  Need for an interpreter was a favourable risk 
factor for survival.  Conclusions Ethnicity is a significant determinant of survival in type 
2 diabetes, and this is substantially but not completely mediated by smoking and 
vascular risk factors.  The favourable impact associated with less competence in 
English may represent a Healthy-migrant effect.  
 
Article · Jan 2015 · Current Diabetes Reports  
Morbidity and Mortality in Young-Onset Type 2 Diabetes in Comparison to Type 1 
Diabetes: Where Are We Now? (3) 
Jencia Wong · Maria Constantino · Dennis K Yue  
ABSTRACT: Increasingly, we recognise that type 2 diabetes in youth is a disease with 
an aggressive time course and a significant complication risk.  On the other hand, 
outcomes for youth with type 1 diabetes generally appear to be improving.  With 
increasing numbers of both types of diabetes in youth, it is timely that a comparative 
perspective is offered to help clinicians prognosticate more appropriately. 
Contemporary comparative studies add a new perspective to a consistent story that for 
youth-onset type 2 diabetes, the development and progression of cardio-renal 
complications increased, and the survival prognosis is significantly worse than for type 
1 diabetes.  Here, we review this mounting evidence, highlight the importance of 
metabolic syndrome factors in the excess risk and underscore that there remains a 
significant mortality gap for youth with either type of diabetes, to be addressed as a 
matter of urgency  
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Abstract: To test whether the rate of diabetic retinopathy development in a population 
calculated from the prevalence of retinopathy and duration of diabetes can be used to 
assess their prior glycaemic control.  Research Design and Methods: 9281 patients 
with type 2 diabetes (T2DM) were grouped by duration of diabetes and plotted against 
the % of retinopathy in each band.  The slope was used to calculate retinopathy 
development/year (RD/y).  We correlated the RD/y with updated HbA1c within groups of 
different ethnicity, age of diabetes onset, year of the eye examination, socio-economic 
status and fluency in English. 
Results:  Differences in ethnicity, age of diabetes onset and year of the eye 
examination affect RD/y to a degree predictable from their respective updated HbA1c. 
No such relationship with updated HbA1c was evident when a factor has no apparent 
effect on RD/y.  Conclusions: This relationship between prevalence of retinopathy and 
duration of diabetes can be used to assess future retinopathy burden.  Perhaps more 
intriguing, the camera can be reversed to allow an estimate of prior glycaemic control of 
a population from its retinopathy prevalence.  Health care organisations can use this 
method to project future needs and to assess the adequacy of prior glycaemic control. 
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Abstract: This study compared the prevalence of complications in 354 patients with 
T2DM diagnosed between 15 and 30 years of age (T2DM15-30) with that in a duration-
matched cohort of 1,062 patients diagnosed between 40 and 50 years (T2DM40-50).  It 
also examined standardised mortality ratios (SMRs) according to diabetes age of onset 
in 15,238 patients covering a wider age-of-onset range.  Complication status was 
assessed according to a standard protocol and extracted from our electronic database. 
Survival status was ascertained by data linkage with the Australian National Death 
Index.  SMRs were calculated in comparison with the background Australian population 
and analysed according to age of onset.  After matching for duration, despite their 
younger age, T2DM15-30 had more severe albuminuria (P = 0.004) and neuropathy 
scores (P = 0.003).  T2DM15-30 were as commonly affected by metabolic syndrome 
factors as T2DM40-50 but less frequently treated for hypertension and dyslipidaemia (P 
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< 0.0001).  An inverse relationship between age of diabetes onset and SMR was seen, 
which was the highest for T2DM15-30 (3.4 [95% CI 2.7-4.2]).  SMR plots adjusting for 
duration show that for those with T2DM15-30, SMR is the highest at any chronological 
age, with a peak SMR of more than 6 in early midlife.  In contrast, mortality for older-
onset groups approximates that of the background population.  The negative effect of 
diabetes on morbidity and mortality is greatest for those diagnosed at a young age 
compared with T2DM of usual onset.  These results highlight the growing imperative to 
direct attention toward young-onset T2DM and for effective interventions to be applied 
before middle age. 
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Association’s 73rd Scientific Sessions, June 21-25, 2013 in Chicago, Illinois. 
 
A Multi-Ethnic Study of Diabetic Retinopathy: Poorer Outcomes Continue for Australian 
Aborigines and Pacific Islanders.  Oral Presentation.  International Diabetes 
Epidemiology Group (IDEG) and International Diabetes Federation (IDF) Congress 
Melbourne 2013 
 
Secular Trends in Diabetes Related Mortality:  Increasing Longevity but Also 
Complexity ADS-ADEA Scientific Meeting 2013 ADS Oral Presentation 2013 
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Reduced Secular trends in diabetes mortality but not complications: The burden of 
diabetes treatment success 2729 – Published poster, 73rd Scientific Sessions, June 
21-25, 2013 in Chicago, Illinois. 
 
A Cross-Sectional Multiethnic Study of Diabetic Retinopathy: A Useful Method of 
Assessing Quality of Diabetes Care; Poster; American Diabetes Association's 74th 
Scientific Sessions Moscone Center, San Francisco, CA June 13 - 17, 2014 
 
Data Collection in The Diabetic Foot International Diabetes Federation (IDF) –Western 
Pacific Region (IDF-WPR) Foot Care Project Meeting 2014" held on 21-22 February 
2014 in Osaka, Japan.  Invited Speaker 
 
Complications And Comorbidities In Type 2 Diabetes In Youth - World Diabetes 
Congress 2015 Vancouver:  Date: 3 December 2015. Invited Speaker 
 
The use of systematic data collection on retinopathy to assess prior glycaemic 
control:  The Hubble telescope equivalent of looking back in time", ADS ADEA 2015 
Annual Scientific Meeting program, Oral presentation, Finalist ADS Clinical Young 
Investigator Awards 
  
                                                                                                             25   
 
Thesis Overview 
The prevalence of Diabetes Mellitus (diabetes) is increasing worldwide with the 
International Diabetes Federation (IDF) estimating that in 2017, 455 million people were 
affected by diabetes.  This number is expected to rise to 629 million in 2045 with the 
majority having type 2 diabetes (7).In addition to diabetes, the IDF estimates that 
globally more than 352 million adults have pre-diabetes/ impaired glucose tolerance 
and that 16.2% of live births in 2017 were affected by hyperglycaemia in pregnancy, the 
majority having gestational diabetes.  The latter observation is particularly concerning 
given the increased risk of later diabetes in the mother and the transgenerational impact 
on obesity in the offspring.  Diabetes (and pre-diabetes) is a major public health 
concern impacting on both developed and developing countries, affecting every age 
group and placing great demands on healthcare budgets globally.  The IDF reports that 
on average the proportional expenditure on treating diabetes and related complications 
ranged from 6% of the total health care budget in Africa to 17% in Middle East and 
North African regions in 2017  (7).  Future expenditure will be further increased, with the 
added pressures of increased urbanisation, lifestyle changes and population growth in 
low and middle-income countries all negatively impacting diabetes prevalence(7).  It is 
clear the greatest impact will be from the numbers with type 2 diabetes and although we 
have greater clarity over the projected burden, there remain large gaps in our 
knowledge, and there is much research to be done to overcome this epidemic.  There 
are many challenges in diabetes research and this is made especially so by the 
realisation that type 2 diabetes is a heterogeneous disorder (8) and that the “diabetes” 
landscape is evolving not least due to rapid changes in lifestyle, migration and quality of 
medical care in recent decades.  It is clear that a one- size fits all approach to diabetes 
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care is not ideal given this heterogeneity and the challenge now is to know how to 
personalise and provide a precision medicine approach to diabetes care.  Thus, further 
research into diseases subtypes is thought to provide the answer. 
In terms of diabetes research, it is the randomised controlled trials (RCTs) that have 
long been promulgated as the gold standard and the ideal source of evidence and the 
data on which clinical decisions should be made.  However, for many reasons RCTs 
cannot provide all the answers; the trials are usually of short duration with a restricted 
population characteristic not always generalisable to the wider population.  
Furthermore, research involving complications, given the long timeframe over which 
these develop may not be served adequately by the RCT design, which is expensive 
and time limited.  On the other hand, widespread observational data such as population 
based epidemiological studies may not contain specific patient level data to illuminate 
this issue of heterogeneity nor provide information regarding specific subgroups.  New 
ways of obtaining valuable health information need to be utilised.  
Patient level data are often captured now in electronic format of various forms, and one 
of the largest repositories is the electronic health record (eHR) which contains 
information captured in the course of usual patient care.  Such datasets, given their 
longevity, can provide many years of follow up, especially important as diabetes 
complications require a long time over which to develop.  Such “real world data” can 
potentially augment the shorter term RCT approach. Furthermore, the ability to link 
disparate datasets can potentially provide new knowledge despite a non-randomised 
approach and could potentially be a powerful research tool.  In this situation, the data 
contained in various forms of routinely collected electronic health records, which are 
collected, systematically and longitudinally, provide a possible alternative source of 
valuable information, complementary to approaches that are more traditional.  
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The overarching tenet of this thesis is that routinely collected clinical data captured 
within the eHR can be utilised for diabetes research; the eHR can provide new 
information with specific regard to further characterising sub-populations within the 
diagnosis of diabetes, which can meaningfully inform patient care.  The success or 
failure of such an approach could inform future new approaches to utilising such data 
sources for diabetes research and care.  To examine the value of this type of dataset, 
this thesis presents studies, which interrogated a long established eHR, the Royal 
Prince Alfred Hospital clinical diabetes database, to investigate some areas of type 2 
diabetes which have changed, emerged or gained prominence in recent decades. 
 An initial study was performed to examine the heterogeneity of survival outcomes in 
type 2 diabetes in different ethnic groups (Chapter 3), important given the changing 
demographics of this disease, particularly in Australia with its rapidly evolving 
multicultural background.  Previously, many such studies on diabetes and ethnicity 
have focussed on assessing a single ethnic population, either in the minority (e.g., Pima 
Indians) or the majority (e.g., Chinese) often residing in their own country.  The 
multicultural society in Australia brought on by increasing migration, affords an 
opportunity to compare seven different ethnic groups in their diabetes phenotype, 
complications and mortality whilst living in a similar environment.  Significant differences 
in diabetes complications and mortality were observed amongst these 7 ethnic groups, 
allowing the roles of medical and sociological factors such as language fluency and 
socioeconomic status to be assessed.  A surprising finding was that for some ethnic 
groups with type 2 diabetes, despite, perhaps being more socially disadvantaged, 
survival was better than the majority Anglo-Celtic Australian group.  For example, the 
Chinese had the lowest hazard ratio for death (HR 0.4, CI 0.4 – 0.5) and the survival of 
the Anglo-Celtics (HR 1) was also poorer than for Indian (HR 0.6, CI 0.5 – 0.8), Arab 
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(0.7, CI 0.6 – 0.8) and Mediterranean (HR 0.8, CI 0.7 – 0.9) groups.  These findings 
may be due to the pre-selection of the migrant groups according to health status before 
migration.  By contrast, the Indigenous Australians had the highest HR for death (HR 
2.3, CI 1.7 – 3.0). 
We noted that some of the ethnic groups (Indigenous Australian, Pacific Islander, Indian 
and Arabic) are characterised by the younger onset of type 2 diabetes (9) than what 
has been traditionally described for this condition and this raised the question as to 
whether there were differential survival patterns by the age of diagnosis.     
Therefore, the second area examined in this thesis compared the survival and clinical 
characteristics of young onset type 2 diabetes (YT2DM) against the reference group of 
young onset type 1 diabetes (YT1DM) with a similar age of onset (Chapter 4).  Here 
the two types of diabetes were compared, and cohorts of similar age of onset were 
examined allowing us to equate for duration of diabetes.  This minimised the possibility 
of a lead-time bias affecting survival due to the longer duration of T1DM at any given 
age compared to usual type 2 diabetes.  Interestingly, when the age of onset and 
duration of diabetes were accounted for, our study revealed a greater adverse impact of 
YT2DM than YT1DM on survival.  We were able to demonstrate that YT2DM is 
associated with a 2 fold greater hazard for mortality than YT1DM (HR for death 2.0, CI 
1.2- 3.2, p=0.003) and deaths occurred after a significantly shorter diabetes duration 
(26.9 vs. 36.5 years).  There were more cardiovascular deaths in YT2DM (50% vs 30%, 
p < 0.05) and the HR for CVD deaths were 3.5 (1.4-8.5, p=0.004).  Furthermore, 
despite equivalent glycaemic control and shorter disease duration, the prevalence of 
albuminuria and less favourable cardiovascular risk factors were greater in the YT2DM 
cohort, even soon after diabetes onset.  Neuropathy scores and macrovascular 
complications were also increased in YT2DM.  Additionally, this study illustrated the 
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utility of research by data linkage, in this case between an eHR and the Australian 
National Death Index (NDI), a repository of all mortality statistics in Australia.  The 
survival data are concerning, and the published results were editorialised as until 
recently, a previously unreported finding (10). 
 The above study then led to the question, “what is the survival impact of diabetes at a 
young age, i.e. YT2DM relative to those with the more usual age of diabetes onset?”.  
The next study outlined in Chapter 5 examined the mortality of YT2DM versus those 
with onset in the middle and older age groups.  By the nature of the question being 
examined, those with an older age of onset at any given duration would inevitably be 
older.  As age alone is a significant confounding factor in mortality, a Standard Mortality 
Ratio (SMR) method was employed to understand risk by age of onset against the age 
and gender matched background Australian population.  A Poisson modelling approach 
was utilised to compare age of onset groups by current age and duration of diabetes.  
Once analysed in this way, the results showed an unequivocally higher impact of a 
younger age of type 2 diabetes onset on relative mortality.  An inverse relationship 
between age of diabetes onset and SMR was seen, which was the highest for YT2DM 
(3.4, CI 2.7 – 4.2).  SMR plots at any duration of diabetes or at any current age show 
that for those with YT2DM, SMR is the highest; the peak SMR of more than 6 is seen in 
early midlife. 
In contrast, SMR for older onset groups at any current age approximate that of the 
background population.  These findings have significant implications for health care 
planning.  It suggests that future strategies for screening and intensive treatment of 
diabetes should focus on those with YT2DM.  
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One of the pressing public health concerns is the targeting of finite and limited health 
resources to different patient groups.  A clear understanding of sub-population risk and 
the ability to predict future burden of disease would greatly assist in public health 
planning. The latter half of this thesis is therefore concerned with the utility of routinely 
and systematically collected retinopathy data in informing patient care and service 
delivery.  
The relationship between retinopathy and duration of diabetes is well established. 
Furthermore, the direct impact of glycaemic control on retinopathy development is 
equally well understood.  In Chapter 6, we explore the utility of using these 
relationships to predict the future burden of disease for different groups and to explore 
the heterogeneity of risk that exists within diabetes.  We used cross-sectional 
retinopathy data and plotted group retinopathy prevalence against diabetes duration for 
various sub-populations with diabetes.  By using simple linear regression, the slope of 
this relationship provides a population estimate of the cross-sectional “rate” of 
retinopathy development over time.  Such an analysis provides an estimate of 
population retinopathy burden and an index of relative susceptibility to retinopathy.  We 
demonstrated the consistency of this method across diverse populations defined by 
ethnicity, age of diabetes onset, year of eye examination, socio-economic strata and 
language fluency.  Furthermore, by plotting the cross-sectional ‘rate’ of retinopathy for a 
particular group against updated HbA1c, a linear relationship is confirmed for all 
subgroups, which suggests that the rate of retinopathy development can be further 
used as a relative index of population glycaemic control.  These findings and 
methodology can be extrapolated to administration databases for any arbitrary sub-
group of interest and thus, may have widespread potential application as a public health 
tool to estimate future retinopathy burden and past glycaemic control.  
                                                                                                             31   
 
The studies, which underpin this thesis, were made possible by the systematic and 
ongoing collection of clinical data captured within the Royal Prince Alfred Hospital 
diabetes database.  One of the core issues in the use of such databases in a clinical 
setting is data quality.  Some of the steps taken to maintain this are outlined in Chapter 
2, describing the procedures for ongoing data collection.  Nevertheless, despite 
implementing quality measures, many changes in the knowledge and mode of clinical 
care over the decades can also have a major impact on data collection.  One example 
of this is the availability of retinal photography in the primary care setting brought on by 
changes in technology, medical manpower and government regulation.  In the course of 
processing data for the prior studies, it became apparent that the comprehensiveness 
of the retinopathy data in the RPAH diabetes database had declined, primarily due to 
the outsourcing of eye examinations.  This led to the systematic examination of the 
difficulties involved in the retrieval and interpretation of eye data from non-hospital 
based ophthalmologists and optometrists; this study and its publication is presented in 
Chapter 7. In reviewing 355 letters from ophthalmologists and optometrists, we showed 
that when retinopathy is present,16.2% of communications to the Diabetes Centre did 
not clearly differentiate vision-threatening retinopathy from milder forms of retinopathy 
and 38.3% of correspondence did not comment on the presence of macular pathology. 
Given the presence or absence of significant complications can impact on management 
decisions such as glycaemic targets and the use of fibrates, these data illustrate the 
need for standardised and accurate reporting of retinopathy grading to facilitate patient 
care.  
The study also revealed that the prevalence of retinopathy varied according to whether 
the eye examination was performed in-house or by an ophthalmologist or optometrist in 
a non-hospital setting.  For any duration of diabetes, more patients from 
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ophthalmologists had retinopathy compared to the RPAH cohort.  However, the 
difference in prevalence between these two groups diminished over time with the longer 
duration of diabetes.  Patients screened by optometrists had a very low prevalence of 
retinopathy in the first 15 years of diabetes compared to the other two groups.  These 
observations may reflect the issue of referral bias to optometrists and ophthalmologists 
and highlights the importance of understanding patient selection criteria in the 
interpretation of any data extracted from any given system. 
In summary, this thesis describes a series of studies in the area of diabetes and its 
complications based on the use of healthcare information captured and stored within 
the routinely collected eHR used for usual care by a single ambulatory diabetes service. 
The results highlight the ongoing utility of clinical information systems to facilitate 
meaningful clinical research and the caveats within.  The published studies in this thesis 
support the use of such routinely collected datasets to provide information of value, and 
allow this to be done quickly in a cost-effective way; a process so keenly sought by 
health administrators.  The harnessing, mining and data linkage of routinely collected 
datasets in this manner can provide valuable insights into how to individualise therapy 
within a heterogeneous disease such as diabetes.  
The results presented herein, some with translational impact, support the noble 
sentiment expressed by Atul Butte that “Hiding within those mounds of data is 
knowledge that could change the life of a patient, or change the world” (11).  The hope 
is with the now widespread use of the electronic health record (or electronic medical 
record) that systematic collection can be championed by health professionals and data 
managers alike with the specific understanding of the value of such data to the broader 
population with diabetes.   
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Central Aim and Hypotheses of the Thesis 
The overriding postulate is that routinely collected clinical data within an electronic 
health record (eHR) over time can provide new information with respect to diabetes and 
has utility in terms of health decision making in the context of personalised and 
precision medicine.    
To examine this issue, this thesis specifically addresses the following questions  
1. Can the electronic health record be used to examine the clinical outcomes and 
mortality in subgroups of patients with type 2 diabetes, specifically by  
a. Ethnicity  
b. Age of onset  
2. Can the electronic health record be used to inform public health measures and 
identify gaps in patient care specifically looking at diabetic retinopathy data?  
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Chapter 1 
Literature Review 
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Introduction 
Diabetes Mellitus (diabetes) refers to a disorder characterised by hyperglycaemia which 
is thought to arise from impairment of both insulin secretion and action to varying 
degrees.  The name ‘“diabetes mellitus’ is an ancient one; a term first ascribed to the 
Greek physician Aretaeus who in 100 C.E. observed that the urine of patients so 
afflicted was sweet to the taste.  Since that time, diabetes has risen to now be one of 
the most prevalent chronic diseases of this century with a now well documented and 
seemingly inexorable rising global burden (7).  
Rather than describing a single disorder, diabetes refers to a heterogeneous group of 
disorders.  In common, the various forms of diabetes can lead to acute and life 
threatening presentations with ketoacidosis or hyperosmolar coma.  More chronically, 
persistent hyperglycaemia is associated with long term microvascular complications 
(including retinopathy, nephropathy and neuropathy) and macrovascular complications 
(including cerebrovascular accidents, cardiovascular disease and peripheral vascular 
disease).  The most common form of diabetes is type 2 diabetes, which is the subject of 
this thesis. 
Despite recent advances, type 2 diabetes remains a challenging disease with still many 
knowledge gaps.  Traditional research avenues have known limitations such that novel 
approaches are now needed as a pathway to new knowledge to inform clinical care.  As 
outlined before, the overriding postulate for this thesis is that routinely collected clinical 
data within an electronic health record (eHR) over time can provide new knowledge with 
respect to diabetes and as such has the added utility of being a valuable research 
resource.  This is particularly relevant as the eHR is increasingly being utilised by 
                                                                                                             36   
 
healthcare services.  In this context, the present chapter provides a background for the 
research presented in this thesis.  Part I is concerned with modalities used in clinical 
research and the current use of electronic data (eData).  Part II provides a general 
overview of diabetes with specific areas highlighted relevant to this thesis.  With 
reference to the specific aims and hypothesis outlined, the areas highlighted and 
discussed in Part II are (i) the relationship between ethnicity on diabetes outcomes and 
(ii) retinopathy management. Part III provides an overview of the emerging 
phenomenon of young onset type 2 diabetes.  This provides context for the specific aim 
outlined to examine the impact of age of onset on diabetes outcomes. 
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Part I: Health decision making and the current role of eData:  
What do we use to make health decisions? The current approach to gathering data to 
inform health decision making is discussed herein.  
1.1 Evidence based medicine  
Prior to the advent of what has now been termed evidence based medicine (EBM), 
much clinical decision making was made on experiential grounds; expert opinion with a 
degree of intuition thrown in.  However, from the early 1990’s a paradigm shift in 
medical science occurred which advocated scientific evidence as the basis for clinical 
decision making and the only rational basis from which to make clinical decisions. The 
foundation of this new paradigm was the success of the randomised clinical trial (RCT) 
and the utility of this methodology to analyse the efficacy of new pharmacotherapy, to 
test surgical interventions and diagnostic tests.  The assumptions made in this new 
paradigm are firstly “that in the absence of systematic observation, one must be careful 
in the interpretation of information derived from clinical experience and intuition, for it 
may at times be misleading” and secondly that “the rationales for diagnosis and 
treatment, which follow from basic pathophysiologic principles, may, in fact, be 
incorrect, leading to inaccurate predictions about the performance of diagnostic tests 
and the efficacy of treatments” and that thirdly “understanding certain rules of evidence 
is necessary to correctly interpret literature on causation, prognosis, diagnostic tests, 
and treatment strategy” (12).  Overall the EBM paradigm emphasises a shift away from 
(although not a rejection of) authority and opinion towards the primacy of data.  Thus, 
the practice of evidence-based medicine de-emphasised the importance of 
unsystematic clinical experience and tools such as the pyramid of evidence in Figure 1 
                                                                                                             38   
 
which shows how to access the quality and quantity of evidence available.  More 
recently, grading systems have been developed to assess the quality of evidence. 
Examples of these grading systems used in medicine are:   
• Centre for Evidence Based Medicine (CEBM) Levels of Evidence Developed by 
Oxford Centre for Evidence-Based Medicine (13)  
• National Health & Medical Research Council (NHMRC) Evidence Hierarchy 
Levels of evidence for intervention, diagnostic accuracy, prognosis, aetiology 
and screening intervention questions (14).  
• JBI Levels of Evidence Developed by the Joanna Briggs Institute Levels of 
Evidence and Grades of Recommendation Working Party, 2013 (15). 
  
Figure 1: Pyramid of Evidence for RCTs 
(from https://www.ellismedlibrary.org/uploads/9/1/9/0/91901496/evidencepyramid_orig.jpg ; viewed on line 
08/01/2019) 
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1.1.1 Randomised Controlled Trials And Their Limitations.  
Evolving from the above paradigm and the general principle that best medical practice 
should be based on the highest quality of scientific data, modern research in medicine 
has had its basis strongly rooted in the use of evidence arising from RCTs to inform 
patients and clinicians on the effects of treatments.  The RCT is considered to be the 
highest form of evidence in clinical grading systems with randomisation accounting for 
both known and unknown confounders.  However, these grading systems are biased 
towards the RCTs and potentially discourage consideration of non-RCT data to answer 
important questions in health. 
Despite all the benefits, there remain several limitations to RCTs.  Firstly, these are 
notoriously difficult and expensive to carry out; they may take many years to plan and 
execute and by the time they report, newer strategies may have already arrived, limiting 
the ability of the RCT to keep pace with new developments.  The RCT by design may 
study a restricted population defined by various characteristics which limit 
generalisability.  Also this strategy may mask potential adverse reactions seen in the 
wider population, not seen in the study population (16).  Further, the resource-intensive 
nature of the RCT has led to the use of surrogate markers which may or may not 
correlate with important endpoints.  This is evidenced, for example, by studies using 
reduction in albuminuria as an endpoint for reno-protection in diabetes (17).  In truth, 
much of current clinical medicine is not supported by RCT data, and this would be 
particularly true in the situation of rare disease or phenotypic variations.  Thus, 
researchers need to consider other methodologies to fill remaining evidence gaps.  
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1.1.2 Meta-Analysis  
In this context other study designs can offer alternatives to RCTs.  One of these is the 
use of meta-analysis as in theory it can use all the data available from all the studies 
that address a particular question.  Gene V. Glass (18) coined the term meta-analysis 
by saying “...Meta-analysis refers to the analysis of analyses”; this type of study design 
is particularly good in providing information on rare conditions by pooling results where 
RCTs may be difficult to perform as the number of subjects may be limited.  Using this 
technique the statistical power to test a hypothesis can be reached and it allows for 
patterns and effects to be identified without new data collection undertaken.  The 
process of aggregating all the data available from single trials in a meta-analysis can 
provide more power and precision allowing for more definite information than one 
reported by each trial individually.  Although in theory meta-analysis should be 
considered an excellent tool to provide evidence based medicine it has weaknesses 
(and has suffered from some bad press as a consequence) when studies of diverse 
quality are included.  Scoring systems are now available when undertaking such a 
project that can help with evaluating study quality for inclusion and meta-analysis 
(19; 20).  Furthermore, there is a well-known bias in the scientific literature towards 
publication of only positive results; hence a publication bias may be present with 
potential impact on meta-analysis results.  Careful consideration should be given to the 
total number of studies included as if there are not sufficient published literature, it can 
be a meaningless exercise.  This is quite important for very rare diseases where there 
is not a great breadth of publications.  Another issue is to ensure that the data are 
comparable given that different methods may be used to measure the same outcome.  
In fact, for a meta-analysis to be considered of a high standard, it should include 
individual patient data obtained from the original studies.  This increases the complexity 
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of requirements as the original authors need to be contacted and agree to provide the 
data.  Nevertheless, this action will improve the quality of the analysis as it can reveal 
differences between the different studies that had not been previously highlighted.  
Without these requirements, meta-analyses, in general, can provide a false sense of 
precision.  With the caveats mentioned above other largely observational study designs 
have been employed.  These are further discussed. 
1.1.3 Prospective Cohort Studies  
Prospective studies are designed to follow a group of study participants over a period of 
time who are observed to determine how long it takes for a pre-set condition or disease 
to manifest.  The data collected are bespoke to the study and the outcome of interest. 
They allow authors to identify risk or protection factors involved in the disease 
manifestation.  Some issues with prospective studies include the need for significant 
resourcing over long periods of time.  Furthermore, as subjects have to be followed-up 
for long periods of time, there is potential for the inclusion of less representative study 
populations due to losses to follow up of certain patient groups, for example, exclusion 
of less mobile patients who may not be able to attend visits.  This will introduce bias, 
which must be considered in the interpretation of such studies. 
1.1.4 Retrospective Cohort Studies  
In a retrospective study, an outcome of interest is identified and by looking back at a 
group of subjects these studies can help to establish temporal relationships, a range of 
outcomes per exposure or protective or risk factors.  The major problem encountered is 
that such studies can be subject to bias such as recall bias and misclassification.   
Some strategies that can be used to reduce this confounding are the use of 
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randomisation to avoid selection bias and subject matching to control for variables that 
are known to impact; for example, matching for age if the outcome of interest is 
vascular disease.    
1.1.5 Case-control Studies 
Case-control studies provide a comparison between a group of individuals with a 
disease (case) and a group of individuals without the disease that is observed (controls) 
(21).  The same data are collected in both groups regarding the exposure to the study 
subject.  In this type of study, the outcome data are used in a comparison of the 
proportion of the exposed individuals in the case group versus the control group.  Case-
control studies can provide significant scientific findings with comparatively little time, 
funding and effort compared with other study designs.  Schulz and Grimes (22) in their 
paper “Case-control studies: research in reverse” describe important caveats required 
to make sure that the study is valid and reliable.  Some of these include a rigorous 
description of criteria used for diagnosis of a case; the control population must be from 
the same population as the cases studied and they should be selected because they 
are at risk of developing a similar disease.  The research team collecting the data 
should be blinded to the main hypothesis of the study.  Careful consideration needs to 
be given to study procedures.  For example, it would be important to train the research 
team when interviewing both cases and controls that the same words and memory aids 
be used in order to obtain the exposure information in the same manner.  
1.2 Electronic data (eData) and Research  
Recognition of the limitations of the RCT and the acceptance of other observational 
studies to provide valid evidence as described above comes with an understanding that 
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there is no single best approach to the study of health interventions.  Decisions are 
often made with imperfect data.  However, new ways of obtaining valuable information 
need to be sought, and potential opportunities are provided by the modern digital era. 
The use of electronic health records has the promise of overcoming some of the 
limitations of the RCT and cohort studies.  Obviously, many pre-planned research 
programs would design a purpose-built system to capture the necessary data to 
facilitate analysis.  However, many computer information systems in use are designed 
to capture data, which can be subsequently “mined” to show patterns and trends for the 
purpose of informing diabetes care.  In this regard post marketing and surveillance 
studies have been utilised to support evidence from RCTs and facilitate access to new 
pharmaceutical agents.  Expert bodies have recently endorsed the evidence from such 
observational studies, where the data are high quality, to aid therapeutic decisions (23). 
The term “electronic health record ‘ (eHR), sometimes also known as the electronic 
medical record (eMR) has been defined as the systematised collection of patient and 
population health information stored in a digital format (24).  These can encompass a 
wide variety of electronic data sources including but not limited to data from medical 
care records, disease specific registries and health insurance claims databases.  There 
are several potential advantages to the use of the eHR for research.  Firstly, studies are 
cost-effective given that data are already collected for other purposes (25).  Recall bias 
that plague retrospective studies are not an issue given that data collection is 
prospective and often collected in real-time, with near real-time availability for analysis.  
The large sample sizes and patient level clinical data often allow for greater granularity 
to ascertain specific risk or protective factors for example. Depending on the source, 
data may include prescribing and dispensing information and allow for detailed health 
economic analyses.  The potential for linkage across many datasets exists, and often 
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the data can be widely generalisable given the source population are less selective than 
for RCT.  Several eHRs internationally and within Australasia have been used or may 
be available for use in diabetes research.  These are discussed further.  
1.2.1 Disease Registries:  
These are a clearly defined set of data kept in computerised systems primarily for 
recording the presence of diabetes in affected individuals.  Originally such registries 
were more commonly designed to capture those with childhood onset type 1 diabetes 
due to the smaller numbers of individuals affected, the relative ease of capturing the 
targets in hospital-based facilities and the better defined features of this condition.  
However, with the emerging higher prevalence of young onset type 2 diabetes, the 
exclusivity of registries for type 1 diabetes is becoming less.  Examples of the use of 
such registries for research include the Diamond Study (26)  and the EURODIAB  study 
based in Europe (27).  Particularly relevant to the studies described in this thesis 
involving young onset diabetes is the SEARCH for Diabetes in Youth study based in the 
United States (28).  This observational registry study over many States in the USA was 
designed to record individuals with type 1 or type 2 diabetes diagnosed when less than 
20 years of age.  This study now provides information on the prevalence, the incidence 
of diabetes in young people as well as their demography and treatment.  As an example 
of how registries can facilitate research, the SEARCH Study, in its wisdom, has an 
embedded longitudinal cohort to study the natural development and of the risk factors 
for acute and chronic diabetes-related complications, the quality of care and life of 
persons with diabetes from diagnosis to adulthood (28).    
Locally, the Australasian Paediatric Endocrine Group (APEG) (29) collects information 
on young people aged less than 15 years who require insulin to treat their diabetes and 
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therefore the great majority of these people are likely to have Type 1 diabetes.  This 
registry exists in every state of Australia and data are ascertained by contacting 
diabetes services, diabetes educators, general practitioners and specialists.  The 
National Insulin-Treated Diabetes Register (30) is another registry maintained by the 
Australian Institute of Health and Welfare (AIHW) and captures information on people 
with T2DM, gestational diabetes and other forms of diabetes as long as they take 
insulin as part of their treatment.  For this registry, the data are sourced from APEG as 
well as the National Diabetes Services Scheme (NDSS).  NDSS is discussed later 
under administration databases.  
It is evident that registries differ in their targets and their approach to case 
ascertainment; thus there will be variations in the capture rate of the total cohort in the 
community (31).  They also differ in the additional data they may collect to assist 
research.  In general, information gathered is relatively restricted to ensure the 
registration process is not cumbersome.  This fact imposes several limitations on the 
utility of such registries as they lack the granularity regarding patient indices that add 
the necessary detail to add context to any observations.  Further limitations may be 
imposed, as formal diagnostic criteria for diabetes type may not be available.  Another 
limitation highlighted in a review of using registries to identify type 2 diabetes patients 
are the limited data linkage possibilities as personal records are often de-identified.  
Often and unlike the SEARCH study, the lack of systematic follow-up of registry 
patients limits the analyses to cross-sectional data only (32). 
1.2.2 Audits and Surveys 
Computerised information systems can be used to monitor various aspects of a 
population with diabetes.  For example, in Australia for the last two decades, the 
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Australian National Diabetes Audit (ANDA) and its forerunner Australian National 
Diabetes Information Audit & Benchmarking (ANDIAB) have collected biennially, clinical 
diabetes data ascertained as a one month cross-sectional snapshot of selected patient 
populations.  The participating centres are given instructions as to which de-identified 
data fields are required and in what format they are to be collected.  Results are then 
forwarded to a central site for analysis.  In so doing, the ANDA data provides a picture 
of the current status and time trends, which can be used by the Department of Health 
and other agencies.  This is one of the few long-standing national data collections in 
Australia.  The ANDA definitions are the first clinical diabetes definitions to be included 
in the National Health Data Dictionary.  The dataset has since been enhanced and is 
now online as part of the AIHW – Metadata Online Registry (‘METeOR’) as the clinical 
Diabetes Data Set Specification (33).  Collective data are reported to the Department of 
Health annually.  For example in 2015, 48 diabetes centres and one private specialist 
provided de-identified data on 5183 patients (34).  The ANDA data set is also utilised 
for benchmarking of diabetes performance measures for participant sites, and most 
recently these ANDA data has been utilised for diabetes research (35). 
Internationally, other surveys include data on diabetes but are not specific for this 
condition.  Examples of these are the National Health Interview Survey (NHIS) (36) and 
the National Health and Nutrition Examination Surveys (NHANES) (37).  The NHIS is 
an ongoing nationwide cross-sectional survey of the health status and behaviours of 
Americans and conducted by the National Centre for Health Statistics and by the US 
Bureau of Census  (38).  The NHANES survey measures the health and nutritional 
status of both adults and children in the United States of America (39). 
The accuracy, comprehensiveness and utility of information that can be extracted from 
such systems depend on the cooperation and in-house data collection system of the 
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feeder sites.  Major limitations for research are similar to those for registry data; 
difficulty with data linkage given the de-identified nature of the collections and that only 
limited types of clinical data are collected to facilitate ease of collection. 
1.2.3 Administrative Databases 
Some computerised information systems are established by governmental agencies to 
facilitate and supervise the distribution of resources to assist in the treatment of 
diabetes.  In Australia, the National Diabetes Services Scheme (NDSS) includes such 
an administrative database.  The NDSS collects information on people with diabetes 
who join the scheme voluntarily so they can access subsidised consumables such as 
blood glucose testing strips, insulin needles and insulin infusion pump equipment.  The 
database generated from this organisation can also be used to provide information on 
diabetes such as the number of individuals on insulin or the types of diabetes and many 
other items.  Being a voluntary system encouraged by incentives, the completeness of 
enrolment would be higher in those favourably affected by the subsidies.  This in itself 
may introduce an ascertainment bias, for example, only those who are willing to self-
test blood glucose would be interested in registering for the NDSS strip subsidy, 
potentially excluding those who might not be testing, for example those treated with diet 
alone or arguably those with more limited adherence to self-care practices.  Healthcare 
insurance companies have often established their digitised information systems to 
service their clientele and collect information on their health status and requirements 
including those pertaining to diabetes.  A good example of this is Kaiser Permanente, a 
large health care organisation based in the USA, which has used its database to 
publish information on diabetes (40; 41).  By definition, it would only include data on 
those who have health insurance, and thus, information such as treatment modalities 
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would be biased by in-house regulations of the company.  It is noteworthy that the 
Australian universal health care provider (Medicare) collects information on the usage 
of individual patients on healthcare but not their disease status. Thus, the computerised 
information in Medicare systems cannot by itself provide useful information on diabetes.  
Further limitations may be introduced by the criteria for inclusion such as patients on 
diet alone who are underrepresented in a prescription database, and inaccuracy over 
the type of diabetes recorded; for example type 1 diabetes being recorded on the basis 
that treatment is with insulin and therefore may include insulin treated type 2 diabetes.   
1.2.4 Clinical Databases and Electronic Medical Records:  
Due to the large number of patients, increasingly healthcare facilities from primary, 
secondary care and some hospitals have developed in-house computer information 
systems to house eHRs, often termed electronic medical records (eMR) in this context.  
In general, the increased digitisation of information for use in health care settings over 
the last few years has become more prevalent particularly in hospitals where 
administrative and financial databases form the backbone of the day to day workload.   
These systems can identify and track the progress of individual patients with diabetes 
(42; 43).  This was the primary original purpose and structure of the diabetes database 
at RPAH Diabetes Centre which provides the data used in this thesis.  These in-house 
systems have the advantage that the format of data and its capture can be more easily 
standardised and more detail can be captured, overcoming some of the deficiencies 
encountered by the other data systems mentioned above.  The granularity in terms of 
clinical detail captured by these datasets is often superior to the aforementioned forms 
of electronic health record.  Diagnosis of acute and chronic conditions, prescription 
data, clinical monitoring metrics (blood tests, BP, health check data), as well as 
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demographic, family and lifestyle information (e.g. alcohol and smoking), may all be 
captured within.  Other data on admissions, procedural codes and administrative data 
allow for more detailed cost analysis.   
These data sets have the additional and important advantage, as they are often 
longstanding and therefore allow the progress of individual patients or types of patients 
to be tracked longitudinally.  Furthermore, such detailed and sequential clinical data can 
be linked to external datasets to produce important and novel information.  For example 
data linkage with databases such as ANZDATA (Australian and  New Zealand Dialysis 
and transplant registry) and the Australian National Death Index potentially will allow for 
renal and mortality outcomes to be ascertained respectively.  The use of data linkage 
with a clinical eHR form the basis of the studies presented in Chapter 4 and 5 of this 
thesis.  
Independent and standalone systems such as the Diabetes Centre database at RPAH 
are challenged to keep up with the advances in database design; often their original 
creators have faded from the market leaving most of these products without support.  
Thus in parallel, web-based systems that are set up for collaboration with other 
institutions have been developed.  As an example, the JADE program in Hong Kong 
has broadened this approach of “in house” database by making available a web-based 
interface allowing participation of other hospitals and centres in various countries to 
document patient profiles and care delivered at primary and specialist levels using the 
same standardised data (44-46).  The BIOGRID system in Australia is also attempting 
to standardise data collection so that again many hospitals can jointly pool their data to 
give more numbers and more generalised representations using a data sharing 
platform.  Currently, there are only 6 institutions that are using this system (47).   
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In practice, there are often difficulties in designing systems that cater to both clinical 
care as well as research.  One of the main issues is that clinicians continue to prefer to 
document in free text in the eMR.  Clinicians perceive that structured data would not 
allow them to express the problems and nuances of each case in an adequate manner. 
Nevertheless, the ability to data mine free text has increased with improvements in 
analytical tools.  Largely to date, the eMR has been relatively underutilised as a 
research tool in diabetes, and its utility as a research tool is not widely recognised.  
Thus, the overriding focus of this thesis is to explore the utility of such an eHR to 
provide new knowledge in the diabetes arena. 
1.2.5 Big Data  
Health care organisations such as insurers and hospitals have used information 
systems for decades to collect data but these data usually only provided knowledge 
related to their subscribers or patients and mostly the data remains in silos.  Following 
on from the increasing prevalence of eHRs, in recent years there has been a change in 
the data landscape with greater ascertainment and availability facilitated by a revolution 
in hardware technology allowing more efficient data storage at low cost.  Furthermore 
international and national initiatives such as Obama Care (Health Information 
Technology for Economic and Clinical Health Act Of 2009 (48)) and the Australian 
National Digital Health Strategy 2016, have facilitated greater access. Thus, the amount 
of digital health data being collected that could inform patient outcomes and clinical 
decisions is potentially vast and has increased remarkably in recent times.  Notably the 
amount of health care data availability in the USA has been cited to be approaching the 
zettabyte level (1021 bytes of data) (49).  The utility of large data repositories termed 
“Big Data” have been used in business to improved efficiency and productivity.  
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Businesses such as Google have been using their expertise in cloud technology and 
data science to create partnerships with research teams to get better and more precise 
outcomes in research (50).  The converging of this increasing data availability and the 
development of large data analytical systems have resulted in what has been termed 
the ‘big data analytics’ (BDA) era in healthcare.  To date, there is no formally accepted 
definition of what constitutes big data however, it is often defined by the presence of the 
three v’s ; volume, variety and velocity of data (49; 51).  Volume is often in the order of 
at least 1 petabyte (1015 bytes) of data.  Variety in big data comes from the combination 
of data from multiple sources including diverse data types (see Fig 2).  The velocity of 
the analytical systems is essential for the data to provide meaningful results in a timely 
manner.  
Figure 2: Overview of big data analytics and applications. From (49) 
Data sources and analytical methods can be diverse and in theory, are unconstrained. 
In healthcare, these include eHR datasets such as administrative databases, clinical 
prescribing databases and pharmaceutical claims, clinical records and registries (52). 
Datasets can also include biometric data, imaging data from wearable technologies and 
even social media use.  Modern analytical platforms and computational capacity are 
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available as open source frameworks with a view to true democratisation of the 
technology of BDA.  
In terms of analytical frameworks, in general, analysis is correlative and focuses on 
identifying patterns in complex data although traditional statistical methodology are also 
applied.  The expectations are that big data will allow predictive modelling to identify 
high risk or high-cost patterns, facilitate population management and case finding, allow 
drug and medical device surveillance utilising eHR data and clinical registries to identify 
disease treatment heterogeneity.  In terms of prescriptive analytics, the applicability to 
integrate omics platforms and integrate the systems biology approach with hard 
outcomes holds great promise.  
Despite the potential, the challenges in utilising Big Data are many and have yet to 
translate into major advances for diabetes care specifically.  The evidence base at the 
moment for benefit is still in its infancy.  There are significant issues of data quality and 
data inconsistency to be overcome for this tool to have true impact.  Data are still 
observational and subject to unmeasured bias as all observational studies are prone. 
Furthermore, the problem of missing data and imputation methodology at scale may 
impact the conclusions drawn.  Then there are the additional challenges of patient 
privacy, consent, data security and other legal considerations.  It would be reasonable 
to say that the promise of big data has yet to be realised in the field of diabetes. 
1.3 Knowledge Gaps and The Utility of The Routinely Collected eHR 
In summary, in the context of an increasing prevalence of diabetes and a need to 
further examine the heterogeneous disease that is type 2 diabetes, there are great 
opportunities provided by the growing adoption of eHR systems in healthcare to further 
                                                                                                             53   
 
diabetes research.  This is especially attractive given the cost and other limitations 
defined by the traditional gold standard approaches to inform clinical decision making 
such as the RCT.  As mentioned, the promise of Big Data has yet to be realised for 
diabetes, and the utility of administrative databases, disease registries and the like are 
limited in the data they capture.  It is the routinely collected clinical electronic medical 
record that, often overlooked, still holds great promise as a research tool.  Specifically, 
the detailed patient data contained in the eHR has the potential to answer many 
different types of questions in diabetes (53).  Disparate questions that would inform 
patient care, such as “are the risks for complications similar for different subgroups of 
diabetes patients?” to “can the electronic health record be used to inform public health 
measures and identify gaps in patient care?” could be potentially explored with this 
facility.  That said, the utility of the routinely collected eHR as a research tool, given its 
relatively recent advent has not been greatly explored in diabetes.  Thus, the studies 
undertaken in this thesis examine the overarching issue of the research utility of smaller 
datasets such as the routinely collected eHR from a single site in this context.  The 
studies presented in this thesis leverage the advantage of access to data housed in a 
long established clinical eHR provided by the RPA Diabetes Centre.  The RPAH 
Diabetes Centre were early adopters of the eHR and this dataset houses clinical 
information from over 30,000 patients collected over a greater than 20 year period.  
This is expanded on further in Chapter 2.  The data have been collected in a 
standardised way which allows the full research potential of such an eMR from a single 
centre to be studied.  If utility is proven, this would have significant implications given 
that worldwide implementation of the eHR is a recent phenomenon with as yet un-
harnessed potential. So in addition to the promise of Big Data, if these smaller 
databases, all developed primarily for the management of our patients in medical 
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settings could be utilised to also provide data for meaningful research, this will have 
implications ongoing for diabetes care.  Specifically, data managers and clinicians alike 
would be encouraged to design systems that in addition to routine patient care, facilitate 
data that can advance the field. This concept is a primary theme that underpins the 
studies presented herein.    
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Part II: General Aspects of Diabetes  
1.4 The Global Burden of Diabetes 
Diabetes Mellitus used to be considered a disease of affluent societies alone.  This is 
no longer the case with 1 in 11 adults diagnosed with diabetes and an estimated total of 
425 million people living with the disease globally, with the largest growth in developing 
countries (54).  Globally, diabetes prevalence is projected to continue to increase, and 
thus diabetes is considered a priority non-communicable disease (NCD) for the World 
Health Organisation (WHO).  NCD are chronic conditions that are not caused by 
infectious agents but may result from a combination of genetic, physiological, 
environmental and behavioural factors (55).  These include apart from diabetes, 
cardiovascular diseases, cancer, and chronic respiratory diseases.  Factors identified 
as having an impact on the development of these diseases are rapid urbanisation, 
unhealthy diets and lack of physical activity.  These in turn are associated with raised 
blood pressure, increased blood glucose and lipids creating a milieu of metabolic risk. 
Diabetes is now responsible for 12% of global health expenditure ($727 billion) and this 
is projected to increase in line with prevalence (54).  Moreover, diabetes is now the 
leading NCD in terms of causing premature death.  The IDF states that diabetes is 
responsible for 10.7% of all-cause mortality and this is higher than the combined 
percentage of deaths from HIV/AIDs, tuberculosis and malaria (7). 
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1.5 Diagnosis of Diabetes and Pre Diabetes 
The diagnosis of diabetes can be made on a number of tests of hyperglycaemia, either 
fasting plasma glucose, the 2-hour plasma glucose following a 75gm glucose load, 
random plasma glucose or by way of glycated haemoglobin (HbA1c).  
This framework of systematically classifying hyperglycaemia thresholds as diabetes 
was first developed by the National Diabetes Data Group (NDDG) in 1979.  This 
classification was endorsed by the World Health Organisation (WHO).  In June 1997 an 
International Expert Committee released a report with revised recommendations for the 
classification and diagnosis of diabetes mellitus using data from epidemiologic studies 
that measured blood glucose levels and quantified retinopathy (56).  These studies 
identified a point at which the levels of fasting and 2 hours glucose correlated with the 
prevalence of retinopathy increased linearly.  This standardised framework for the 
diagnosis of diabetes has proven to be of great importance in epidemiological studies 
as it provides a uniform platform across many countries and different health systems, 
hence making the results comparable and relevant. 
A fasting blood glucose level to determine the diagnosis of diabetes should be collected 
in the morning, after an overnight fast of at least 8 hours.  To collect the 2 hour plasma 
glucose, an oral glucose tolerance test must be undertaken as prescribed by the WHO 
(57).  This involves the consumption of 75 g of anhydrous glucose dissolved in water.  
In asymptomatic individuals, a second test in the diabetes range, taken on another day 
is required to confirm the diagnosis of diabetes.  In patients who present with symptoms 
of diabetes (polyuria, polydipsia and unexplained weight loss) a single random blood 
glucose (that is a test carried out at any time of the day) ≥11.1 mmol/L (≥200mg/dl) is 
diagnostic of the disease. 
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An Expert Committee determination for the inclusion of HbA1c for diagnostic purposes 
was presented in 2009.  The rationale for its inclusion was the poor reproducibility of the 
OGTT and the variance in the measurement of plasma glucose.  The HbA1c test 
represents a weighted measure of glycaemia over the last 2-3 months and prior to 2009 
was used to assess glycaemic control only in already diagnosed patients.  Until recently 
the assay had not been standardised until the development of the International 
Federation of Clinical Chemistry and Laboratory Medicine (IFCC) reference 
methodology allowing the standardisation and unified reporting of HbA1c in universal 
units (mmol/mol) (58; 59).  This development paved the way for its use as a standalone 
diagnostic test for diabetes.  The threshold determined for the diagnosis of diabetes 
using HbA1c is 6.5% (≥48 mmol/mol).  It is above this measurement that the prevalence 
of retinopathy increases (56; 60).  The caveats for its use include conditions affecting 
the red blood cell (RBC) turnover.  HbA1c is not recommended to diagnose gestational 
diabetes nor type 1 diabetes.  
The Australian Diabetes Society (ADS) current criteria for the diagnosis of diabetes in 
Australia are: 
• HbA1c ≥6.5% (48 mmol/mol) 
• Fasting glucose ≥7.0 mmol/L (≥ 126ml/dL) 
• Random glucose ≥11.1 mmol/L (>200m/dl) 
• 75 g oral glucose tolerance test: fasting glucose ≥7.0 mmol/L or 2 hr glucose 
≥11.1 mmol/L 
In an asymptomatic patient, the test should be repeated for the confirmation of the 
result and diagnosis.  An abnormal result on 2 different diagnostic tests is also 
acceptable (61).  
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These criteria are in line with international societies such as the American Diabetes 
Association(62) and the World Health Organisation.  Currently, the guidelines for testing 
are the same for adults as well as for children and adolescents.  Studies have 
questioned the validity of HbA1C in paediatric populations and suggest that the oral 
glucose tolerance test or a fasting plasma glucose are more accurate, although there is 
no validation in paediatric populations for any of the tests (63; 64).  
1.5.1 Prediabetes 
This condition describes elevated blood glucose ranges but which are below that for 
diabetes.  The condition is further split into those with impaired fasting glucose (IFG) 
and impaired glucose tolerance (IGT).  Management of prediabetes is largely by 
lifestyle measures although some studies have shown the benefit of pharmacological 
agents (65-71).  IFG is diagnosed if fasting plasma glucose is 6.1-6.9mmol/l; IGT is the 
2 hr plasma glucose is ≥ 7.8-11.1 mmol/L following a 75g 2hr OGTT.  Prediabetes 
infers a higher risk of diabetes and an increased CVD risk.  Confusingly, the ADA 
reduced the IFG diagnostic threshold from ≥ 6.1 mmol/L to ≥ 5.6 mmol/l, but this has 
not been widely accepted internationally.  Neither is there a widely accepted HbA1c 
threshold for prediabetes.  Specific recommendations for screening in children and 
adolescents are discussed in Part III. 
1.6 Types of Diabetes 
Traditionally, diabetes has been classified broadly into two main groups, type 1 and 
type 2 diabetes mellitus.  However, of importance and relevant to the theme of this 
thesis, the clinical criteria that have been used to distinguish diabetes type in the past 
(age of onset, weight and insulin therapy requirement at diagnosis) have blurred 
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considerably in recent times.  Furthermore, several more ‘types’ of diabetes have now 
been added to an aetiological classification of diabetes given that specific genetic 
defects have been identified as well as diabetes associated with other 
endocrinopathies, medications and other immune disorders.  Table 1 is taken from 
American Diabetes Association position statement of 2014 (72) and shows the current 
understanding of the different subtypes of diabetes and underscores the complexity for 
physicians now in establishing the correct subtype of diabetes.  
In the following, the main subtypes of diabetes mellitus are discussed briefly.  As one of 
the specific aims in this thesis focuses on age of onset of type 2 diabetes, type 2 is 
discussed more fully here, and youth onset type 2 diabetes will be discussed separately 
in Part III. 
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Table 1: Etiologic Classification of Diabetes Mellitus. Adapted from the American Diabetes Association; 
From  (72) 
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1.6.1 Type 1 Diabetes 
Type 1 diabetes accounts for 5-10% of all diabetes and is an autoimmune disease.  It is 
characterised by the immune destruction of pancreatic beta cells resulting ultimately in 
a failure of endogenous insulin production, leading to ketoacidosis if exogenous insulin 
is not administered.  This type of diabetes can affect any age group, but its classical 
age of onset is in childhood or young adults.  The rate of beta cell loss is typically more 
fulminant in younger onset type 1 diabetes.  
With respect to pathophysiology, there is a genetic component to the development of 
type 1 diabetes, although genetic influences are less than for type 2 diabetes.  Type 1 
diabetes is considered to be a polygenetic condition, with many genes of small effect 
size contributing to disease susceptibility.  The risk of developing type 1 diabetes is 
~5% if a parent is affected and higher if paternally inherited (73).  Gene variants in the 
major histocompatibility locus human leukocyte antigen (HLA) contribute 50-60% to the 
variance, i.e. most of the genetic risk in type 1 diabetes and do so by modulating 
antigen presentation to immune cells.  There are ~50 additional gene loci also 
implicated in type 1 diabetes.   
Environmental influences also contribute to the development of type 1 diabetes 
(74; 75).  The importance of environmental influences is evidenced by discordant 
diabetes rates in genetically identical twins and the regional variations in prevalence.  
The current paradigm for the pathogenesis of type 1 diabetes is for an environmental 
trigger or triggers acting in the context of an at-risk genetic background, culminating in 
the T cell mediated autoimmune destruction of beta cells.  Some putative environmental 
triggers are enterovirus and other infections, the gut microbiome composition and 
dietary composition including gluten, milk proteins and cereal triggers (76; 77).  
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Temporally the autoimmune destruction of beta cells occurs well before the onset of 
clinical diabetes.  Abnormal insulin secretion has been found at least 2 years before 
diabetes diagnosis and the decline in secretion accelerates proximate to clinically 
evident hyperglycaemia.  Furthermore, there is a decline in the beta cell sensitivity to 
glucose following the same trajectory (78-81).  There is further decline in insulin 
secretion, post-diagnosis, which is more rapid in younger patients.  
In type 1 diabetes, circulating antibodies against insulin, glutamic acid decarboxylase 
(GAD) and protein tyrosine phosphatase ( IA2) and Zinc transporter 8 (ZnT8), all 
markers of beta cell autoimmunity, can be detected in the early stages and even before 
the onset of clinical disease.  The presence of two or more such antibodies in the 
context of either the presence of HLA risk alleles or a relative with type1 diabetes is 
associated with a 75% risk of developing type 1 diabetes within 10 years.  Risk 
increases with increasing numbers of autoantibodies.  The progression of type 1 
diabetes can now be staged based on the presence of autoantibodies and symptoms 
as outlined in Table 2 below (73).  Nevertheless, despite being able to stage type 1 
diabetes and prognosticate, there are to date no successful therapeutic strategies that 
can prevent or reverse type 1diabetes.   
From a clinical utility perspective, the presence of islet cell antibodies (GAD ab, IA2ab 
and ZnT8ab) can be used in diagnostic phenotyping, and their strong presence 
identifies an autoimmune basis for diabetes suggesting type 1 diabetes in terms of the 
etiological classification.  Furthermore, plasma c-peptide is often low or undetectable in 
type 1 diabetes.    
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Table 2: Staging of type 1 diabetes – From (73) 
 
1.6.2 Gestational Diabetes 
Gestational diabetes mellitus (GDM) has been defined as hyperglycaemia first 
discovered during pregnancy.  Over time, the definition of GDM and diagnostic criteria 
have changed.  The landmark Hyperglycaemia and Adverse Pregnancy Outcome 
(HAPO) Study demonstrated the linear association of fasting, I hr and 2hr post load 
diabetes and adverse foetal outcomes such as birthweight > 90th central, cord blood c-
peptide primary caesarean section and neonatal hypoglycaemia (82; 83).  Two other 
landmark studies, the Australian Carbohydrate Intolerance Study in Pregnant Women 
(ACHOIS) and a Multicentre Randomized Trial of Treatment for Mild Gestational 
Diabetes (84; 85) demonstrated efficacy in terms of reducing glycaemia and 
subsequently reducing poorer pregnancy outcomes.  Following on from this evidence 
base, the International Association of the Diabetes and Pregnancy Study Groups 
(IADPSG) proposed new diagnostic criteria which have been supported by the WHO 
and taken on by most but not all expert bodies to date (86; 87).  Furthermore, the 
category of more severe hyperglycaemia in pregnancy that would be consistent with 
diabetes outside of pregnancy is now termed ‘Diabetes in Pregnancy” or DIP and 
separate from GDM.  DIP constitutes a higher risk group. 
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GDM is managed with controlled carbohydrate and caloric intake, gentle exercise and 
blood glucose monitoring.  If these methods are not sufficient to control blood glucose, 
then insulin is used.  Alternatively, the use of metformin has been an option with proven 
efficacy (88), and although sulfonylureas have been used, these agents have recently 
been shown to have unwanted sequelae (89; 90).  Regarding the longer term outcomes 
of GDM, the developmental origins of human disease including gestational diabetes are 
increasingly recognised.  These mothers have a higher risk of developing diabetes in 
later pregnancies and in later life, their offspring appear to be at higher risk of obesity 
and consequently developing diabetes as teenagers and young adults.  This is relevant 
and discussed in Part III. 
1.6.3 Maturity Onset Diabetes of the Young (MODY) 
Maturity onset diabetes of the young (MODY) is a subtype of diabetes that results from 
a mutation in a single gene.  It is part of the wider etiological group referred to as 
monogenic diabetes which represents <5% of all diabetes cases.  Largely, the gene 
mutations involve genes that regulate beta-cell function and in rare instances insulin 
resistance.     
Historically MODY was identified by characteristics such as diabetes diagnosed at less 
than 25 years of age and an autosomal dominant pattern of inheritance.  The single 
abnormal gene causing diabetes resides on one of the 22 autosomal (non sex) 
chromosomes from either parent with a typical inheritance pattern of 50% affected 
offspring (91; 92). Thus, children of an affected parent with MODY have a 50% chance 
of inheriting the affected gene and developing MODY themselves.   
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The three most common MODY subtypes are mutations  of i) hepatocyte nuclear factor 
1 alpha (HNF1α, MODY3), which accounts for up to 61% of MODY cases in the United 
Kingdom ii) Glucokinase (GCK, MODY2) has been found to account for 22% of MODY 
and iii) hepatocyte nuclear factor 4 alpha HNF4α (MODY1) being rarer and accounting 
for ~4% of MODY (93).   
Table 3: The table from Bishey et al. (94) gives a snapshot of the genetic and key clinical features common in 
the most prevalent types of diabetes.  
 
Table 3 taken from (94) gives a snapshot of the genetic and key clinical features 
common in the most prevalent types of diabetes.  These features will allow 
differentiation between young onset type 2 diabetes and MODY, acknowledging that 
clinically the differences may be challenging without genetic analysis.  In the past given 
reduced awareness and lack of genetic testing, MODY diabetes has often been 
misdiagnosed as either type 1 or type 2 diabetes.  
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1.6.4 Mitochondrial Diabetes 
Diabetes is a common feature of mitochondrial disease.  Specifically, and most 
commonly, mitochondrial diabetes arises from a specific mutation in the mitochondrial 
genome, 3243A >G.  Mitochondrial DNA is maternally inherited, and this pattern of 
inheritance is an important distinguishing feature.  Mitochondrial diabetes can present in 
youth and should be differentiated from both type 2 diabetes and type 1 diabetes.  The 
occurrence of deafness, retinal changes, myopathy and lactic acidosis may be other 
indicators of mitochondrial disease.  It should be noted that the severity of the clinical 
phenotype is determined by heteroplasmy (the amount and presence of abnormal 
mtDNA) which defines the burden of abnormal mitochondrial in any given cell.  Thus, a 
high index of suspicion should be maintained as other organ effects may not be 
immediately obvious (95; 96).  
Diabetes presenting in younger patients can also be part of clinical syndromes such as 
Laurence-Moon-Biedl syndrome and other endocrinopathies.  These are not discussed 
here further but are usually clinically evident at diagnosis and are rare (Table 1).  
1.7 Overview of Type 2 Diabetes Mellitus 
1.7.1 Type 2 Diabetes 
Type 2 diabetes is the most common type of diabetes but that said, it is a diagnosis of 
exclusion.  Type 2 diabetes has famously been described as “a disease in search of a 
definition” and notably the esteemed diabetologist Edwin Gale (97) writes “It has no 
hallmark clinical features, is generally diagnosed by default (no other cause for diabetes 
being evident), has very heterogeneous pathophysiological features, and varies widely 
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between populations in clinical presentation and consequences.  Despite this obvious 
heterogeneity, laboratory and clinical research is typically done as if type 2 diabetes 
were one disease entity with uniform characteristics, thus assuming standard causal 
mechanisms and universal treatment pathways”.  Nevertheless, type 2 diabetes is 
thought to arise from a combination of insulin resistance and inadequate insulin 
secretion.  The pathophysiology is discussed more fully later.  Type 2 diabetes 
predominantly affects adults but is increasingly being diagnosed in children and 
adolescents paralleling a rise in childhood obesity.  Youth onset type 2 diabetes is 
described more fully in Part III.  
 As individuals with type 2 diabetes can still produce some insulin (albeit not of the best 
quality and produced in a dysregulated way), the disease can remain undiagnosed for 
many years.  Nevertheless, the high glucose levels damage tissue cells, hence many 
patients at diagnosis already have microvascular complications (retinopathy, 
nephropathy and neuropathy) and macrovascular disease (coronary artery disease, 
peripheral arterial disease, and stroke).  Type 2 diabetes is the most predominant form 
of diabetes, and in developing countries, it affects ~90% of people with diabetes, and 
although considered in the past a disease of the wealthy, it has had an exponential 
increase due to excess body weight, physical inactivity and poor nutrition widespread in 
the community.  Other factors which play a role are ethnicity, family history of diabetes, 
obesity, past history of gestational diabetes and advancing age.  Risk factors type 2 
diabetes will be discussed more fully in section 2.0. 
In the presence of diabetes, damage to the body tissues resulting from hyperglycaemia 
and other metabolic disturbances can lead to diabetes complications involving many 
organs with serious medico-economic consequences for both the individuals and the 
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community.  The impact of diabetes on individual organs will be discussed later in this 
review.   
In T2DM there is a gradual decline in beta cell function, and hyperglycaemia is present 
prior to the diagnosis of diabetes.  A usual pathway would be moving through a 
diagnosis of pre-diabetes, which encompass two conditions, impaired fasting glucose 
(IGF) or impaired glucose tolerance (IGT) leading eventually to the full diagnosis of 
T2DM.  This progressive process can take from 5 to 10 years to occur (98; 99) in the 
older patient with type 2 DM but in YT2DM is much shorter.  D’Adamo et al. suggested 
an accelerated process in the paediatric population compared with adults (100), 
especially in the setting of obesity.  Notably at the prediabetes stage, prevention studies 
in adult populations have shown success for diet and lifestyle and metformin (101-106).  
Other pharmacotherapies shown to prevent diabetes are acarbose (107), glargine (69) 
and rosiglitazone (108) but not Ramipril (68; 109).  
1.8 Prevalence of Type 2 Diabetes in Australia 
The Australian Bureau of Statistics (ABS) estimated the Australian population to be 
24,127,200 people on the 30 June 2016 (110).  Currently, there is not a single national 
data source to provide definitive prevalence data for diabetes in Australia.  The 
following estimates come from various data sources.  One of the latest estimates of 
diabetes prevalence was obtained from the National Health Survey (NHS) 2014-2015 
conducted by the ABS (111).  It is estimated that more than 1.2 million people aged 2 
years and over have some form of diabetes in Australia, representing 5.1% of the 
population.  The NHS relies on self-reported data; it asks the participants if they have 
ever been told by a health professional if they have diabetes, irrespective of whether 
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the person considered their diabetes to be current or long-term.  By this methodology, 
type 2 diabetes in 2014-15 affected one million people (4.4% of the population overall, 
representing ~85% of the population with diabetes) whilst in the 2011-12 survey this 
number was 3.8%.  These results are likely an underestimate given the nature of the 
data collection and the lack of biochemical testing (111), but even using these crude 
measures there is evidence for an increase in self-reporting of this condition.  
There are three other national sources of information to estimate the prevalence of 
diabetes in Australia that importantly incorporate some biochemical measure of glucose 
tolerance.  These are as follows: 
1.  The National Diabetes Services Scheme (NDSS) is a government funded national 
scheme that provides subsidised consumables for self-monitoring of blood glucose 
strips, insulin needles and insulin pump consumables.  Using this administration 
database, there were 1,273,917 people (5.3% of the Australian population) (110) with 
diagnosed diabetes registered with this service at the 31/12/2017 (112); 1,108,301 
people were reported with type 2 diabetes, representing 87% of the total sample which 
is in accordance with the NHS 2014-2015 estimates above.  Of note, regarding this 
population sample, registration with the NDSS is voluntary, therefore there may be a 
subgroup of the population who have never registered as they did not perceive that this 
would be of benefit to them, i.e. they are not performing home blood glucose monitoring 
or requiring insulin, or they may have an individual objection to organisations having 
their name in this register.  Again the implication here is that the NDSS data may also 
underestimate the true population prevalence.  
2. The National Health Measures Survey 2011–13 (113) is considered the largest and 
most comprehensive health survey ever conducted in Australia and for the first time in 
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2011-13 included blood and urine samples from over 11,000 participants as well as 
health status, risk factors, health service usage and medications.  Using two tests, 
fasting blood glucose and HbA1c (glycated haemoglobin ≥6.5% as the diagnostic 
criteria for diabetes) it found that 5.1% of the population over the age of 18 had 
diabetes, of these 0.9% were new cases and that men were more likely than women to 
have diabetes (6.3% vs 3.9%).  The survey cut-offs used for each test to determine 
whether a person has diabetes or is at high risk of diabetes are shown in Table 4.  
Using these criteria, 3.1% of all surveyed were identified at high risk of developing 
diabetes.  Oral glucose tolerance tests were not used for diabetes diagnosis in this 
study.  So those with milder degrees of hyperglycaemia or conditions confounding the 
use of HbA1c that would otherwise be diagnosed as diabetes could have been missed. 
Please also note that the formal diagnostic type of diabetes are not reported in this 
study. 
 
 
 
 
 
3 The Australian Diabetes, Obesity and Lifestyle study (AusDiab) (114) was conducted 
between 1999-2000 and for the first time used an oral glucose tolerance test (OGTT) 
considered the gold standard test to diagnose diabetes.  The study included 11,247 
adults (aged 25 years and above), and it estimated the prevalence of diabetes at 7.5%, 
numbers higher than the NDSS.  Unfortunately, the authors of AusDiab did not report 
Table 4: Adapted from Australian Health Survey: Biomedical Results for Chronic Diseases, 
2011-12 (55) 
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the prevalence of type 2 and type 1 separately in their data.  They state that the vast 
majority was classified as type 2. 
The different sources of information described above rely on disparate methodologies 
such as self-reporting, non-mandatory registrations, HbA1c measurements only or 
using the gold standard method of the oral glucose tolerance test.  Combining these 
measures one can estimate the prevalence of diabetes in Australia to be between 5.1% 
and 7.5% of the population and the prevalence of type 2 diabetes between 4.2% and 
4.6 %. 
1.8.1 Indigenous, Ethnic Specific and Migrant Population Prevalence of Diabetes 
in Australia 
The above estimates are for the total Australian population; however, Australia is a 
multi-ethnic and multicultural society with migrants from high-risk ethnic groups, which 
is relevant for diabetes risk.  Knowing the prevalence rates in our migrant communities 
and our own indigenous populations would be important; 28.5% of the estimated 
resident population was born overseas, or 6.9 million persons (115) and 686,800 
people or 3% of the total Australian population identifies itself as Aboriginal and Torres 
Strait Islander in 2014 (116).  Figure 3 shows the rise in the overseas born population in 
Australia over the years (115).  Perhaps due to Australian immigration policies over the 
last few decades, 46% of Australians have at least one parent born overseas.  Earlier 
migrants came predominantly from the United Kingdom, and UK migrants now account 
for 5.0% of Australia's total population as of the 30th of June 2016.  Subsequent to this, 
migration from the eastern and southern European countries followed and then 
migration from the Middle East and Asia.  Specifically, the ABS (115) notes that the 
number of migrants from Nepal, Pakistan, Brazil, India and Bangladesh have had the 
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highest rate of increase from 2006 to 2016.  There have been progressively higher 
numbers of migrants from African countries in recent years and being geographically 
proximate, the Pacific Islands have also been a major source of migrants in the recent 
decade.  Figure 4 shows the top 10 country of origin for overseas born people in 
Australia and the growth or decline of these groups of migrants in the years of 2006, 
2011 and 2016. 
Figure 3: Source Migration, Australia (cat. no. 3412.0) 
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Figure 4: Top 10 country of origin for overseas born people in Australia and their growth or decline over 3 
different years.  Source: Migration, Australia (cat. no. 3412.0) (51) 
 
The relevance is that diverse migrant groups are likely to be characterised by a differing 
susceptibility to diabetes and even different clinical manifestations of diabetes.  Minority 
groups in Australia come from areas of the world with a high prevalence of type 2 
diabetes signalling an ethnic specific increase in risk. 
Additionally, the age structure of migrants also impacts on population risk for diabetes.  
For example, the ethnicities of the oldest migrant groups are shown in Table 5.  It is 
likely that the ethnicities with a higher prevalence of older migrants have a higher 
prevalence of diabetes with perhaps a longer duration of pre-existing diabetes.  Migrant 
and ethnic specific comparative data with respect to diabetes are discussed below. 
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Table 5: Oldest and youngest migrant groups, 2015 Source: The demographer’s Christmas: countdown to 
the census: (117; 118) 
 
 
Of note is that 686,800 people or 3% of the Australian population in 2014 identified itself 
as Aboriginal and Torres Strait Islander (116) and there is a relative dearth of data for 
this indigenous Australian group.  However, all information available, when compared 
with the general population, shows that they carry a disproportional burden of diseases, 
including diabetes.    
In 2014 the National Aboriginal and Torres Strait Islander Social Survey (NATSISS), 
2014-15 (119) found that almost half of this indigenous group were under the age of 20 
years.  Importantly in this survey, the authors found the prevalence of diabetes to be 
12.8%, much higher than the Australian average with most diabetes being type 2 
diabetes in origin. However, the authors do acknowledge that their methodology was 
not robust enough to provide secure prevalence data.  They recommend 2012-13 
National Aboriginal and Torres Strait Islander Health Survey (NATSIHS) (119; 120) data 
for this purpose.  NATSIHS 2012-2013 is the largest biomedical survey conducted in 
Indigenous Australians and surveyed 3300 individuals over 18 years of age.  It reported 
a prevalence of diabetes in this population of 11.1%, with a range of 9.4% in major 
cities and regional areas and 20.8% in remote areas.  After adjusting for age 
differences, Aboriginal and Torres Strait Islander people were three times as likely as 
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non-Indigenous people to have diabetes.  This survey noted that the age pattern for the 
prevalence of diabetes between indigenous and non-indigenous was similar but 
diabetes and newly diagnosed diabetes tended to occur at a younger age in indigenous 
Australians.  The authors found that the rate of diabetes for indigenous people aged 35-
44 years (9.0%) was equivalent to that of non-indigenous people aged 55-64 years 
(8.2%).  Similarly, the rate for those aged 45-54 years (17.8%) was similar to those non-
indigenous aged 65-74 years (15.0%).  This is illustrated in Figure 5.  
Figure 5:  Proportion with Diabetes by Indigenous status and age (From:  4727.0.55.003 - Australian 
Aboriginal and Torres Strait Islander Health Survey: Biomedical Results, 2011-13) 
 
Minges et al. in 2011 (121) performed a systematic review of the literature for studies 
that reported the diabetes prevalence in the Australian indigenous population.  The 
studies were conducted between 1997 and 2010, and the diagnosis of diabetes was 
based on self-reports or standard diagnostic criteria.  Minges found the prevalence of 
diabetes and impaired glucose tolerance (IGT) in Indigenous Australians to range 
between 3.5% to 33.1% in the 24 studies reviewed. 
The current comparative data pertaining to migrant and ethnic specific diabetes 
prevalence are now discussed.  Abouzeid et al (122) reported that using the NDSS 
registry and the 2006 Australian National Census data in the state of Victoria in 
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Australia, in all migrant groups, the odds of them developing type 2 diabetes versus 
those who were Australian born was higher, even after adjusting for age and socio-
economic strata.  In this study, the groups from the Pacific Islands, Southern and 
Central Asia, North Africa and Middle East had the highest odds ratio (OR) of diabetes 
compared to the reference group.  For example, the OR for persons born in the Pacific 
Islands is 6.3 for men and 7.2 for women compared to the Australian born reference 
group.  These are illustrated further in Tables 6 and 7.    
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Table 6: Crude and Adjusted prevalence rates for males with Type 2 diabetes.  Table from Abouzeid et al. 
(114) 
 
 
Table 7: Crude and Adjusted prevalence rates for females with Type 2 diabetes.  Table from Abouzeid et al. 
(122) 
 
 
  
                                                                                                             78   
 
The authors in this work stated that the reference group, the Australian born group 
included Indigenous people, who are known to have a higher prevalence of diabetes, 
and thus may have artificially lowered the prevalence OR for other ethnicities reported. 
However, the authors further mention that they were unable to analyse the Indigenous 
group separately due to uncertainty over the demographic characteristics of this 
population in Victoria.  They argue that the National Census for Victoria in 2006 only 
identified 0.6% of the population as Indigenous and thus their inclusion would not 
greatly impact on the overall prevalence OR reported. Furthermore, this work could only 
account for first generation migrants because the NDSS only records country of birth 
rather than ethnicity data.  The implication is that many of the Australian born in the 
reference group would be second or more generation migrants, but the authors were 
not able to distinguish.  This issue may also mean that the OR reported are an 
underestimate of the relative prevalence of diabetes in migrant and indigenous 
communities in Australia. 
The origin of this migrant specific excess risk of diabetes is not entirely clear.  Of 
course, genetic predisposition may account for differences in risk.  It has also been 
postulated that an increase in BMI, as a result of greater economic prosperity achieved 
upon migration to Australia, may also be a factor (123; 124).  Montesi et al. (125) 
suggest that lower the social, economic status in the country of origin the higher the risk 
of the population to become obese in the new country, further exacerbating any 
background ethnicity specific predispositions to diabetes. 
In addition to the migrant prevalence data presented above, in terms of ethnicity alone 
irrespective of migrant status, there are few Australian data that examine this.  McGill 
and Twigg (126) in 2012 pointed out in an audit of more than 9000 patients in Sydney 
that in all non-Caucasian groups, the diabetes diagnosis occurred at a significantly 
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younger age than in Caucasian groups and that they had poorer blood glucose control 
and higher rates of microvascular and in some cases macrovascular complications 
such as higher prevalence of  retinopathy and ischaemic heart disease.  In the 
Fremantle Diabetes Study, the prevalence of type 2 diabetes in Asian patients was 
similar to the background population; however, these Asian patients with diabetes were 
younger and less obese.  The researchers also found that these patients had a higher 
prevalence of retinopathy despite accounting for similar diabetes control and duration; 
27.3% for Asians vs 13.5% for Anglo-Celtic (127).   
Despite the established multi ethnic composition of the Australian population, there are 
few data on the multi ethnic differences in diabetes outcomes in Australia and, in 
particular, mortality data are lacking.  In this context, using a single centre eHR, ethnic 
specific differences in complications and survival are explored further in this thesis in 
chapter 3.  The potential confounding from geographic variation in the treatment of 
diabetes and risk factors on mortality, in addition to variations in access to care, are 
attenuated by exploring data from a single site.  
1.9 Pathophysiology of Type 2 Diabetes 
Type 2 diabetes, like type1 diabetes, is considered to be a polygenic disease.  The 
genetic factors are discussed more fully later in this chapter under risk factors.  Briefly, 
using genome wide association studies the genetic architecture of type 2 diabetes has 
been assembled to a certain degree.  What has been identified are that approximately 
130 gene variants are associated with type 2 diabetes.  Most of these genes, most of 
which are involved with beta cell function, only explain a small proportion (~15%) of the 
observed heritability of this condition (73).  Nevertheless and in contrast to type 1 
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diabetes, the lifetime risk of type 2 diabetes is ~40% if one parent has type 2 diabetes 
and higher if the mother has the disease (128).  The relative risk of siblings developing 
type 2 diabetes is 1 in 3.  The identified risk gene alleles have been used to predict the 
risk of type 2 diabetes. Nevertheless, clinical risk factors such as family history, body 
mass index (BMI) and glucose levels continue to be the best predictive tools.  
Genetics aside, type 2 diabetes develops when β-cells do not produce enough insulin to 
maintain blood glucose homeostasis as a result of the progressive destruction of the β-
cell mass (129; 130) and/or its dysfunction (131).  In type 2 diabetes beta cell 
dysfunction is also often found on a background of increased insulin resistance, mostly 
associated with obesity, a major risk factor in type 2 diabetes.  Insulin resistance is 
associated with ectopic fat in the liver and muscle with evidence for causality.  
Furthermore, Van der Zijl et al. (132) observed that fat also accumulates in the 
pancreas and this may have a pathogenic effect on the β-cells contributing to 
dysfunction.  It should be noted that this area of study is still developing due to difficulty 
in measuring accurately pancreatic fat.  It is recognised that the ectopic visceral fat 
depots produce inflammatory cytokines, which impact both peripherally and centrally on 
insulin sensitivity and secretion.  Not all obese patients develop diabetes, and diabetes 
presents in patients at quite different levels of BMI or body fat.  This is particularly true 
for Asian populations, where the development of type 2 diabetes occurs at a much 
lower weight threshold and at higher levels of visceral fat for any given BMI (133).  
That said, the pathogenesis is more complex than just beta cell dysfunction and 
increased insulin resistance in muscle and liver discussed above.  Contemporary 
understanding includes known defects in many of the other organ systems that impact 
glucose homeostasis.  The gut incretin system has been identified to be defective in 
type 2 diabetes with reduced levels of incretin peptides such as GLP1 (glucagon like 
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peptide 1) and GIP (gastric inhibitory polypeptide) which normally facilitate meal related 
insulin secretion (134; 135).  The incretin system also modulates alpha cell glucagon 
outputs and gut motility.  Incretins appear also to have central effects on satiety. 
Furthermore, the kidney also plays a role in regulating glucose by gluconeogenesis and 
also by renal reabsorption of filtered glucose (136).  This occurs via the SGLT2 
transporters expressed on renal tubules.  These transporters, paradoxically, have been 
found to be upregulated in type 2 diabetes resulting in a maladaptive increase in renal 
glucose reabsorption.  The figure below (Figure 6) reproduced from (137) provides an 
overview of the defects involved in type 2 diabetes pathogenesis and also illustrates the 
site of action of modern pharmacotherapies for type 2 diabetes discussed more fully 
later.  The central areas such as the ventral medial hypothalamus responsible for 
control of appetite and satiety as well as neural outputs also impact on glucose 
homeostasis and are targets for new drug therapy (137).  
  
                                                                                                             82   
 
Figure 6: Pathophysiology and drug targets.  Pleiotropic drug effects are illustrated by the frame and colour 
of the boxes.  Green indicates body weight loss, blue indicates body weight neutrality, and red indicates 
body weight gain. A dotted frame indicates blood pressure reduction and a solid frame indicates blood 
pressure neutrality.  Source (137)  
 
 
2.0 Risk factors for Type 2 Diabetes 
As discussed above, conceptually the development of type 2 diabetes may arise due to 
a non-modifiable inherited genetic susceptibility coupled with modifiable environmental 
and behavioural factors.  These factors are further discussed below. 
2.0.1 Genes 
There is a large body of evidence to support that specific genes are implicated in the 
development of this disease (138).  The strongest evidence base for this arises from 
twin studies where the concordance of type 2 diabetes in monozygotic twins (resulting 
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from the division of a single fertilized egg, which usually share a common chorion and 
placenta) is ~70% compared with 20 to 30 % in dizygotic twins (non-identical twins). 
The challenge has been in finding the specific genetic components that explain this 
familial risk.  The complexity of type 2 diabetes, being a heterogeneous phenotype with 
many underlying aetiological and pathophysiological processes that encompass many 
organs and tissues, presents a difficulty.  To date, a candidate gene approach has been 
unfruitful in identifying type 2 diabetes genes.  With the advent of the Genome-wide 
association studies (GWAS) now over 80 risk loci (the position of a particular gene on a 
chromosome) have been identified from populations including Europids, South and East 
Asians, African-Americans and Hispanics (139; 140).  The majority of the identified type 
2 diabetes genes only have a small effect size; TCF7L2 being the most common risk 
allele for Europeans.  Researchers are currently studying isolated populations in order 
to research the idea that type 2 diabetes in these populations may have a more specific 
genetic aetiology (141; 142).  These populations live in isolated geographical areas or 
have radical lifestyles or religions, which have helped to maintain cultural isolation.  
Examples of such isolated populations are those residents in Greenland who are 
descendants of a small group of Inuit whale hunters who arrived in a single migration 
wave.  The Old Order Amish population is also an example of a religious community 
that did not integrate with the local community in Pennsylvania and continue to marry 
within the community.  By studying these populations which have a simplified genetic 
background, the effect of a fewer number of genes for type 2 diabetes may be amplified 
and thus more easily identified (143).   
As mentioned above, despite a large number of loci being identified, it remains that in 
large populations genes only explain about 15% of the estimated heritability of the 
disease.  Other risk factors, some of these modifiable are discussed below.  
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2.0.2 Ethnicity 
Type 2 Diabetes is prevalent in all ethnicities, but some groups are more affected than 
others.  The Aboriginal and Torres Strait people, Australia’s first nation groups, have a 
disproportionately high rate of diabetes (121; 144). 
The propensity of the indigenous population being more at risk for diabetes (120) is not 
unique to Australia with similar findings reported for other international groups including 
the American Pima Indians, the Canada First Nation, and South Asian indigenous 
groups (145-153).   
Additional information regarding differences in ethnicity and diabetes risk can be 
gleaned from The IDF Atlas which showed the top 10 countries with adult diabetes in 
2015 (Table 8).  
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2.0.3 Family History 
There has been a long-held belief that “diabetes seems to run in families “and twin 
studies have been used to support a genetic origin for diabetes as mentioned prior.  
However, a family history of type 2 diabetes conceptually represents a composite of 
both genetic epigenetic and environmental risk.   
A positive first-degree family history is generally associated with an approximate 2 fold 
increased risk of future type 2 diabetes across the wide spectrum of diabetes 
prevalence globally (154; 155).  For example, Harrison et al. in a comprehensive review 
Table 8; Top Ten Countries/territories for number of people with diabetes (20-79), 2017 and 2045.  Source 
The IDF Atlas (5) 
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of this topic (156) reported that studies in the Pima Indians (a population with high risk 
for type 2 diabetes ) showed that participants with one affected parent were 2.3 times 
more likely to progress to diabetes than participants who did not have affected parents 
(157).  The Honolulu Heart Program, a study of Japanese-American men, similarly 
showed an increased risk of incident diabetes in those with a parental history of 
diabetes (158).  In a report from the EPIC-InterAct (159), the world’s largest study of 
incident T2DM, a case-cohort study within the pan-European EPIC study which has 
gathered 4 million person-years of follow-up (160) reported that a family history of type 
2 diabetes was associated with a higher incidence of the condition with a hazard ratio of 
HR 2.72,( 95% CI 2.48, 2.99), consistent with the Pima data. 
Furthermore, there are parent of origin effects reported for diabetes.  Groop et al. (128) 
showed that there is a lifetime risk of developing the disease of ~40% in offspring if one 
parent has type 2 diabetes, which is greater if the mother is affected.  In Norway 
Bjornholt et al. (161) reported that in a study of men without diabetes followed for 22.5 
years that 7.4% went on to develop diabetes.  In this study the risk of developing 
diabetes associated with a maternal family history was greater than for a paternal family 
history; RR(95%CI) were 2.51 (1.55-4.07) and 1.41 (0.657-3.05) respectively.  The San 
Antonio Heart Study examined a large cohort of Mexican Americans and non-Hispanic 
whites (162).  In this study, there was a difference in parent of origin effects in men and 
women.  In short, men with a parental history of diabetes had a higher prevalence of 
type 2 diabetes and impaired glucose tolerance, regardless of which parent had 
diabetes.  In contrast, for women, only a maternal history of diabetes was associated 
with a higher prevalence of type 2 diabetes and impaired glucose tolerance. 
In many studies and not unexpectedly, the risk for offspring is even greater if both 
parents are affected.  For example, in the study reported by Groop et al. (128) the 
                                                                                                             87   
 
lifetime risk of developing the disease was increased from 40% to 70% if both parents 
have diabetes.  Similar findings have been seen in the Framingham Offspring Study 
(163) where the risk for type 2 diabetes among offspring with a single diabetic parent 
was increased 3.5 fold and for those with two diabetic parents was 6-fold higher 
compared with offspring without parental diabetes.  Interestingly in this study, there was 
a strong signal that the younger the age of onset of the mother, the earlier the offspring 
were diagnosed (Table 9).  Again from the EPIC-InterAct study (159), the greatest risk 
of type 2 diabetes was in those with both maternal and paternal history of type 2 
diabetes (HR 5.14, 95% CI 3.74, 7.07) and those whose parents had diabetes 
diagnosed at a younger age (<50 years; HR 4.69, 95% CI 3.35, 6.58).  This effect was 
more strongly associated with the maternal history of diabetes (164).  
The underlying mechanism that might explain the parent of origin effects on diabetes 
risk are not yet fully elucidated.  Suffice to say maternal diabetes, and especially having 
a mother with diabetes diagnosed at a young age, underscores the potential for 
epigenetic in utero effects of maternal diabetes on offspring (165-167).  It is notable that 
even in monogenic diabetes, the maternal parent of origin infers a risk for earlier age of 
onset (168).  The relationship of intrauterine hyperglycaemia and earlier onset of 
diabetes is of concern given the growing numbers of those with GDM and the poor 
outcomes for younger onset type 2 diabetes, discussed in Part III.  
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Table 9: From Meigs et al. (163); Offspring from young maternal diabetes age of onset are significantly 
younger at diagnosis 
 
  
2.0.4 Age 
Type 2 diabetes has been considered a disease of mature age and the highest 
incidence and prevalence are seen in older age groups (7; 169-172).  The common 
understanding is that the risk of developing type 2 diabetes increases considerably after 
age 45 and this is the age at which distinguished bodies such as the ADA and ADS 
recommend testing for diabetes in the overweight and obese (62; 173). 
 It is notable, however, although still a minority, type 2 diabetes is being seen in 
younger age groups.  Different ethnic groups behave considerably differently from 
Caucasian populations with younger age of onset of diabetes being well documented 
(147; 174-176).  In the context of multicultural Australia with the potential for greater 
numbers of type 2 diabetes in the young, the question arises whether age of onset 
might have an impact on disease outcome.  This is a question addressed by some 
studies in this thesis, the background is discussed more fully in Part III.  
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2.0.5 Obesity  
Obesity is considered to be the key risk factor for the development of Type 2 diabetes 
(177).  In Australia, the rate of obesity (28% of the population aged 15 and over) is 
fourth highest among 34 OECD countries, behind the United States (37%), Mexico 
(30%) and Hungary (29%).  However, the rates of overweight and obesity in children 
and adolescents aged 5-17 have remained stable at 25% (178).   
The SEARCH for Diabetes in Youth Study reported that the prevalence of overweight 
was 10.4% and obesity was 79.4% among the youth with T2DM (179).  Moreover, 
within certain ethnicities, the prevalence of obesity in YT2DM seems to be higher than 
their background non-diabetic populations.  For example, Non-Hispanic white, African 
American and Hispanic youth with T2DM were nearly 4 times more obese than their 
peers without diabetes.  In fact, the issue of obesity and its associations including 
diabetes, hypertension, dyslipidaemia, the components of the metabolic syndrome, in 
the Asia Pacific has been well documented and has become a focus for governments 
due to the socio economic implications for the region (180).  Hillier and Pedula 
described this phenomenon of earlier onset of diabetes which progressively increases 
with obesity, and subsequent work continues to observe this inverse relation between 
BMI and age at diagnosis of type 2 diabetes (181). 
2.0.6 Metabolic Syndrome and Cardiovascular Risk Profile 
As mentioned above, obesity is a common feature of type 2 diabetes and a significant 
risk factor in its pathogenesis.  A concomitant of obesity are the other metabolic 
syndrome features such as dyslipidaemia and hypertension providing a milieu for the 
development of macrovascular disease.  The ‘common soil” in all of this is thought to be 
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insulin resistance mediated largely by abdominal fat deposits, contributing obesogenic 
and inflammatory cytokines that antagonise insulin action. The importance of abdominal 
obesity is reflected in the more recent diagnostic criteria for the metabolic syndrome.  
There have been many different diagnostic criteria for the metabolic syndrome, all of 
which are largely constructs to dichotomise risk.  The most widely accepted being the 
IDF definition of the metabolic syndrome for which abdominal obesity is sine qua non as 
shown in Table 10.  The other diagnostic factors include hypertension, elevated fasting 
glucose, elevated plasma triglyceride and low high-density lipoprotein cholesterol (HDL) 
(182). 
The corollary of these associations are that reduction in obesity, and especially 
abdominal adiposity should be a target for intervention, both in prevention of diabetes 
and in the management of diabetes, with a view to both improving glycaemic control 
and improving CVD risk factor profiles.  
Table 10: Criteria for waist circumference thresholds for diagnosis of Metabolic Syndrome; Reproduced from 
Hillier et al. (181) 
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2.0.7 Obstructive Sleep Apnoea (OSA) 
Sleep, sleep deprivation and sleep-related disorders have been linked to the 
development of insulin resistance and type 2 diabetes through multiple pathways. 
These include a deleterious effect on glucose homeostasis by increasing inflammation 
and an adverse effect on appetite regulation, leading to increased food intake, weight 
gain and ultimately obesity (183). 
Sleep disturbances are common in the community; The 2016 Sleep Health Survey of 
Australian Adults surveyed 1,011adults aged over 18 years across Australia and 
reported that sleep disordered diseases affected 33-45% of adults in this study.  
Furthermore, this study found that a medical diagnosis for the most common sleep 
conditions already existed showing how prevalent disturbances of sleep affect our 
population.  A medical diagnosis for obstructive sleep apnoea (OSA) was present in 8% 
of the sample size as well as other conditions including significant insomnia at 20% and 
restless legs at 18% in adults.  
OSA is described as a condition where there is repetitive cessations of breathing 
(apnoea) or partial upper airways obstructions (hypopneas) occur.   
For the diagnosis of OSA to occur these apnoeas or hypopneas need to occur five or 
more times per hour of sleep (183).  Clinically, the diagnosis of OSA is suspected in 
patients that complain of snoring and disrupted sleep including daytime sleepiness.  
Once a sleep study confirms the diagnosis of OSA the current treatment is interventions 
related to weight reduction and the use of continuous positive airway pressure (CPAP). 
The relationship between type 2 diabetes and OSA is well recognised and obesity and 
age are common risk factors for both.  Patients with OSA are considered at high risk of 
developing diabetes.  In a study of 8678 individuals, the incidence of diabetes was 
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14.9% over 5 years in those with severe OSA (184).  In diabetes populations, OSA is a 
frequent comorbidity and prevalence of OSA have reported in the range of 23.8% -70% 
(185).  Pathophysiologically speaking, patients with OSA and especially those with 
excessive daytime sleepiness (the severity of which is indicated by the Epworth 
Sleepiness scale and Multiple sleep latency test), had higher measures of insulin 
resistance when measured by the homeostatic model assessment (HOMA-IR) (186).  It 
is unknown if the relationship is entirely due to obesity or if there are other significant 
factors contributing. Even in lean individuals, the presence of OSA increases insulin 
resistance (187; 188). 
Additionally, OSA is associated with impaired beta cell function.  Interestingly, pre-
clinical studies (189) have linked periods of intermittent hypoxia to an increase in beta 
cell death resulting in overall beta cell secretory dysfunction.  In these ways, OSA has 
been linked to the main pathophysiological processes leading to type 2 diabetes.    
The impact of OSA on metabolic control has been examined, and the presence of OSA 
has been reported to increase the adjusted mean HbA1c in the range of 0.7-3.7% 
(185).  In type 2 diabetes hyperglycaemia, as indexed by HbA1c, has been shown to be 
related to the degree of nocturnal hypoxaemia but not necessarily to the hypopnoea 
(190).  Furthermore, treatment of OSA with CPAP in small non-controlled studies has 
been shown to improve insulin sensitivity and glycaemia (191), but there is conflicting 
evidence in the literature (192-196).  Suboptimal adherence to CPAP therapy may 
account for variability in studies of treatment efficacy.   
Interestingly, lifestyle intervention in type 2 diabetes improves OSA and specifically the 
Apnoea Hypopnoea Index (AHI), independent of loss of weight. 
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Not only is OSA associated with type 2 diabetes and glycaemia, the presence of OSA 
predicts the progression of some diabetic vascular complications. In a longitudinal 
study, patients with type 2 diabetes and OSA were more likely to develop advanced 
diabetic retinopathy after adjusting for confounding factors.  The OR found was 6.6 
(95%CI 1.2-35.1) (197).  Similar findings were found in a study examining neuropathy 
associations with OSA with an OR of 2.82 (95%CI 1.44-5.52) reported (185).  With 
respect to nephropathy, a study of those with type 2 diabetes, after adjustment for 
confounders demonstrated that the presence of OSA increased the incidence of 
albuminuria or reduced eGFR).  Snoring, as a surrogate for OSA, was independently 
associated with microalbuminuria although data in this area are somewhat conflicting.  
There are fewer data available on the impact of OSA in macrovascular disease and 
type 2 diabetes The LOOK AHEAD study of lifestyle interventions in type 2 diabetes 
showed that the apnoea-hypopnoea index (a quantitative assessment of OSA (198)) 
was associated with self-reported stroke but not coronary ischaemia.  
Thus, OSA is an important comorbidity of type 2 diabetes with increasing evidence of 
an impact on diabetes outcomes.  Future studies are needed on the impact of 
therapeutic treatment on diabetes.  
2.1 Contemporary concepts  
2.1.1 Microbiome 
There is growing evidence that environmental factors such as diet, viruses, bacteria and 
chemicals can influence the development of both type 1 and type 2 diabetes (199).  
Recent interest in gut microbiota, as one of these environmental factors, is predicated 
on evidence of gut microbiota dysbiosis in pre-clinical and human studies.    
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The human GI tract plays host to a large and complex collection of 10-100 trillion 
microorganisms.  The bacteria are the largest group and the most diverse (200).  The 
most common bacterial groups in the human GI tract are Firmicutes (gram-positive), 
Bacteroidetes (gram-negative) and Actinobacteria (gram-positive) [Figure 7].  The 
colonisation of intestinal bacteria in humans begins immediately after birth, and it 
becomes a stable ecosystem around the age of 2 to 3 years.  However, the load and 
diversity continue to increase as we get older and its size and composition vary 
between individuals and during periods of disease. 
The complex microbiota contribute over 100-fold more unique genes than the human 
genome and this genetic potential in our GI tract can impact strongly on health and 
disease.  This collective genome has been dubbed the metagenome.  The advent of 
high-throughput sequencing of the metagenome (metagenomic analysis) allows 
investigators to analyse all the intestinal microbiota of an individual instead of culturing 
individual microbes.  In recent times, metagenomic analysis has been combined with 
the clinical data in metagenome-wide association studies (MGWAS) also including 
studies of diabetes. 
The microbiome is larger than the human genome (200), and it is referred to as an 
“organ” that contributes to overall metabolism and plays a role in converting food into 
nutrients and energy in the human body.  There is evidence from pre-clinical studies in 
mice of a causal relationship between certain intestinal micro-organisms and obesity.  
Turnbaugh and colleagues (201) performed microbiota transplantation experiments in 
mice and showed that the microbiome of obese mice have a greater capacity to yield 
energy from the diet.  Furthermore, this capacity is transferrable because when the 
“obese microbiota” was transplanted in mice with “lean microbiota” these mice had a 
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significant increase in total body fat and the type of micro-organisms changed in the 
“lean” animal’s biota. 
In humans, the micro-organisms appear to have a causal role in decreasing insulin 
resistance, and this was shown by experiments undertaken by Anne Vrieze et al. (202).  
The researchers used the knowledge that the small intestine has an important role in 
carbohydrate and fat uptake.  They infused microbiota from lean donors into obese 
recipients, and after six weeks, the insulin sensitivity of recipients increased as well as 
the levels of butyrate-producing intestinal microbiota.  It has been suggested that 
butyrate, a free fatty acid, prevents the transfer of endotoxins which have been shown 
to cause insulin resistance (203).  Furthermore, butyrate has been shown to prevent 
and treat diet-induced obesity and insulin resistance in mouse models.   In 2013, two 
pivotal MGWAS studies published, in Nature, strengthen the knowledge how intestinal 
microbes are implicated in obesity, metabolic syndrome and type 2 diabetes.  The first 
study by Karlsson et al. (204) used shotgun sequencing (sequencing long DNA strands) 
to characterise the faecal metagenome of 145 European women with normal, impaired 
or diabetic glucose control.  They report observing compositional and functional 
alterations in the metagenome of women with type 2 diabetes, and then developed a 
mathematical model based on metagenomics profile that identified type 2 diabetes with 
high accuracy.  When they applied the model to women with impaired glucose 
tolerance, they were able to identify who had a more specific “blood plasma markers” 
hence being at high risk of developing type 2 diabetes. 
The second study by Qin et al. (205) also in Nature found similar correlations for 
specific intestinal microbes and their genes with type 2 diabetes.  This group studied a 
total of 345 Chinese T2D patients and non-diabetic controls using a case-control 
MGWAS based on deep next-generation shotgun sequencing of DNA of stool samples.  
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Qin et al. showed that patients with type 2 diabetes have a specific microbiota signature 
which is characterised by a decrease in some universal butyrate-producing bacteria and 
an increase in various opportunistic pathogens and other microbial functions including 
sulphate reduction and oxidative stress resistance.  An analysis of 23 additional 
individuals demonstrated that these gut microbial signatures had utility in identifying 
those with type 2 diabetes, an area for further investigation.  De Vos et al. (206) in an 
editorial in Nature points out that both researchers found the presence of fewer 
Clostridiales bacteria that produce the short-chain fatty acid butyrate (Roseburia 
species and Faecalibacterium prausnitzii) and this was highly discriminant of T2D. 
Nevertheless, there were several differences with the Karlsson cohort having high 
Lactobacillus gasseri and Streptococcus mutans, usually found in the mouth and upper 
intestinal tract, in their T2D cohort, whereas Qin et al. found mainly Proteobacteria, 
which may produce inflammatory lipopolysaccharides that lead to endotoxaemia.  De 
Voss et al. assert that these two studies support a model in which when our healthy gut 
bacteria are undermined by infections, use of antibiotics, unhealthy diet and lifestyle, 
the composition of the gut micro-organisms are changed (Figure 8).  In Type 2 
diabetes, these changes affect insulin sensitivity of the liver and muscles. 
Furthermore, these two studies highlight the need for more information in multi-ethnic 
cohort studies, to further establish, if there are major differences in the gut biome of 
different ethnic groups.  These new studies will also need to take age and gender into 
account as they have a significant impact in the ecosystems of the human biota.  It is 
not clear if abnormal microbiota signatures will be used as a predictive/diagnostic tool 
or lead to the development of pro and pre biotics as a therapeutic tool.  Nevertheless, 
studies using MGWAS are taking a step closer to personalising therapy to delay, treat 
or even maybe cure Type 2 diabetes. 
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Reproduced from Vrieze et al. (200) 
 
Figure 7:  Phylogenetic tree representing the groups of bacteria most frequently detected in human faeces 
using 16S rRNA gene sequencing. The extent of the bold areas indicate diversity and abundance of the 
bacterial groups 
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. 
“A model of how the composition of gut microorganisms can influence the health of an individual. The model 
proposes that external factors such as infection or diet alter the healthy, resilient microbial composition to which can 
cause tissue destruction, and ultimately chronic disease.  lf this occurs, it is possible that healthy microbial  diversity 
can be restored, and damaged tissue repaired, only by delivery of specific 'therapeutic' bacteria”; Reproduced from 
de Vos (206) 
 
  
Figure 8: Microbiota in Health and Disease; Reproduced from de Vos 
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2.1.2 Omics 
 Personalised therapy is the goal of every clinician; to be able to deliver for patients the 
best-targeted clinical management plan for their condition.  The great hope of 
personalised and precision medicine has been the study of systems biology and 
“omics”.  Wikipedia (207) states the “…word omics informally refers to a field of study 
in biology ending in -omics, such as genomics, proteomics or metabolomics.  The 
related suffix -ome is used to address the objects of study of such fields, such as the 
genome, proteome or metabolome respectively…”.  Therefore, precision medicine can 
be defined as when the clinical and the omic data combine to lead to better health 
outcome for our patients.  Understanding this new paradigm and linking it to the clinical 
information has provided clinicians with opportunities to step outside generic clinical 
treatment guidelines and be able to provide precision diagnosis in some types of 
diabetes, e.g., monogenic diabetes.  Genetic analysis allows the precise identification of 
these patients with specific molecular defects and avoid their incorrect classification as 
type 1 or type 2 diabetes, often for many decades.  The most striking example of this 
are patients who have MODY1 and MODY3; these patients have a monogenic defect 
affecting insulin-related transcription factors and are clinically sensitive to 
sulphonylureas.  Many of these patients have used insulin for many years only to find 
out that oral therapy such as sulphonylureas are just as effective in their treatment 
(208; 209). 
Another advance has been in the optimisation of treatments in our patients by using 
pharmacogenomics or the study of how genes affect our response to drugs.  This major 
work has led to ways to reduce adverse drug reactions in patients or in identifying why 
some patients respond to some drugs and others not.  For example, Metformin is 
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considered the first line of treatment in diabetes.  It has major clinical advantages over 
other therapies because of its safety record, it does not induce hypoglycaemia or weight 
gain, and has possible cardiovascular benefits (210).  The most common side effect of 
metformin treatment is gastrointestinal (GI) upset, which occurs in ~30% of patients.  
In~5%of patients treated with metformin, GI symptoms are so extreme that the drug is 
ceased (211).  Dujic et al. (212), studied the impact of genetic factors on the 
gastrointestinal intolerance to metformin treatment in the Genetics of Diabetes Audit 
and Research in Tayside Scotland (GoDARTS) study.  The authors examined the 
genotype of two genes, one with potential involvement in metformin absorption (the 
organic cation transporter 1 (OCT1) and a gene involved in enterocyte serotonin 
(serotonin reuptake transporter (SERT).  The authors showed the link between a SERT 
polymorphism and metformin gastrointestinal intolerance in 1,356 tolerant and 164 
extreme metformin-intolerant patients.  The number of low-expressing SERT S* alleles 
significantly increased the odds of metformin intolerance.  Moreover, there was a 
multiplicative interaction between the OCT1 and SERT genotypes, suggesting a 
complex genetic control of metformin intolerance.  These results show how precision 
medicine could inform our management of patients at the front line of drug management 
in diabetes. 
The fundamental manner in which our genome, transcriptome and proteome impact on 
every human structure and can cause pathogenic processes that impact in our health is 
now better understood.   
Big data initiatives have been embraced in science and health care communities with 
the human genome scientists leading the way in many ways.  Fundamentally, under big 
data projects the disparate knowledge of the human genome is harnessed in an 
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organised way.  These data combined with clinically routine collected data can lead to 
faster and more precise clinical and public health solutions (213; 214). 
To this point, Floyd and Psaty (215) in a review of the application of genomics in 
diabetes, point out that for genomic information to be integrated into clinical practice it 
requires strategies to ensure that both clinicians and patients understand how these 
data can enhance clinical outcomes.  Furthermore, it is important to understand some 
of the limitations of electronic health care data that can impact directly on genomic data.  
For example, disease diagnostic codes associated with each health care encounter are 
assigned for billing and clinical description of the encounters.  Data collected in the 
electronic health record is representative only of the required information to dispense 
clinical care in an occasion of service, and it may not include a complete medical 
history.  Neither of these data are collected for research purposes; hence, the use of it 
without further validation in studies including the human genome may be fraught with 
problems.  Notwithstanding, electronic health records need to be developed in a way 
where research is an integral part of the clinical encounter and the data collected is able 
to be harvested in a standardised and meaningful manner.   
2.2 Treatment of Type 2 Diabetes 
Guidelines for the medical management of type 2 diabetes are widespread and expert 
bodies including the European Association for the Study of Diabetes (EASD),  American 
Diabetes Association (ADA) and Australian Diabetes Society (ADS) have published 
guidance in this regard (216-219). These have been reviewed recently by all expert 
bodies in light of new data from cardiovascular outcome trials.  This section provides an 
overview of the medical management of type 2 diabetes.  Lifestyle management, 
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including medical nutrition therapy as a component of lifestyle intervention, is 
recommended with individualised eating styles and calorie intake in the context of 
exercise and activity and body weight goals established in the context of personal and 
cultural preferences.  Pharmacotherapy is advised either following a period of lifestyle 
modification or at diagnosis.   
Practitioners are encouraged to elect an individualised HbA1c glycaemic target.  The 
generic target is ≤ 7% (≤ 53 (mmol/mol) with lower targets considered depending on 
duration of disease, life expectancy and hypoglycaemic risk.  Similarly, more relaxed 
targets for those with long standing disease, high CVD burden, risk of hypoglycaemia 
and reduced lifespan are recommended.  Adherence, occupation and patient 
preference are also considerations (219).  
In terms of pharmacotherapy treatment options are diverse.  The preferred initial agent 
in most guideline algorithms is metformin and second line agents are added if HbA1c 
targets are not reached.  Other therapeutic options are sulphonylurea agents, 
thiazolidinediones and acarbose.  More recently, newer classes of agents have become 
available.  The dipeptidyl peptidase‐4 (DPP-4) inhibitor and glucagon-like peptide-1 
receptor agonists (GLP1 RA) agents are active on the incretin system with pleiotropic 
effects including glucose lowering, reducing blood pressure, reducing glucagon release, 
increasing satiety and reducing gastric motility.  The sodium-glucose co-transporter 2 
inhibitors (SGLT2-i) class of medications act to reduce renal tubular reabsorption of 
glucose to lower HbA1c and have the added effect of reducing body weight and blood 
pressure. 
 It is notable that most recent cardiovascular outcome trials for DPP-4 show no effect on 
major adverse cardiac/cardiovascular events (MACE) outcomes however so far GLP-
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1RA and SGLT2-I cardiovascular outcome trials (CVOTs) have shown significant 
benefit for MACE outcomes independent (largely) of glycaemic control.  Trials of newer 
agents are ongoing, and these findings are likely to change treatment algorithms, 
especially for those with increased CV risk.  In addition to pharmacotherapy, bariatric 
surgery has shown benefit over medical therapy across a short timespan (220). 
2.3 Treatment Efficacy  
The UKPDS investigated outcomes for type 2 diabetes in those with high or lower 
glucose (intensive therapy achieving an HbA1c of 7%).  At the end of the 10 year, study 
there was an approximate 25% reduction in microvascular endpoints in the intensive 
therapy group.  In the epidemiological follow-up study, despite a loss of glycaemic 
differences after study close out, a continued reduction in microvascular risk was found 
for the intensively treated group (which was deemed to be a legacy effect of intensive 
treatment), and emergent benefits were seen in respect to mortality and MI.  
The Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled 
Evaluation (ADVANCE)(221), Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) (222) and Veterans Affairs Diabetes Trial (VADT) (223) studies were set up 
to investigate the question of whether excellent control by further lowering glucose is of 
particular benefit in established high risk type 2 diabetes. These studies confirmed the 
microvascular benefit seen in the UKPDS study, but the results on macrovascular risk 
and mortality were largely disappointing.  The ACCORD study was terminated early 
with the finding of an excess of deaths in the intensive treatment arm, which is still 
unexplained.  These trials have had added to the impetus to individualise HbA1c targets 
especially for those with high CVD risk.  
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In addition to hyperglycaemic management, management of blood pressure has been 
shown to delay diabetes related complications, especially renal related complications. 
The achievement of LDL lowering with statins and ezetimibe is recommended, and 
arguably, fenofibrate has been considered in the context of hypertriglyceridemia, 
especially for secondary prevention.  The Steno diabetes trial confirmed that this 
combined risk factor approach has a significant positive impact on survival in high risk 
patients (224). 
 2.4 The Complications of Diabetes 
Diabetes complications are diseases or conditions that can be broadly divided into 
macrovascular complications; disease of the large blood vessels leading to 
cerebrovascular, cardiovascular and peripheral vascular disease and microvascular 
complications; disease of the small blood vessels which typically include retinopathy, 
nephropathy and neuropathy.  People with diabetes are at higher risk of complications 
with increasing duration of the disease.  What follows is an overview of the general field 
of diabetic complications that can occur in diabetes in the next few pages and with 
particular emphasis on diabetic retinopathy, a topic for study in this thesis. 
2.4.1 Microvascular Complications 
2.4.1.1 Diabetic Retinopathy 
2.4.1.1.1 Epidemiology, Prevalence and Incidence 
Diabetic retinopathy (DR) is a common complication of diabetes which causes 
considerable morbidity.  It is a specific microvascular complication of both type 1 and 
type 2 diabetes.  In the landmark UKPDS study of newly diagnosed type 2 diabetes, 1 
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in 3 patients had a diagnosis of retinopathy at baseline (225) and the IDF atlas (7) 
states “that DR affects over one-third of all people with diabetes and is the leading 
cause of vision loss in working-age adults”.  Wong et al. (226) in a review of DR states 
that whilst diabetic retinopathy is present in 30% of people with diabetes, only 5 to 10% 
of them will develop the sight-threatening states of proliferative DR and diabetic 
macular oedema (DMO).  Furthermore, in two seminal Wisconsin epidemiologic studies 
of diabetic retinopathy, it was calculated that the lifetime risk of developing DR was 50-
60% in type 2 and up to 90% in type 1 diabetes (227; 228).  It is postulated that these 
risks are an overestimation as management of retinopathy has significantly changed 
since these papers were published.  Yau et al (229) in a meta-analysis of 35 studies 
with 22,896 individuals with both type 1 and 2 diabetes, from the U.S., Australia, Europe 
and Asia, after controlling for methodologies and outcome definitions, reported that the 
age-standardized prevalence was 35.4% for any DR, 7.24% for proliferative diabetic 
retinopathy (PDR), 7.48% for DMO, and 11.7% for vision-threatening diabetic 
retinopathy (VTDR).  The authors then extrapolated these prevalence rates against the 
2010 world diabetes population, and estimated that 92.6 million adults had any type of 
DR, 17.2 million had PDR, 20.6 million had DME, and 28.4 million had VTDR.  The size 
of the problem worldwide is alarming considering that diabetes eye disease has a 
significant impact on an individual’s health and well-being and given many are unable to 
work as a result.  Furthermore, DR has a significant impact on the health budgets of 
individual countries as diabetes is still the primary reason for blindness globally (7; 229).   
The incidence and progression of DR is of considerable importance as it can guide 
policy in relation to appropriate screening of populations.  To this end, there have been 
a number of studies worldwide that have informed this particular issue.  Burger et al. 
(230) studied a population of 231 young type 1 patients (mean age 17.6± 4.0 years) 
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with a mean duration of diabetes of 8.5 ± 4.9 years for a period of 5 years.  At the study 
end, the authors reported that 47% of the participants with no DR at baseline had 
developed retinal changes and found that the median interval between the 'onset' of 
retinopathy, (as indicated by the finding of a few microaneurysms and background 
retinopathy) was 5 years.  In the Wisconsin study, it was reported that the 10 year 
incidence of DR in type 1 was 74% increased 97% to after 25 years (231).  In type 2 
diabetes one of the largest incident studies published was done in England where 
Jones et al. (232) followed 20,686 people with type 2 diabetes, managed in primary 
care, who underwent annual retinal photography up to 14 times between the years of 
1990 and 2006 in a community screening programme.  The authors found that the 5 
year cumulative incidence in T2DM patients (calculated by dividing the number of new 
cases of a disease in a population during a specific period of time (the numerator) by 
the total number of people at risk of developing the disease in that population during the 
same period of time (the denominator) with no DR at baseline to pre-proliferative DR 
was 4% and it increased at 10 years to 16.4%.  In Australia, the Blue Mountains Eye 
Study undertaken by Cikamatana et al. (233) examined 3654 residents of the Blue 
Mountains area aged 49 years and above.  Of these, 284 had diabetes (mostly type 2 
diabetes) and after 5 years of follow up 150 patients were re-examined.  The difference 
in subject numbers was accounted for by those who had died (24.3%) or were lost to 
follow up.  The authors reported a 5 year cumulative incidence rate for DR of 22.2% 
(see Table 11) and the rate of DR progression was reported to be 25.9% in this cohort.  
In Hong Kong, Song and colleagues reported a 4 year cumulative incidence of 15.2% in 
5,160 patients with type 2 diabetes mellitus who attended at least two diabetic 
retinopathy screening sessions.   
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Overall, there are differences in the prevalence and incidence of DR amongst all 
studies, and these can be attributed to differences in methodologies used, such as a 
handheld ophthalmoscope, non-stereoscopic photographs vs non-mydriatic retinal 
photography as well as the number of subjects involved in the studies.  Nevertheless, 
more recent studies point to a reduction in the prevalence and incidence of DR 
particularly in type 1 diabetes (234-236).  This may be attributed to a better 
understanding of the causes of DR and more targeted treatment of diabetes risk 
factors, specifically, hyperglycaemia, hypertension and lipids.  Public health campaigns 
by diabetes organisations may have contributed to a better understanding of the need 
to seek treatment earlier and the need to screen all patients for retinopathy at diagnosis 
and thereafter at regular intervals.  One important caveat in this picture is that for 
patients in rural areas and in poorer countries the access to screening is limited or non-
existent, leaving these patients still at high risk of developing significant DR (237; 238).  
 
Table 11: Table from the Blue Mountains Eye Study (233): CI calculated only on those patients that the study 
examiners had both images at baseline and 5 years later 
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2.4.1.1.2 Retinopathy Risk Factors 
Long standing duration of diabetes, hyperglycaemia and hypertension are considered 
the most recognised and studied risk factors for DR (225; 226; 237; 239-241).  It is 
interesting that despite persistent hyperglycaemia not all patients with long standing 
diabetes go on to develop DR, hence hyperglycaemia and hypertension may not be the 
only factors involved in this process, and there may be unknown protective 
factors.  Most of the literature states that >90% of patients with type 1 diabetes, after 20 
years of diabetes, will develop some form of DR (227; 228) and this is in the context of 
hyperglycaemia, but Keenan et al. (242) studied a group of patients that had more than 
50 years of diabetes.  These patients were identified from the 50-Year Medal Program 
of the Joslin Diabetes Centre, and against a background of a long duration of 
hyperglycaemia, only 47.9% of these survivors were found to have retinopathy.  The 
remainder without diabetic retinopathy were older, had longer diabetes duration, and 
had lower triglyceride levels.  Although a survival bias could explain these results, i.e. 
those with retinopathy would have died earlier, these results also suggest that other 
factors must be at play in the development of DR.   
Nevertheless, hyperglycaemia has long been associated with the development of DR in 
pre-clinical and clinical studies.  In ground-breaking clinical trials such as the Diabetes 
Control and Complications Trial (DCCT) in type 1 diabetes and the United Kingdom 
Prospective Diabetes Trial (UKPDS) for type 2 diabetes patients, participants were 
randomised to intensive treatment or conventional treatment.  In both studies the 
intensive treatment arm showed reduced amounts of retinopathy; in the 
DCCT(243; 244) there was a 76% reduction in the mean risk of development of 
retinopathy whilst in the UKPDS (239) there was a 21% risk reduction to the 
progression of retinopathy (245).  
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Interestingly, in both trials after study closeout, in both the intensive and conventional 
groups, diabetes control as measured by HbA1c converged.  In the case of the DCCT 
(236), the conventional group HbA1c improved, and in the UKPDS the intensive group 
regressed towards the conventional treatment arm.  When both groups were surveyed 
years later the intensive groups in both trials continued to develop retinopathy at a 
lower rate than their counterparts.  This gave rise to the concept of “metabolic memory” 
and “legacy effect” leading to a change in the paradigm of diabetes management; 
clinicians now aim to intensify treatment from diagnosis and to maintain the lower 
HbA1c by a more intensive management of oral and injectable treatments.  This same 
occurrence has now been observed in pre-clinical studies of retinopathy in different 
animals models (246).  Studies of epigenetic regulation in the development of 
retinopathy show that detrimental effects associated with hyperglycaemia persist 
despite subsequent normalisation of glucose.  Such studies are in support of the 
metabolic memory and legacy effects seen in human studies.   
Without a doubt, the management of hyperglycaemia has a central role in the 
prevention and treatment of diabetes eye disease, but dyslipidaemia has also been 
considered to play an important role (247) although the evidence is less conclusive.  
The Wisconsin Epidemiology study of diabetic retinopathy (248) originally reported an 
association between total cholesterol and hard exudates.  In a follow up study of these 
patients, 30 years later, published in 2015 (249) the authors reported that there was no 
association between total cholesterol and HDL in the incidence of DR and macular 
oedema and concluded that the type of serum lipids studied may not be implicated in 
the development of DR and DMO.  However several other studies both in type 1 and 
type 2 diabetes report that patients with severe visual loss have persistently higher TC, 
triglycerides and LDL.  This is the case for the Early Treatment Diabetic Retinopathy 
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Study (ETDRS) (250) original study, and subsequent follow-up study as well as the 
Pittsburgh Epidemiology of Diabetes Complications (EDC) (251).  In the DCCT cohort, 
Miljanovic et al. (252) reported that the total cholesterol to HDL ratio and LDL could 
predict the development of clinically significant macular oedema and hard exudates.  
However, the authors also found that once adjusted for glycaemic control lipid profile 
could not predict the progression and development of DR.  In an up-to-date review of 
lipids and diabetic retinopathy, Modjtahedi et al (253) suggest that apolipoprotein 
subclasses may be more sensitive than conventional lipid profiles in detecting a 
relationships with retinopathy and may be more implicated in the pathogenesis of DR.  
This may occur by transient damage occurring to the blood retina barrier allowing for 
lipoproteins to escape to the intra-retinal environment where they are remodelled 
causing damage into this space, contributing to the development of DR.   
Hypertension control was examined as an independent risk factor for DR in the UKPDS 
study.  It reported that tight blood pressure control showed a clinically significant risk 
reduction in the progression of DR (239; 245).  Do et al. (254) undertook a Cochrane 
Review on the topic of blood pressure control for diabetic retinopathy and found some 
mixed evidence.  They found that treating blood pressure may prevent DR for up to 4 to 
5 years but also found that there is a lack of evidence with regard to retarding the 
progression of DR. 
These findings suggest that there must be several mechanisms involved in the 
development of DR with the primary cause being the metabolic effects of long standing 
hyperglycaemia which leads to vascular changes and subsequent retinal injury and 
ischemia.  Nevertheless, hyperglycaemia may only explain up to10% of the risk of 
developing DR (255), and hypertension and dyslipidaemia combined may explain <10% 
risk.  Clearly, there are some less defined risk factors for retinopathy yet to be identified.  
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In addition, puberty and pregnancy are also important risk factors in the development of 
DR especially in type 1 diabetes (256; 257).  At puberty Mitchell et al (258) suggests 
that the marked increase in growth hormone (GH) is the underlying cause of 
development of DR.  In pregnancy Mallika et al. (259) suggested that retinal 
autoregulation may be modified by the pregnancy-related hormonal changes, and 
volume and cardiac output increases leading to the worsening of retinopathy.   
2.4.1.1.3 Pathophysiology of DR 
Diabetes retinopathy is a complex progressive condition that can be dormant for many 
years without any clinical symptoms and when discovered can be quite advanced.  
Thus far, molecular and biochemical pathways have been described and shown to be 
involved in this disease development, but the actual mechanism by which the disease 
develops is still not fully known.     
The biochemical pathways in DR, mostly linked to glycaemia that have been 
established are as follows: 
Polyol or sorbitol pathway:  Responsible for metabolising excessive glucose.  This 
pathway is under the control of two enzymes.  The first is the aldose reductase enzyme 
that converts excessive glucose to sorbitol.  The second enzyme is sorbitol 
dehydrogenase which has the role of converting sorbitol to fructose.  Sorbitol is not 
soluble, and the process of converting sorbitol to fructose is slow and leads to the 
accumulation in the retinal cells which cause damage. 
Advanced glycation end products (AGEs):  When proteins are exposed to glucose for a 
significant amount of time it leads to a reaction where the glucose becomes attached to 
the protein and through cross-linking damages the protein and produces AGEs.  The 
                                                                                                             112   
 
production of these products is accelerated in the presence of diabetes due to the high 
level of glucose.  AGEs, when found in retinal membranes, is associated with most 
complications including DR. 
Protein kinase C (PKC):  Hyperglycaemia causes an increase in diacylglycerol (DAG) 
which in turns increases the expression of PKC.  PKC then increases the expression of 
transforming growth factor beta (TGFB) and endothelial growth factor (VEGF).  These 
two products are implicated in the development of macular oedema and new vessel 
formation.   
Oxidative stress:  This condition occurs when there is an imbalance between the 
reactive oxygen species (ROS) and the ability of the cells to neutralise the ROS using 
antioxidants.  Oxidative stress damages cells and contributes to the development of 
many diseases such as DR.   
Hexosamine pathway: This pathway is triggered when there is an excess of intracellular 
glucose that cannot be dissipated by glycolysis.  When glucose is high in the cells, 
glucose is converted to glucose-6-phosphate and subsequently leading to an increased 
flux of fructose-6- phosphate to the hexosamine pathway. Activation of hexasamine is 
implicated in retinal capillary apoptosis by altering protein function and gene 
expression.  
Inflammation:  Early and late stages of retinopathy appear to be related to an 
inflammatory process in the retina (260).  It is known that hyperglycaemia, oxidative 
stress and AGEs contribute to the inflammatory process but inflammation per se then 
creates a self-propagating cycle that keeps stimulating the other pathways.  Chronic 
inflammation also involves the production of vascular endothelial growth factor (VEGF) 
in the retina leading to angiogenesis of new weak vessels which have a propensity to 
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leak.  This leads to the appearance of haemorrhages in the retina and leukostasis 
(leukocyte adhesion to endothelial cells) which causes capillary obstruction and non-
perfusion. 
Overall, there are many biochemical and molecular pathways that lead to the 
development of DR; it is not the result of a single common pathway.  Nevertheless, to 
date, the established, most effective treatment is the use of anti-VEGF therapy.  This 
will be discussed further on. 
2.4.1.1.4 Evaluation of the Retina in Diabetes 
The retina in diabetes can be visualised using a hand-held ophthalmoscope after 
applying dilating drops or by taking colour photographs of the fundus using a camera or 
slit lamp.  In the ETDRS study 7 standard field colour photographs, using 35 mm colour 
film able to visualise 30 degrees of the fundus each was used.  Since then, 
photographs have become a validated international standard for the classification of 
DR.  From this study, what has been termed “the modified Airlie House” classification of 
diabetic retinopathy has been the accepted method for determining severity and 
grading DR.  In more recent times, ultra-wide field colour photographs and fluorescein 
angiograms can now capture over 80% of the retina in a single image giving an 
assessment of what is happening in the periphery of the retina.  Silva et al (261) 
showed that in a cohort of 200 eyes (100 participants) in a longitudinal prospective 
study that the presence and severity of peripheral lesions is predictive of worsening DR.  
The use of retinal photographs to visualise the retina at a cellular level is also now 
available using adaptive optics technology (262).  Studies using this type of technology 
have allowed for the imaging of early vascular changes that have not been able to be 
captured on standard images or ophthalmoscopy.  
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Optical coherence tomography (OCT) is another tool for monitoring retinal changes in 
patients.  OCT uses interferometry (techniques in which electromagnetic waves are 
superimposed causing interference in order to extract information) to differentiate 
individual retinal layers.  It allows for the measurement of retinal thickness and 
morphologic changes in eyes including DR and DMO.  
A newer wave of screening tools in the diabetic eye include electroretinography that can 
demonstrate abnormalities in retinal electro signalling.  These devices such as 
RETeval-DR (263) use 3 parameters to assess normality or abnormality in the retina.  
RETeval-DR first measures the implicit time that it takes the retina to respond to each 
flash of lighting.  As the eyes become more ischaemic the time response increases.  It 
also measures the amplitude of the response or the strength of the response to the 
flashlight.  The amplitude will decrease with disease progression.  Lastly, it looks at 
change in pupil size between the dimmest and brightest flash.  As disease progresses, 
the pupils will change less.  Overall, electroretinography devices are currently not 
sensitive or specific enough for DR or DMO grading, but they are a useful tool in 
screening by streamlining referral of patients to eye services when digital photographs 
are not available. 
2.4.1.1.5 Classification of DR 
DR is classified in two broad categories; the early stage referred to as non-proliferative 
DR (NPDR), or the advanced stage referred to as proliferative DR (PDR).  NPDR 
clinical features include microaneurysms, retinal haemorrhages, intra-retinal 
microvascular abnormalities (IRMA) and venous calibre changes.  PDR, on the other 
hand, is characterised by new blood vessel growth (neovascularisation), which can lead 
to severe complications and blindness.   
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Diabetes macular oedema (DMO) is a condition that can occur in both NPDR and PDR, 
and is the leading cause of vision impairment with diabetes and occurs when fluid 
accumulates leading to abnormal retinal thickening and cystoid oedema in the macula. 
2.4.1.1.6 Treatment  
Minimising vision loss in the presence of severe retinopathy is the holy grail of diabetes 
eye management.  Overall, we have few treatment modalities to use, and these include: 
Laser photocoagulation:  Argon-Laser retinal photocoagulation therapy was introduced 
in the 1960s and was the first treatment that provided an effective mean of preventing 
visual loss and has been the standard treatment for PDR and DMO (264).  The use of 
this methodology was underpinned by 2 randomised clinical trials, the Diabetic 
Retinopathy Study (DRS) (265) and the Early Treatment Diabetic Retinopathy Study 
(ETDRS) (266).  The DRS showed a reduction in risk of severe vision loss from 33% 
down to 13.9% at 5 years in patients with proliferative or severe non-proliferative DR 
whilst the ETDRS showed a risk reduction from 24% down to 12% on those with 
clinically significant DMO.  The mechanism of action of laser on the retina is not fully 
understood (226), but the authors postulate that the laser scars lighten hypoxia and 
this, in turn, affects the haemodynamics of the retina.  The goal of patients receiving 
laser has been to preserve useful vision and prevent blindness.  Reversal of visual loss 
is rare, and laser photocoagulation has significant side effects.  In a paper by Deschler 
et al. (267) a comprehensive review of side effects was undertaken by the authors.  
Some of these included severe pain during the procedure, worsening of macular 
oedema following laser therapy, loss of peripheral visual fields and reduction in night 
vision, decreased colour vision and contrast sensitivity.  Moreover, there is a high 
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chance for laser burns to be deployed to other sites in the macula leading to damage of 
the macular and of other structures nearby such as lens etc.   
Intravitreous steroid:  The intraocular injection of steroids became part of the suite of 
treatments for DR and DMO in the 2000s as a way of trying to suppress inflammation 
and was particularly directed at those patients who were not responding to laser 
therapy.  This form of treatment is mostly directed at patients with chronic DMO and 
who have undertaken previous cataract extraction as the use of steroids increase the 
risk of cataract.  In 2011, Elman et al. (268) reported in a clinical trial that the benefits of 
intravitreal triamcinolone did not persist beyond 1 year, and by 2 years the visual 
outcome was generally not better than laser photocoagulation.  Moreover, there are 
considerable adverse events with the use corticosteroids; more cataracts as mentioned 
but also glaucoma and an increased risk to eye infections due to the 
immunosuppressive properties of the drug.   
Intravenous injections of anti-VEGF: This type of injectable therapy has been highly 
effective in regressing PDR and can be considered a turning point in the treatment of 
severe DR and DMO.  Anti-VEGF therapy works by restoring the integrity of the blood-
retinal barrier by stopping the formation of small, leaky, abnormal blood vessels in the 
eye (269).  This drug in clinical trials has been shown to have achieved the same visual 
acuity (VA) as the subjects treated with laser photocoagulation at the end of the 2 year 
trial (241; 270).  Furthermore, it is reported that patients achieved a better average VA, 
less peripheral visual field loss, decreased rates of new DMO onset and fewer 
vitrectomies over the 2 year period.  Nevertheless, some patients find it difficult to 
adhere to the treatment routine of monthly injections into the eye. 
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Vitreoretinal Surgery:  Although new modalities of treatments such as laser and anti-
VEGF therapy appeared to have been the answer to so many patients with very severe 
eye disease, for a smaller group that has not responded pars plans vitrectomies are an 
option (271).  These group of surgeries are conducted in patients where vitreous 
haemorrhages do not get reabsorbed or who have retinal detachments mainly due to 
the fibrous bands that appear with the onset of new vessels on the retina or require 
peeling of the epiretinal membrane amongst others conditions.   
The current guidelines for the management of DR and DMO have been evolving with 
the introduction of therapies such as anti-VEGF.  This is most relevant in those with 
DMO, and where it involves the fovea, and there is vision loss, anti-VEGF is the first 
line of treatment.  Laser therapy remains still an important tool in DMO not involving the 
central vision and in PDR with steroid therapy being the last resort therapy (226). 
Despite improvements in glycaemic and blood pressure control of our patients and an 
overall better understanding of the management of complications in diabetes, DR 
continues to be diagnosed, and it will continue to increase as more people are 
diagnosed with diabetes.  This is particularly important in countries in Asia and Africa 
where health resources are scarce, and there is less chance for early screening of DR.  
In countries such as Australia it is important to continue to develop systems where the 
screening of our patients in the community is integrated in the ehealth record so that 
gaps in clinical care are minimised. This is the focus of a study presented in Chapter 7. 
2.4.1.2 Diabetic Nephropathy 
Diabetic nephropathy occurs in approximately 30% of patients with type 1 diabetes and 
up to 40% of individuals with diabetes (272; 273) and is the leading cause of chronic 
kidney disease (CKD) worldwide.   
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CKD refers to all kidney conditions that are present for ≥3 months, and the most severe 
form of this condition is referred to as end-stage kidney disease (ESKD).  At this stage 
patients will require dialysis or kidney transplantation to survive.  In Australia in 2014, 
there were around 22,100 people with treated ESKD—55% of patients were on dialysis 
while 45% were living with a transplanted organ (274).  CKD can be asymptomatic with 
up to 90% of all kidney function lost before patients become aware of symptoms (274).  
The diagnosis of CKD is considered when persistently abnormal urine albumin 
excretion, defined as urine ACR > 2.5 mg/mmol in males or > 3.5 mg/mmol in females 
and/or estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2 is found (273) .   
CKD is categorised into 5 stages where 1 is the least amount of kidney disease, and 5 
is the highest.  These categories are arrived at by using biological markers such as the 
blood and albumin in the urine described above.  Table 12 (275) shows the different 
categories and levels of markers required for categorisations. 
The pathophysiology of diabetes related CKD is complex and with molecular and 
biological pathways described.  It includes glomerular hyperfiltration caused by 
haemodynamic changes related to systemic blood pressure changes or at the local 
level within the kidney.  The haemodynamic changes occur due to alterations in the 
metabolic milieu with the release of vasoactive factors, alterations in cell signalling and 
others.  These changes in diabetes lead to glomerular hypertrophy, glomerulosclerosis, 
and tubule-interstitial inflammation and fibrosis (272; 276). 
2.4.1.2.1 Treatment 
In addition to excellent glycaemic control being the major preventative factor and a 
means of retarding the progression of CKD, control of blood pressure is also of 
paramount importance.  Renin-angiotensin-aldosterone system (RAAS) blockade is first 
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line therapy in the context of diabetes and Ca antagonists have shown benefit.  Newer 
agents such as the SGLT2i show some renal benefit but these observations are 
awaiting RCT outcomes for confirmation these data needs to be updated in light of 
recent renal outcome trials.  It is clear from the ONTARGET study the ARB and ACEi 
combination therapy is not of benefit and may accelerate renal function decline. 
Table 12: CKD categories.  From AIHW (275) 
2.4.1.3 Diabetic Neuropathy 
Neuropathy is a group of disorders that can affect up to 50% of patients with diabetes 
(277).  Diabetic neuropathy can be divided into acute reversible neuropathy and 
persistent neuropathies.  Persistent neuropathies form a large group of pathologies that 
cause considerable morbidity and mortality and can be broadly divided into two 
categories: distal symmetrical or peripheral neuropathy, which can be subdivided into 
focal and generalised; and autonomic neuropathy.  The focal and multifocal 
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neuropathies include carpal tunnel syndrome, ulnar nerve compression at the elbow, 
and diabetic amyotrophy of the femoral nerve, III and VI cranial nerves and truncal.   
Autonomic neuropathy can include orthostatic hypotension, erectile dysfunction and 
gastroparesis.  Peripheral neuropathy can be asymptomatic in up to 50% of patients 
and if not recognised and managed, patients are at high risk of suffering devastating 
foot injuries and amputations (278).   
The main clinical features of distal symmetrical or peripheral neuropathy include 
bilateral symptoms, predominantly loss of sensation in the distal lower extremities, and 
neuropathic pain.  To date, the only strategy to prevent or delay nerve damage in 
neuropathy is to tighten glycaemic control conceding that it will not prevent nerve cell 
loss.  The evidence for tightening glycaemic control is stronger in type 1 diabetes and 
only moderate for type 2 diabetes (279-281).  Currently, Pregabalin and Duloxetine are 
the two pharmacologic drugs recommended for the treatment of neuropathic pain (279). 
Papanas and Zigler (280) in a review of risk factors and comorbidities in diabetic 
neuropathy list duration of diabetes, hyperglycaemia, age, hypertension, dyslipidaemia 
and obesity as the major risk factors and cite additional risks as height, smoking, insulin 
resistance and hypo-insulinaemia.  Furthermore, the authors suggest that 
hyperglycaemia, hypertension, dyslipidaemia, smoking and obesity are the only 
modifiable risk factors currently for patients to minimise this complication.   
ADA (279) recommends that a medical history and clinical tests should be done in all 
patients with type 1 diabetes with >=5 years duration and all patients with type 2 
diabetes annually for peripheral neuropathy.  These tests assess both the small and 
large nerve fibres function and how insensate the feet are.  They help predict future risk 
of complications and the presence or absence of an abnormality or impairment in the 
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feet.  Screening and monitoring of patients with peripheral neuropathy is the 
cornerstone of managing our patients.  Small fibre function can be monitored by using 
pinprick and temperature sensation, and for large fibre function, vibration perception, 
ankle reflexes and the 10g monofilament is used.  The 10g monofilament is the 
suggested test to estimate the loss of protective sensation. 
2.4.2 Macrovascular Complications 
Macrovascular disease are diseases of the circulatory system and affect the heart and 
any large blood vessels in the human body.   
2.4.2.1 Cardiovascular Disease 
Cardiovascular diseases (CVD), broadly includes stroke, transient ischemic attacks 
(TIA), angina, myocardial infarction, claudication, and critical limb ischemia and are 
major healthcare issues in both developed and developing countries.  Cardiovascular 
disease appears to have decreased in the last decades, and this has been attributed to 
better health care including the use of statins and aspirin (282-284).  WHO states that in 
2015 CVD was the number one cause for deaths implicated in 31% of all deaths 
globally (285).   
The risk factors for CVD include non-modifiable ones such as age, gender and family 
history and life long behavioural issues such as tobacco and alcohol use, physical 
inactivity, and poor diet amongst others.  These risk factors lead to the diagnosis of 
hypertension, dyslipidaemia, obesity and diabetes and in an individual the greater the 
number of these risk factors the higher the chance of heart attack or stroke.  Diabetes is 
associated with an increased risk of CVD due primarily to atherosclerosis, i.e. deposits 
of plaque lining the artery (282; 284; 286; 287).  The mechanism by which 
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atherosclerosis develops is unclear, but it appears to be the result of chronic 
inflammation and injury to the arterial walls.  This process leads to the narrowing of all 
the artery walls in the human body resulting in a decrease in blood flow to heart 
muscles (leading to heart attack), brain (leading to stroke) and to the extremities 
(leading to pain, poor healing of foot ulcers and later amputation).    
2.4.2.2 Cerebrovascular Disease - Stroke 
Cerebrovascular disease or stroke is the leading cause of disability worldwide and the 
second primary cause of death in people aged >60 years and in those aged 15 to 59 
years, the fifth leading cause of death (288).  The disabilities that patients suffer from 
stroke include paralysis, loss of vision and confusion.   
Stroke occurs when a) a clot either obstructs blood flow to the brain referred to as 
ischaemic stroke or b) when a blood vessel ruptures and prevents blood flow to the 
brain referred to as haemorrhagic stroke.  Transient ischaemic attacks (TIA) are 
temporary partial blockages of the blood vessels and predispose patients to having 
strokes. 
There is a plethora of information in epidemiologic studies that indicate that diabetes is 
an independent but modifiable risk factor for both ischemic and haemorrhagic stroke 
and it confers a higher mortality in a diabetic population (289-292). 
2.4.2.3 Peripheral Vascular Disease 
Peripheral vascular disease (PVD) or peripheral artery disease (PAD) is defined as 
narrowing of the lumen of arteries causing a reduction in circulation and in the arteries 
to the legs, pelvis and less commonly the arms.  PAD is linked with an increased risk of 
lower extremity amputation.   
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Data from the UKPDS showed that the glycaemic control and duration of DM are 
significant predictors of both the incidence and the extent of PAD.  In this study, each 
1% increase in HbA1c was correlated with a 28% increase in the incidence of PAD, and 
higher rates of death, microvascular complications and major amputation (293; 294).   
The usual symptom of this condition is pain in the legs whilst undertaking some physical 
exertion, and this is relieved by rest.  Simple tests such as an assessment of pedal 
pulses and ankle brachial index in conjunction with history taking for symptoms can be 
undertaken to assess for PAD. 
2.4.3 Non Traditional Complications  
2.4.3.1 Cognitive Dysfunction 
It is known that the brain represents only 2% of the body weight but its primary 
metabolic fuel is glucose and in adults, the energy intake of the brain accounts for 25% 
of the total body glucose consumption (295) to maintain its function.  In recent years a 
body of evidence underpinned by studies using MRI has identified subtle structural and 
functional changes to the brain in the setting of long term diabetes referred to as 
“diabetic encephalopathy”, usually presenting itself by cognitive dysfunction and 
dementia (296; 297).  These findings are present in both in type 1 diabetes and type 2 
diabetes (296; 298), and the cognitive domains most affected include attention and 
executive function, processing speed, perception and memory (296; 297).  Elizabeth 
Seaquist (299) in an editorial titled “The final frontier: how does diabetes affect the 
brain?” suggests that persistent hyperglycaemia has negative impacts especially in 
cognitive function evidenced most recently in the ACCORD study. Here those with type 
2 diabetes and an elevated HbA1c showed the most unfavourable performance in 
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neurocognitive testing.  Koekkoek et al. in a review of the literature states that in T2DM 
patients the speed of cognitive decline is twice as fast compared with normal ageing 
subjects (298; 300-302).  In type 1 diabetes the DCCT is the only randomised trial 
where cognition was included as an outcome measure.  After 18 years of follow up, it 
reported that there was no clear deterioration of overall performance except in the 
subgroup with advanced diabetic microvascular disease and this showed an 
accelerated cognitive decline (303).  This cognitive decline in epidemiological studies 
shows itself as vascular dementia and Alzheimer’s disease and are more common in 
patients with type 2 diabetes, after adjusting for risk factors such as previous 
cardiovascular disease, history of hypertension and dyslipidaemia in aged matched 
controls (304). 
Diabetic encephalopathy appears to share many underlying pathophysiologic 
mechanisms with other forms of dementia.  Some of these mechanisms include the 
impairment of insulin signalling, the presence of low-grade inflammation and the 
amassing of AGEs and increase oxidative stress.  The presence of amyloid plaques 
and neurofibrillary tangles are present in the hippocampus of patients with diabetes 
(305) examined at autopsy, but these changes are augmented in patients with both AD 
and DM (297).  In a person with diabetes Simo et al. (306) propose that it is possible for 
diabetes to be an accelerator for the development of Alzheimer’s disease. 
Nevertheless, the co-occurrence in diabetes of cerebrovascular disease leading to 
neurodegeneration and development of progressive cognitive impairment and dementia 
make it difficult to tease out which comes first (307).  Of note, severe hypoglycaemia is 
also a well-known independent risk factor for cognitive impairment and dementia in 
elderly patients with type 2 diabetes (308; 309).   
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To date, there is little that can be done to treat patients to prevent DM related dementia.  
The most robust evidence is for aerobic exercise and dietary interventions (310; 311).  
Both of these are also helpful in diabetes, but to date, most of the treatments are 
ineffective at breaking through the blood brain barrier (297).  Imaging of the brain in our 
patients is not helpful as it does not provide enough precision and omics has not 
provided us with any clear indicators to target our patients at high risk.  However, 
cognitive dysfunction and dementia are clearly present in our clinics and can have 
grave consequences as patients are unable to self-care as shown by their poor 
glycaemic control, increased number of hypoglycaemia episodes in the home leading to 
hospital admissions.  To date, it is important that in our clinics, apart from spotting self-
care issues during the consultation, or by relatives or partners reporting odd 
behaviours, the application of self-administered questionnaires are a solution to screen 
and identify patients with early cognitive behaviours in the clinic.  Some of these include 
the Mini-Mental state examination (MMSE) (312), Test your Memory (TYM) (313), Self–
Administered Gero-cognitive examination (SAGE) and the diabetes-specific dementia 
risk score (DSRRS); a dementia predictive risk score for the prediction of 10 years 
dementia risk in T2DM patients (314). 
2.4.3.2 Liver and Pancreas 
Non-traditional complications of diabetes would not be complete without a mention of 
the growing numbers with non-alcoholic fatty liver disease (NAFLD).  Although not 
specific to diabetes, it is reported to be present in between 21% to 67% of patients with 
type 2 diabetes, depending on the methodology used to measure liver fat (315). Ectopic 
liver fat in itself is thought to trigger a cascade of local changes, which potentiate 
hepatocellular injury.  A proportion of those with NAFLD progress to non-alcoholic 
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steatohepatitis (NASH) with the ultimate endpoint of cirrhosis hepatocellular carcinoma 
and liver failure (316).  To date, weight loss is recommended as well as maintaining 
excellent glycaemic control.  Currently, there is no compelling evidence for any 
pharmacotherapy in NAFLD or NASH.  Ectopic fat in the pancreas similarly is thought to 
play a role in beta cell decline although the study and imaging of pancreatic fat is still in 
its infancy. 
Summary 
Overall diabetes, and specifically type 2 diabetes, remains a challenging chronic 
disease with gaps in knowledge across the spectrum of pathogenesis, optimal 
treatment and complications.  Anyone of these areas could be studied to test our 
hypothesis that the eHR can provide new knowledge, nevertheless specifically in this 
thesis, the areas chosen are the issues of diabetes complications and mortality in 
specific phenotypes of diabetes defined variously by ethnicity and age of onset.  One of 
the specific areas studied is the relatively new phenomenon of youth onset type 2 
diabetes, which is now discussed in Part III. 
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Part III: Young Onset Type 2 Diabetes Mellitus (YT2DM) 
The studies presented in Chapters 4 and 5 examine routinely collected eHR to provide 
information on whether age of onset impacts on diabetes outcomes and specifically 
whether young onset type 2 diabetes behaves differently to type 1 diabetes of a similar 
age or to type 2 diabetes of usual age of onset.  In this context, Part III of the literature 
review pertains to young onset type 2 diabetes (variously described also as youth onset 
type 2 diabetes, YT2DM) as relevant background to these studies.  
2.5 Introduction 
Youth is no longer just the domain of type 1 diabetes (T1DM).  Superimposed on the 
alarming upward global trajectory of diabetes prevalence are the increasing numbers 
with type 2 diabetes (T2DM) being diagnosed before the age of 40 years of age (317-
319).  The global incidence of T1DM is also increasing, and taken together, the net 
result is one, where clinicians will be faced with greater numbers of youth with diabetes 
of either type.  Indeed, recent predictions for the US population are for a greater than 
threefold increase in the numbers of youth with T1DM and a fourfold increase in the 
young-onset T2DM (YT2DM), especially amongst minority youth (320-322).  A rarity 
until recently, little was known of YT2DM, its clinical associations and outcomes.  The 
US epidemiological SEARCH for Diabetes in Youth Study and the landmark Treatment 
Options for Type 2 diabetes in Adolescents and Youth (TODAY) study have illuminated 
this area considerably, and the results are sobering, with evidence for a high 
complications risk and an aggressive clinical course (323-329).  
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2.6 Epidemiology  
There have been many reports in the literature since 1979 (330-332) of increasing 
numbers with YT2DM, and there is little doubt now that the incidence of YT2DM in 
youth has increased since then, at least in the US (320).  One of the most accurate 
perspectives come from the SEARCH for Diabetes in Youth Study (SEARCH) which is 
essentially a US based registry of youth aged less than 20 years, who have been 
diagnosed with either type 1 or type 2 diabetes.  SEARCH started in five American 
Centres in 2000 to determine the prevalence and annual incidence of youth-onset 
diabetes.  From this collection, it has been ascertained that the prevalence of YT2DM 
between 2001 and 2009 increased by 30.5% from 0.37 per 1000 (95% CI, 0.34-0.40) to 
0.48 per 1000 (95% CI, 0.45-0.51) in the United States (320).  Over the same period, 
the incidence of YT2DM increased by about 37%.  US estimates are in the order of up 
to 5000 new cases per annum. 
Globally, there appears to be considerable variation in prevalence and incidence, with 
the lowest rates in Europe.  However, the numbers are notably high in Asia and India 
(133).  For example, using the China Health and Nutrition Survey (CHNS), a large, 
household-based and longitudinal survey in China and the NHANES survey data for 
America, Yan et al (333), reported that the prevalence of diabetes was higher in 
Chinese adolescents than in US adolescents at 1.9% vs 0.9% respectively using data 
from the 1999-2006 National Health and Nutrition Examination Survey for the United 
States (334).  They also compared their adolescent data with South Korea (0.1%) and 
Taiwan (<0.0%) suggesting a higher diabetes prevalence in China.  Xu et al. from the 
Chinese Centre for Disease Control and Prevention (CDC’s) National Disease 
Surveillance Point System reported that the prevalence of type 2 diabetes was 4.5 % in 
                                                                                                             129   
 
people aged 18 to 20 years and 6.6% in those aged 30-39 years.  The assumption here 
given the populations reported is that these are patients with type 2 diabetes, however, 
diabetes type was not ascertained specifically.  
Indigenous children also seem to be disproportionately affected.  American Indians 
have the highest rated of youth onset type 2 diabetes in the US (335).  In Australia 
using two administrative datasets, the Australian Institute of Health and Welfare 
reported in 2014 the prevalence of YT2DM in Australia; estimating that there were 
881,000 Australians aged 10 years and over with type 2 diabetes with a calculated 
estimated prevalence of 4.5 % of Australians in this age group (Table 13).  Among 
those aged 10 – 39, there were nearly 31,000 people (3.5% of all those over 10 with 
type 2 diabetes and 0.3% of this age group of the Australian population) with type 2 
diabetes (336). 
In addition to the US data, the global increase in YT2DM has been observed in all age 
groups except those younger than 4 years (28).  Prevalence increases with increasing 
age with a tripling of numbers from 10-14 years to 15-18 years reported (320).  
Although YT2DM is not common under the age of 10 years, in the SEARCH Study 
involving a population of 1.2 million, 19 children with T2DM were aged between 5-9 
years old.  In the 10-14 years age group, 215 children were identified, and in the 15-19 
years age group, a total of 296 with YT2DM were identified (322).  Recently in the USA 
a young girl aged 3 was diagnosed with YT2DM (337).  At the time of diagnosis, she 
was 35 kg.  Similarly, in Australia, the youngest reported person diagnosed with YT2DM 
was a 5 year old from a remote indigenous community (338) and similarly weighing 
36kg with a height of 1.23m.   
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Table 13: Prevalence of type 2 diabetes; Table from (336) 
 
2.7 Defining Youth Onset Type 2 Diabetes  
Currently, most authors agree that YT2DM refers to the diagnosis of diabetes in 
children, adolescents and young adults.  Nevertheless, there is no universally accepted 
definition in the literature regarding the age threshold for making the diagnosis of 
YT2DM.  This is a challenge when reviewing the literature.  As mentioned previously 
type 2 diabetes is extremely rare in pre-pubertal children.  In the SEARCH study, the 
median age at diagnosis of diabetes was 13.5 years for girls and one year later for boys 
(322; 325).  The SEARCH Study used the age of 20 as the upper threshold defining 
YT2DM, but some older studies have used age of onset only up to age 15 as the cutoff.  
A number of other studies from adult groups have used as high as 45 years old as the 
threshold below which YT2DM is defined (339).  In the studies described in this thesis, 
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we have arbitrarily defined YT2DM as those diagnosed in the 15-30 age range.   It is 
likely that the age definitions selected for various studies would have a major impact on 
the prevalence, demography and outcomes and need to be taken into consideration 
when interpreting the results.  
In addition to the specific age thresholds, the distinction between type 1 diabetes and 
YT2DM has not been systematically addressed.  In the past, the age of 30 or 40 years 
at diabetes diagnosis was broadly used as the threshold to distinguish type 1 from type 
2 diabetes.  Due to the increasing overlap in the age of diabetes onset, the distinction 
between YT2DM and type 1 diabetes may be less clear and becomes an important 
issue for individual patients and also for studies of the type described in this thesis. 
Furthermore, as background rates of obesity are rising in the general population the 
utility of BMI in defining diabetes type in youth may not be as robust as previously. 
Clinically, the presence of low c-peptide in the face of hyperglycaemia and the presence 
of anti-islet cell antibodies are helpful and support an autoimmune aetiology. 
Nevertheless, islet cell antibodies are not always positive in clinically phenotypic type 1 
diabetes, and conversely, there is also a population background of positive antibody 
status in many people without diabetes.  Suggestions have been made to replace the 
categories of type 1 and type 2 diabetes with a more etiologic approach to classification 
of diabetes types in youth, based on the combination of autoimmunity and insulin 
resistance status.  This has yet to be widely adopted but would be a step forward.  It 
should be recognised that many studies have the caveat that the diagnosis of type 2 
diabetes was based on clinical phenotype alone.   
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2.8 Screening for YT2DM 
Widespread screening for diabetes is not recommended although various expert bodies 
have recommended screening in high risk individuals. The current approach outlined by 
the American Diabetes Association (ADA) consensus report “Type 2 Diabetes in 
Children and Adolescents” are summarised in the table below (173).  It is not known 
how widely this is put in to practice in the community.  Nevertheless, these targeted 
screening recommendations capture the known risks for YT2DM being overweight and 
obesity, family history, at risk ethnicity and exposure to maternal dysglycaemia in utero 
as well as clinical signs of insulin resistance.  
Table 14: Type 2 Diabetes in Children and Adolescents - Source: Classification and Diagnosis of 
Diabetes, American Diabetes Association Diabetes Care 2015 Jan; 38(Supplement 1): S8-
S16. http://dx.doi.org/10.2337/dc15-S005 (173) 
 
Criteria for Testing for type 2 diabetes or prediabetes in asymptomatic children* 
• Overweight (BMI >85th percentile for age and sex, weight for height >85th percentile, or 
weight >120% of ideal for height) 
Plus any two of the following risk factors: 
• Family history of type 2 diabetes in first- or second-degree relative 
• Race/ethnicity (Native American, African American, Latino, Asian American, Pacific 
Islander) 
• Signs of insulin resistance or conditions associated with insulin resistance (acanthosis 
nigricans, hypertension, dyslipidaemia, polycystic ovary syndrome, or small-for-
gestational-age birth weight) 
• Maternal history of diabetes or GDM during the child’s gestation 
Age of initiation: age 10 years or at onset of puberty, if puberty occurs at a younger age 
                                                                                                             133   
 
Criteria for Testing for type 2 diabetes or prediabetes in asymptomatic children* 
Frequency: every 3 years 
* Persons aged ≤18 years. 
 
 
2.9 Pathophysiology of Youth Onset Type 2 Diabetes 
The pathophysiology of type 2 diabetes in youth differs from that of type 1 diabetes and 
resembles the pathophysiology seen in older onset type 2 diabetes;  arising from the 
admixture of varying degrees of beta cell dysfunction and insulin resistance.  There are, 
however, differences that are notable for youth.  The TODAY study (Treatment Options 
for type 2 Diabetes in Adolescents and Youth) (323) was a multicentre randomised 
controlled trial examining treatment options for 600 youth with type 2 diabetes.  Patients 
were randomised to 3 treatment arms; metformin, metformin plus rosiglitazone or 
metformin plus intensive lifestyle intervention.  This study has illuminated the rapid beta 
cell decline seen in youth with type 2 diabetes as compared to adult onset disease.  
This was especially evident when compared with results from the ADOPT trial, a similar 
RCT but involving usual age of onset diabetes and the landmark UKPDS trial of newly 
diagnosis type 2 diabetes.  Beta cell failure rates for youth (the proxy being medication 
failure rates) are shown in the figure below (Figure 9) and are clearly most rapid for 
youth in the TODAY trial (340-343).  This rapid β-cell failure has also been shown to 
occur in their obese pre-diabetes phase at a rate of 15% per year with the mean 
transition time from prediabetes to overt diabetes at about 2.5 years (344-346).   
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Figure 9: Beta cell failure rates adults vs youth: From (343) 
 
In addition to the greater beta cell abnormalities identified for YT2DM, modifiable risk 
factors for insulin sensitivity such as adiposity, excess visceral fat, ectopic liver and 
intramyocellular fat, physical activity, diet, sleep and stress may all impact and have 
generally been found to be abnormal in youth with type 2 diabetes (343). 
It is notable that normal puberty is associated with a transient reduction in insulin 
sensitivity (an increase in insulin resistance); this is in the order of 50% in lean non 
obese healthy children.  There is a compensatory increase in insulin secretion, and 
hyperglycaemia may ensue arising from low beta cell reserve.  This beta cell reserve 
may be genetically, epigenetically and environmentally determined and thus puberty 
may be a high risk time for susceptible individuals.  Diabetes onset in puberty may be 
reversible in youth due to this transient nature of insulin resistance (343).  
 
                                                                                                             135   
 
3.0 Glycaemic Control and Psychosocial Aspects in YT2DM 
In concert with the above observations of faster beta cell decline is the reduced 
durability of glycaemic control in YT2DM. This was clearly seen in the TODAY study 
mentioned above (347).  For example, the monotherapy metformin glycaemic control 
failure rate was 50% by 3 years which is much more rapid than we see in adults (348). 
In many studies of older vs younger onset disease, glycaemic control appears to be 
worse in the younger age of onset groups.  In a study involving the RPA Diabetes 
Centre data from 2840 patients, Hsieh et al. (349) noted worse glycaemic control in 
youth irrespective of diabetes duration and treatment.  This in itself heralds a potentially 
increased risk for complications discussed further in this chapter.  
Apart from biological differences there are now documented challenges with respect to 
psychosocial aspects including self-management in YT2DM, contributing (at least in 
their adolescent phase) to poor glycaemic control.  In contrast to young individuals with 
type 1 diabetes, individuals with YT2DM are not acutely sick, they are generally are not 
treated in a specialised clinic dedicated to their condition, and they are in a phase of life 
characterised by a propensity to avoid parental supervision.  Browne et al. undertook an 
online study in Australia where a random sample of the National Diabetes Services 
Scheme registrants with Type 2 diabetes were surveyed, aged 18 to 39 years (350).  
The self-reported results indicated that 63% of respondents had severe diabetes-
related distress and 27% had impaired general emotional wellbeing.  Lack of 
motivation, feeling burned out and being time poor were identified as top barriers to 
self-management.  It was perceived that YT2DM had different healthcare needs than 
their older counterparts (68%) and that most T2DM information/services were aimed at 
older adults.   
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In addition to the psychological disadvantages noted above, globally those populations 
at risk for early onset type 2 diabetes may also be those who are socioeconomically 
disadvantaged.  Thus, the challenges for YT2DM are more than metabolic, and there is 
very little research around the needs and concerns of young people with YT2DM 
(351; 352). 
3.1 YT2DM: Chronic Complications and Mortality 
Given the long duration of diabetes ahead of those with early onset type 2 diabetes and 
the challenges to achieving good glycaemic control noted above, one would predict a 
high lifetime risk for diabetes complications.  An exploration of the complications in 
youth with type 2 diabetes, in comparison to type 1 diabetes and older onset type 2 
diabetes follows.  
3.1.1 Chronic Complications for YT2DM vs Type 1 Diabetes 
How do those who develop T2DM in adolescence and young adulthood fare in the long 
term and in comparison with their age counterparts with T1DM?  This question is further 
explored for traditional chronic complications of diabetes  
Other than recent reports that DKA presentations in YT2DM are declining but remain 
significant for T1DM (353), comparative data on acute complications are still limited. 
Similarly for less classical complications (e.g. hepatic steatosis, periodontal disease, 
cognition) which are therefore not reviewed here. 
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3.1.1.1 Microalbuminuria, Nephropathy and Renal Failure 
3.1.1.1.1. Microalbuminuria at Presentation 
Microalbuminuria is more prevalent at presentation in YT2DM than in T1DM.  Dart et al. 
compared complications ascertained by healthcare utilisation codes for 342 YT2DM 
(onset <18 years and a high proportion of First Nation Canadians) and 1011 T1DM 
subjects (354).  Albuminuria at diagnosis was more prevalent in the YT2DM cohort 
(27.1 vs 13.5 %), despite a similar hypertension prevalence.  In the multi-ethnic 
SEARCH study, within 12 months of diagnosis, the prevalence of an elevated 
albumin/creatinine ratio (ACR) was 16.3 vs 9.9 % in 374 YT2DM and 2885 T1DM 
subjects, respectively (355).  These findings are consistent with earlier reports in other 
ethnicities; albuminuria at diagnosis of YT2DM was present in 22 % of Pima and 14 % 
of Maori peoples (356).  The majority at diagnosis are in the microalbuminuric range. 
Although some of these data are based on single assessments for albuminuria Taken 
together, the prevalence of elevated urinary albumin is in the order of 15–27 % at 
diagnosis for YT2DM, heralding an increased cardiovascular and nephropathy risk and 
a strong argument for screening at presentation.  It is recognised that albuminuria can 
precede diabetes as a component of the metabolic syndrome and may have common 
origins.  The presence of albuminuria at this stage could represent early incipient 
diabetic nephropathy or an obesity-related glomerulonephropathy, the origins and 
prognosis of which are less clear (357). 
3.1.1.1.2 Higher Prevalence of Excess Urinary Albumin at Various Disease Time 
Points for YT2DM than T1DM 
The SEARCH study found that after a shorter duration, the prevalence of elevated ACR 
was still in excess for YT2DM than for T1DM (22.2 % and 9.2 %) and there was a 
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prevalence ratio of 2.4 for excess albuminuria noted for YT2DM (355).  In the SEARCH 
cohort, the association of type of diabetes and elevated ACR persisted after 
adjustments for glycaemia.  Further, insulin resistance parameters (BP, LDL, 
HDL, Tg and BMI) accounted for 19 % of the excess prevalence in YT2DM, with little 
additional information provided by the addition of inflammatory markers to the model 
(fully adjusted odds ratio (OR) 1.68 for YT2DM vs T1DM for elevated ACR).  A similar 
excess in the prevalence of microalbuminuria and macroalbuminuria was seen in Mani- 
toba.  The higher prevalence of microalbuminuria and nephropathy is seen in YT2DM 
despite their shorter disease duration and lower mean baseline HbA1c (354). 
These data together support the conclusion that the risk of excess albuminuria at any 
time point is increased more than twofold for YT2DM over T1DM and the differences 
highlight the impact of metabolic syndrome factors over and above glycaemia.  These 
data also imply a residual excess risk for albuminuria for YT2DM not captured by usual 
clinical measures.  There is, however, a need for a longer-term perspective on the 
implications of this.   
3.1.1.1.3 Evidence for an Increased Rate of Progression of Albuminuria and a 
Shorter Time to ESRD for YT2DM Compared with T1DM 
A current debate in nephrology is whether albuminuria in diabetes, particularly at 
microalbuminuria levels, is a risk factor (the modification of which will affect the disease 
process) or a risk marker (not necessarily causally related) for later renal disease (358).  
It is now recognised that microalbuminuria can regress and estimated glomerular 
filtration rate (eGFR) can decline with no change in albuminuria status.  Therefore, the 
presence of microalbuminuria does not exclusively confirm the presence of kidney 
disease and, indeed, the cross-sectional data described above do not consistently show 
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a difference in eGFR/creatinine clearance between the two youth-onset groups.  A key 
question is whether the cross-sectional observations of higher rates of excess 
albuminuria truly represents an accelerated time course and translate into a higher risk 
for established renal disease.  More recent data do now give us a perspective on the 
rate of progression of albuminuria and to end-stage renal disease (ESRD) in these 
groups.  In the prospectively followed YT2DM TODAY study cohort, the prevalence of 
albuminuria continued to increase, and the progression to new-onset albuminuria in this 
study was 2.6 % per year in the context of optimised clinical care offered in a trial 
setting and aggressive therapy to maintain BP and renin-angiotensin-aldosterone 
system (RAAS) blockade (326).  Dart and colleagues found that the time-based risk of 
renal failure (composite outcomes including all chronic kidney disease codes and end-
stage kidney disease) for YT2DM was increased fourfold compared with T1DM after 
controlling for age at diagnosis, HbA1c, BMI Z score and era of diagnosis.  Notably, 
estimated SES status was not an independent predictor of renal outcomes in this study 
(354).  These findings are consistent with earlier data from Japan that reported an 
increased rate ratio of 2.74 for YT2DM and the development nephropathy (359). 
3.1.1.2 Retinopathy  
The data are less clear if there is an excess risk of retinopathy in youth with T1DM vs 
YT2DM.  Retinopathy has been noted at diagnosis of YT2DM.  In a Manitoba study, the 
prevalence of retinopathy was higher in type 1 vs type 2 (13.8 vs 11.7 %) at a median 
duration of 7.9 and 7.4 years, respectively, and higher mean HbA1c for T1DM.  This 
pattern of excess retinopathy in T1DM was in contrast to the other microvascular 
complications in the same study.  Retinopathy free survival analysis for YT2DM 
appeared more reduced ∼10 years from diagnosis, but differences were not statistically 
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significant (360).  In the SEARCH pilot study, diabetic retinopathy was assessed by two 
45° field retinal photographs.  The prevalence of diabetic retinopathy was 17 % for 
T1DM and 42 % for YT2DM with a short mean follow-up (6.8 years in YT2DM) (361).  
Notably, the prevalence of retinopathy in YT2DM assessed using similar methods and 
criteria was much less in the TODAY study, than in the SEARCH study (13.7 vs 42 %). 
For the TODAY study cohort, the retinopathy assessment was performed in the final 
year of the trial.  The SEARCH cohort had a longer duration of diabetes (mean 4.9 vs 
7.2 years) and did not have the benefit of trial-based intensive glycaemic and BP 
interventions.  Whether these factors alone can account for the differences seen in 
retinopathy prevalence is not clear.  Interestingly, in the TODAY study, a higher BMI 
tertile was independently associated with a lower risk of retinopathy, and it is suggested 
that retinal insulin resistance may have a paradoxically protective effect (329).  
3.1.1.3 Neuropathy  
There are a few studies comparing neuropathy in YT2DM with T1DM.  A pilot study 
from the SEARCH investigators found that the prevalence of peripheral neuropathy 
assessed by the Michigan Neuropathy Screening Instrument was 25.7 % in YT2DM vs 
8.2 % in YT1DM.  The unadjusted OR of neuropathy was fourfold increased for YT2DM, 
the difference not only largely accounted for by age and duration but also metabolic 
syndrome variables (362).  Dart et al. also found that the raw prevalence of neuropathy 
conveyed by health codes was highest in YT2DM compared to T1DM and statistically 
significant differences were noted by approximately 5 years of known duration (360). 
Whether these are clinically significant differences remains to be seen, and there are no 
data on painful vs insensate forms of neuropathy.  These data coupled with the 
observation of an increased prevalence of neuropathy in association with the metabolic 
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syndrome (363) would predict a heightened risk for adverse neuropathy outcomes in 
YT2DM.  Definitive prospective evidence is needed, similarly for autonomic disease.  
3.1.1.4 Macrovascular Disease and Risk Factors 
Cardiovascular disease (CVD) remains the leading cause of death for both T1DM and 
YT2DM and risk factors for cardiovascular or macrovascular disease are similar for 
both: overweight, dyslipidaemia, hypertension, gender, hyperglycaemia and renal 
disease (364).  A higher prevalence of adverse CVD risk factors compared with controls 
or T1DM has been consistently seen in YT2DM (6; 365-367).  We observed significantly 
less favourable lipid and BP indices for T2DM vs T1DM at similar age, duration and 
glycaemic control, despite a higher prevalence of antihypertensive and statin treatment. 
These long-term observations are consistent with the progression of CVD risk factors in 
the face of treatment seen prospectively in the TODAY study (328).  The heightened 
renal risk of YT2DM and previously unrecognised adverse lipid subpopulations in 
YT2DM predict adverse clinical outcomes in YT2DM (368).  Prior studies of 
intermediates for cardiovascular disease, such as IMT, arterial stiffness and diastolic 
dysfunction, have shown early preclinical abnormalities not only in YT2DM but also in 
T1DM (369; 370).  The SEARCH study demonstrated significantly increased arterial 
stiffness measures in YT2DM over T1DM, largely explained by differences in abdominal 
adiposity and hypertension (371).  At the time of planning of these studies in this thesis, 
there were no data on the long term macrovascular complications in YT2DM vs T1DM 
and this area is examined in the study presented in Chapter 4. 
 
                                                                                                             142   
 
3.1.2 Time Trends and Mortality Observations for YT2DM vs Type 1 Diabetes 
T1DM diabetes remains the seventh leading cause of death in the USA and on the top 
10 causes of death globally (372; 373).  Here, we examine the more recent mortality 
trends for T1DM and, where possible, compare the mortality experience with that of 
YT2DM 
In the wake of the landmark, DCCT study and the advent of improved cardiovascular 
and glycaemic management, the outcomes for T1DM have improved significantly.  The 
Pittsburgh Epidemiology of Diabetes Complications (EDC) Study   and the community-
based Allegheny County T1DM Registry (ACR) established in the 1970s have both 
provided valuable and unequivocal evidence of a significant secular decline in mortality 
for T1DM in regional America.  Mortality rates in childhood-onset T1DM have declined 
by 34 % over 15 years, and there has been a 15-year increase in life expectancy for 
those diagnosed in 1965–1980 vs. 1950–1964 (374; 375).  The greatest reductions are 
seen in mortality from acute complications, renal disease and to a lesser extent 
cardiovascular disease. 
Recent data extend these observations internationally and are inclusive of older-onset 
age groups, with nationwide studies from Finland, Denmark, Australia and Japan all 
confirming significant mortality benefits over time, largely attributable to a reduction in 
chronic complications (376-379).  These benefits have not reached all T1DM 
populations, and poorer risks and outcomes persist for some minority groups and 
comparatively for women (375; 380).  Of concern is a report from Finland that found 
increasing mortality rates for T1DM diagnosed aged 15–29 years, driven by a higher 
proportion of alcohol-related deaths and deaths from acute diabetic complications 
(376).  Smaller studies have also reported differential excess mortality dependent on 
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age of onset, which together highlights the increased vulnerability associated with the 
development of a chronic disease in adolescence and young adulthood (381).  More 
contemporary standard mortality ratios (SMR) reported for T1DM populations still range 
from 2.8 to 5.8.  Although mortality improvements are seen in diabetes, there is still an 
excess residual risk as background mortality rates improve (376; 380; 381).  Studies 
from FinnDiane, the EDC and more recently Denmark suggest that this excess risk is 
due to renal disease, in the absence of which mortality rates in T1DM are almost at 
background.  However, there also remains a significant mortality from acute 
complications that are also potentially preventable (377; 382; 383).  
On this background are some comparative mortality data with respect to Type 1 
diabetes vs YT2DM.  The large prospective population-based study Diabetes Incidence 
Study in Sweden (DISS) (384) examined mortality in 6771 incident cases of diabetes in 
the 15–34 age group with an average follow up time of 8.5 years.  The SMR compared 
to the general population for the YT2DM group was higher than for T1DM at 2.9 and 
1.8, respectively, with a greater percentage of circulatory disease being the underlying 
cause of death in YT2DM (58 vs 28 %).  From the Southern Community Cohort Study in 
the USA, Conway et al. examined mortality in youth with diabetes over a shorter mean 
period of 3.9 years stratified by treatment rather than by diabetes type; the HR for death 
compared to the non-diabetic population were 4.3 for those using insulin alone, 4.2 
insulin plus hypoglycaemic agents and 2 for those not on insulin therapy (385).  These 
studies are of short to medium term.  At the time of planning this thesis, long term data 
on these outcomes were not yet available, but such a perspective is important given 
that patients are young at disease onset.  This is the focus of the study presented in 
Chapter 4. 
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3.1.3 Chronic Complications in YT2DM vs Older Onset Type 2 Diabetes  
There is precedence for the idea that age of onset may impact on complications risk in 
diabetes.  In type 1 diabetes a number of studies have investigated the concept of 
whether the onset of type1 diabetes in puberty or before affects complications risk with 
some studies suggesting that the early pre-pubertal years are protective (386; 387). 
Nevertheless, the situation for type 2 diabetes is less clear with a relative paucity of 
data, at least up to the point when the studies in this thesis were planned.  In the 
section following are the data on specific chronic complications in early onset disease, 
i.e. YT2DM in comparison to later onset type 2 diabetes.  
3.1.3.1 Microalbuminuria and Nephropathy  
As noted prior, there have been several studies now which report an increased 
prevalence of albuminuria in Y2TDM at presentation (356; 359; 388).  The rate of 
progression seems to be rapid in young type 2 diabetes in general.  In studies of Pima 
Indian youth with type 2 diabetes, the rate of albuminuria reported increased from a 
base of 22% to 58% with many progressing to macroalbuminuria by 10 years (389).  
Krakoff et al. examined the incidence of diabetic nephropathy in early and later onset 
diabetes and did not find a difference (390).  The study population were Pima Indian 
and included 1359 subjects aged 20-39 with type 2 diabetes, and 971 between 40-59 
followed up for over 25 years. 
Nevertheless, a less sensitive measure of nephropathy, the protein/ creatinine ratio was 
the marker used, and albuminuria was not compared in this early study.  Examining 
ESRD incidence showed an excess in youth and this was largely accounted for by a 
longer disease duration (391).  One of the best known studies is that by Hillier and 
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Pedula who interrogated the Kaiser Permanente database in the US and studied over 
7000 patients with type 2 diabetes (339).  The YT2DM group (identified as age less 
than 45 years old) did have a higher risk of microalbuminuria as compared to older 
onset disease with an HR of 1.2 (95% CI1.1-1.4).  Whether this translates into an 
excess risk of ESRF is not confirmed at this point.  
3.1.3.2 Retinopathy 
The prevalence of retinopathy at presentation of young onset type 2 diabetes appears 
to be less than for albuminuria.  In a Japanese study of YT2DM, ~ 9% had retinopathy 
noted at first visit and retinopathy prevalence was in the order of 18% after 5 years 
(392).  In a robust study using formal seven field photography to grade retinopathy, an 
Australian group found that only 4% of YT2DM had retinopathy after 2 years of diabetes 
duration (365).  Similarly, the prevalence of background retinopathy was 4% after 3 
years of diabetes in youth with type 2 diabetes in a study from New Zealand(393).  
If one examines the issue of young vs older onset diabetes by direct comparison, early 
studies from Pima again noted a lower prevalence of retinopathy in the younger onset 
cohort and a lower risk of retinopathy for young onset disease, after adjusting for 
gender, glycaemia and BP (390).  Hillier and Pedular in the study mentioned above did 
not find an excess of retinopathy for youth although follow up duration was short.  In 
contrast, Chuang et al. (394), in a study from Asia involving multiple sites did show an 
excess of risk for retinopathy in young onset diabetes and this was determined to be 
largely due to a longer duration of disease.  A study of data from our unit, after 
accounting for duration and HbA1c as an index of glycaemic exposure, found an excess 
prevalence of retinopathy in younger age of onset groups suggesting a greater 
susceptibility to retinopathy for youth (395).  
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3.1.3.3 Neuropathy 
There is a paucity of data on neuropathy specifically in YT2DM. 
In the study above by Chuang et al. (394) the prevalence of neuropathy measured by 
various modalities were similar in young vs older onset groups with a prevalence in the 
older of 26% for both.  The SEARCH Study reported that the prevalence of peripheral 
neuropathy was significantly higher in those with type 2 (25.7%) versus type 1 (8.2%) 
and Jaiswal et al. (362) concluded that the prevalence of peripheral neuropathy 
amongst the youth with type 2 was similar to the reported numbers in older adults with 
type 2 diabetes (396-398).  Nevertheless, there is a great need for long term 
comparative data for this complication.  
3.1.3.4 Macrovascular disease 
The data again are sparse in this area with many studies looking primarily at surrogate 
markers for vascular disease. The high prevalence of microalbuminuria, an independent 
risk factor for vascular disease, heralds an increased vascular risk at a young age.  In a 
cardiac echo study, septal wall thickness was increased in YT2DM (399) which would 
be in keeping with studies that showed higher BP measurements compared to non-
diabetic controls (366).  Furthermore, reduced nocturnal BP dipping, a negative 
prognostic factor has been found in studies of youth with type 2 diabetes (400).  A 
Japanese study reported increased atherosclerotic disease and measures of aortic 
pulse wave velocity in a small study of YT2DM compared to controls (401; 402).  In the 
comparison of younger (less than 45 years of age) vs older onset type 2 diabetes Hillier 
and Pedula found a 14 fold increase in the risk of myocardial infarction compared to 
non-diabetic background populations and a 4 fold increase for older onset diabetes 
against background.  For any macrovascular complication, the HR were 7.9 (95% CI 
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4.8 –13.0) for the younger onset group in contrast to the HR 3.8 (95% CI 3.4–4.2) for 
older onset groups.  Providing a different perspective, Chuang et al. found that older 
age of onset, once duration was accounted for (but not age), increases the risk of 
macrovascular disease.  Collectively, the data seem to imply that the absolute risk of 
macrovascular disease is highest for older onset groups, largely due to the effects of an 
older age per se, however, the relative impact of diabetes on macrovascular risk 
compared to those of similar age without diabetes is greater for youth.  One assumes 
this might be so because of the low background risk in younger people.  Whether these 
findings would persist for longer periods of observation and whether this would imply 
differential effects of age of onset on survival is unknown and the focus of the study 
presented in Chapter 5. 
3.1.3.5 Mortality in YT2DM vs usual onset type 2 diabetes 
Similar to the T1DM situation, advances in survival for general T2DM populations are 
also being reported (403; 404).  However, studies in Pima Indians first suggested 
adverse mortality outcomes for YT2DM (391).  The lack of long-term data in other 
populations prompted an interesting study by Rhodes et al. (405).  By using a Markov 
modelling approach to predict the life course for a hypothetical cohort with YT2DM aged 
between 15 and 24 years, they projected a 15-year loss of life expectancy, along with 
the onset of chronic complications by the 40s for those with YT2DM.  At the time of this 
study plan little was known about survival at all in YT2DM, especially given the difficulty 
in obtaining long term data.  Furthermore, being a relatively recent phenomenon, 
prospective longitudinal data on survival are lacking.  
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3.2 Knowledge Gaps Regarding Young Onset Type 2 Diabetes. 
There remain significant gaps in the understanding of youth onset type 2 diabetes as an 
entity distinct from usual onset type 2 diabetes and type 1 diabetes in youth.  The 
poorer glycaemic control, faster monotherapy failure rate and decline in beta cell 
function heralds a significant increased risk for diabetes complications.  At this point, it 
is still unclear how to preserve beta cell function in YT2DM and the most optimal 
treatment for YT2DM pharmacologically.  At the time of planning the studies, these 
newer agents, such as the SGLT2i and GLP1RA, have not been extensively trialled in 
YT2DM.  
Although early studies do suggest a high burden of complications and high prevalence 
of obesity and adverse CVD risk factors, little is known of the longer-term complications 
for YT2DM, especially in comparison to type 1 diabetes.  With this realisation, a 
question arising is how do those who develop T2DM in adolescence and young 
adulthood fare in the longer term and in comparison with their age counterparts with 
T1DM?  One might well ask, what utility would such a long term comparative 
perspective offer?  Of course, assessing the modern burden of disease and the 
characteristics of diabetes at a younger age is essential to healthcare planning and 
delivery.  However, such insights also have relevance at the clinical coalface.  The 
traditional focus of diabetes in youth is on T1DM and clinicians are well versed in these 
challenges; the differences in outcome for YT2DM are not immediately obvious.  Prior 
comparisons of outcome between T1DM and T2DM of usual onset have always been 
hampered by either the older age of the typical T2DM patient or, if age is accounted for, 
the much longer disease duration of the T1DM patient, resulting in seemingly poorer 
outcomes for T1DM.  Until recently, little has existed in the literature to refute this 
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assumption for youth, and as a consequence, historically younger patients with YT2DM 
may not have been treated optimally (402; 406).  By the comparison of YT2DM with 
T1DM of similar age, the confounders of disparate age and duration on outcomes can 
now be attenuated. 
Additionally, a unique and informative perspective as to the degree to which glycaemia 
(common to both types) and insulin resistance/metabolic syndrome features (more 
likely to be represented in YT2DM) contribute to diabetes outcomes can be examined.  
With the changing landscape of diabetes, it is timely that a comparative perspective is 
offered to help clinicians prioritise and prognosticate more appropriately. The available 
evidence suggests that YT2DM is a more aggressive phenotype, but long term data 
remain lacking and especially in regard to survival.  This aspect is examined in the 
study presented in Chapter 4.  
Furthermore, the impact of diabetes in youth compared to older onset in terms of 
mortality and CVD mortality has not been fully elucidated.  It does appear that CVD risk 
factors are present early in YT2DM but whether this translated into worse long term 
survival than older onset disease is not known.  These aspects are explored in Chapter 
5 presented in this thesis.  Furthermore, research is needed to better understand 
complications risk.  If there is truly an inherent susceptibility in youth is not known but 
would inform treatment strategies.  The prevalence of other “non-traditional” 
complications of diabetes such as NAFLD, OSA and cognitive decline is an area for 
further study.     
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CHAPTER 2: 
General Description of the Database (eHR) Used in the Studies of this 
Thesis  
The Royal Prince Alfred Hospital (RPAH) Diabetes Database is the eHR that holds 
clinical information on patients attending the diabetes service since 1986.  It is our third 
attempt at computerising diabetes data.  The first two, between 1979 and 1985 were 
abandoned because the operating systems became obsolete and the programs were 
also difficult to modify according to demands caused by rapid changes in the expanding 
knowledge of diabetes.  The software used to generate data for this thesis is Clinical 
Reporting System (CRS) (407), and the hardware is located at a secured offsite 
location within the hospital.  The CRS system allows usage, as a clinical database for 
multiple health care professionals to record simultaneously clinical findings of patients.  
However, with research always an integral part of our overall aim, we designed the 
program to conform to a relational database format.  This allows different types of 
information about a patient to be stored in and extracted when required from discrete 
but related tables (Figure 10).  This relational design minimises redundancy and 
inconsistency of the data fields in comparison with a flat file design such as an Excel 
spreadsheet, which requires a new and repeating data entry for each patient visit and is 
more cumbersome for different data to be linked for analysis.  Of note, the overall 
design of the RPAH eHR database allows it to serve the two overlapping but distinct 
purposes of clinical care and research.  
For research purpose, depending on the questions being asked, relevant information 
can then be extracted from the various tables and linked for analysis.  For example, a 
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question on the impact of ethnicity and socio-economic status on diabetes 
complications and foot ulceration can be extracted from two tables (Figure 10).  CRS 
database uses a query language to access required data from one or more tables, and 
an example of a query is shown in Figure 11 illustrating how a cohort of YT2DM with 
age of onset between 15-30 years with available data after 1st January 2015 identified, 
and their clinical status examined.  Figure 12 shows an example of the results of the 
query in a format suitable for export for analysis.   
At the outset 30 years ago we chose to retain paper copies of patient data (both 
structured and unstructured) in parallel with the electronic data.  Amongst other 
reasons, this decision was largely due to the fact that computer systems were not as 
reliable at that time, the paper format was still the standard medico-legal requirement, 
and clinicians were anxious to maintain direct interaction with patients during the 
consultation, rather than being distracted by the point of care data entry.  While more 
labour intensive the use of these paper documents in all clinical encounters helps to 
minimise omissions made during clinical assessment and to standardise information 
collected, facilitating cross-sectional and longitudinal comparisons.  With current 
technology and changes in community attitudes and regulatory requirements of utilising 
computer data, our decision may be substantially different.  Because of this historical 
decision, data collection in our system has traditionally been based on the entry of data 
during the consultation into the paper forms with subsequent transcription into the 
electronic database.  The paper documents contain fields for both structured and 
unstructured data.  Data such as family history and status of retinopathy which need to 
be collected for every patient in a standardised way is entered by a series of structured 
tick boxes by staff making the appropriate choice.  An example is shown in Figure 13. 
Information which varies more widely between individual patients and which are not 
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highly relevant to diabetes are entered in free form text as unstructured data.  An 
example is shown in Figure 14. 
Therefore, a great deal of judgement is used during the design of the database to 
determine whether the collection of particular information warrants a structured format.  
In line with this philosophy, a structured tick box would be created for a condition such 
as IHD which is always relevant to diabetes whereas conditions such as the previous 
cholecystectomy would be entered in an unstructured format.  Some items such as 
medications are collected in both structured and unstructured formats.  Of course, this 
type of decision needs to be reviewed regularly as our knowledge of diabetes evolves.  
A prominent example of the requirement for change is the emerging understanding of 
hepatic disease as an important complication of diabetes in the last 2-3 decades.   
Some of the relevant forms are shown in Appendix 5.  The use of our database has 
been approved by the Institutional Ethics Committee.  In addition, each patient at first 
presentation is asked to give consent for their data to be stored in this manner.   
Functions of the RPAH eHR: 
As mentioned above, the database underpins both clinical and research activities of the 
Diabetes Centre.  It also serves an administrative role in identification and tracking of 
every patient who attends the service and enables the preparation of detailed reports 
such as monthly statistics for hospital and government requirements.  Additionally and 
importantly, it is the backbone of our communication with referring doctors.  For a 
clinical encounter, the data in the database is automatically extracted to become the 
first (and factual) part of a hybrid letter and merged with freehand (and advisory) 
comments made by the treating clinicians.  A typical example of such a hybrid letter is 
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shown in Figure 15.  The hybrid letter is always checked by the responsible clinicians 
and health professionals during which mistakes or omissions in data entry can be 
rectified.  As any correspondence cannot be generated without prior data entry, this 
process has the added advantage of ensuring that data have been appropriately 
entered.  We also participate in national data collections such as the Australian National 
Diabetes Audit, allowing our data with that of other centres in Australia to be compared.    
Figure 10: Example of related tables and the information gathered.    
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Figure 11: An Example of a Query on the CRS Interface Screen  
 
 
Figure 12: An Example of the Result of a Query 
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Figure 14: Example of unstructured data 
 
 
 
Figure 13: Example of Structured Data 
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Data Quality 
A core issue in the use of databases is the maintenance of data quality.  This is 
especially important in a system, such as ours, with multiple internal users and 
sometimes deriving input from external sources.   
From the perspective of the internal vs external source of data, training of staff, well-
designed data collection instruments and regular auditing are safeguards to minimise 
errors.  For example, in our system when a clinical encounter is created for a patient, it 
cannot be saved without entering an appropriate date.  Some fields such as height 
Figure 15: Example of correspondence to referring physician 
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would also have built-in upper and lower limits outside which the user will be asked to 
confirm the entry.  The accuracy and completeness of data are facilitated by the use of 
the template during clinical encounters and is checked at a daily staff clinical meeting 
when patient files are reviewed.  The routine checking of data by the reading of the 
‘hybrid’ letters has been alluded to in the previous section.  The generation of various 
administrative reports and research queries also offer additional opportunities to correct 
discrepancies.  The stability and completeness of the electronic data for important 
indices of diabetes, captured at our clinical services over the years, are shown in Table 
15.  
As outlined in Table 15, data are complete for many fields however there are missing 
data noted for a number of complications. With respect to the studies that are outlined 
in this thesis, only files with complete data with respect to the complication of interest 
were analysed. This is evidenced as the denominator changes between the different 
studies. There was no attempt to use imputation methodology to account for such 
missing data in the studies described in this thesis.  
From an external perspective, it would be more difficult to implement any quality 
assurance for data derived from outside sources.  For example, we have confronted 
particular difficulties in maintaining completeness and accuracy of retinopathy data 
because, in the current health care system, this information was progressively being 
derived from external sources.  This led to the study described in Chapter 7 of this 
thesis in which the difficulties encountered in improving the quality of diabetes eye data 
capture was described.  
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Table 15: The stability and Completeness of Data Capture 
Data items 
2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 Total 
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
Number of patients 
with complications 
assessments 
783 810 785 923 953 1084 1143 1283 1219 1431 10414 
Gender                       
Female 39% 37% 40% 40% 42% 43% 42% 41% 41% 42% 40% 
Male 61% 63% 60% 60% 58% 57% 58% 59% 59% 58% 59% 
Missing 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
Ethnicity                       
Anglo 40% 41% 40% 41% 42% 42% 42% 43% 44% 44% 42% 
Other 60% 58% 60% 58% 58% 58% 57% 56% 56% 56% 56% 
Missing 1% 1% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
Type of Diabetes                       
Type 1 8% 10% 9% 10% 9% 12% 11% 12% 10% 9% 10% 
Type 2 90% 89% 90% 88% 89% 87% 88% 86% 89% 90% 88% 
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Data items 
2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 Total 
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
Other 2% 1% 1% 2% 2% 1% 1% 1% 1% 1% 1% 
Missing 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
Date of Diagnosis                       
Missing 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
Visual Acuity                       
Missing 7% 12% 12% 11% 9% 12% 7% 8% 7% 7% 9% 
Retinopathy                       
Missing/Not done 20% 24% 20% 23% 12% 15% 8% 11% 10% 10% 14% 
Weight                       
Missing 1% 0% 1% 1% 1% 11% 0% 0% 1% 1% 1% 
Height                       
Missing 1% 8% 1% 1% 0% 2% 1% 2% 4% 1% 1% 
Vibration Perception 
Threshold 
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Data items 
2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 Total 
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
Missing 3% 5% 4% 5% 4% 7% 3% 3% 4% 4% 4% 
HbA1c                       
Missing 1% 1% 0% 1% 1% 1% 1% 1% 1% 1% 1% 
Microalbuminuria                       
Missing 12% 13% 16% 14% 19% 20% 16% 13% 13% 10% 14% 
Serum Creatinine                       
Missing 4% 5% 3% 5% 5% 9% 6% 7% 7% 6% 6% 
Systolic Blood 
Pressure 
                      
Missing 3% 4% 3% 4% 3% 3% 2% 2% 2% 3% 3% 
Estimated glomerular 
filtration rate 
                      
Missing 4% 5% 3% 5% 5% 9% 6% 7% 7% 6% 6% 
Cholesterol                       
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Data items 
2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 Total 
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
Missing 8% 7% 5% 6% 7% 10% 6% 7% 5% 4% 6% 
HDL                       
Missing 19% 15% 13% 14% 14% 19% 16% 15% 14% 15% 15% 
Triglycerides                       
Missing 8% 7% 6% 6% 7% 10% 6% 7% 6% 5% 7% 
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Chapter 3:  Presented as publication 
Ethnic Specific Differences In Survival Of Patients With Type 2 
Diabetes: Analysis Of Data Collected From An Australian Multi-Ethnic 
Cohort Over A 25 Year Period (2) 
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Supplementary figures 
 
Supplementary Figure 1: Kaplan-Meier survival curves of subjects with diabetes 
duration <1 yr at presentation.  The number of individuals at each time point is shown in 
the accompanying table. 
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Supplementary Figure 2: Kaplan-Meier survival curves according to socio-economic 
status.  (Log rank test=5; p=0.08).  The number of individuals at each time point is 
shown in the accompanying table 
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Supplementary Table 1: Cox regression analysis of factors determining mortality  
 P value HR 95% CI 
Anglo-Celtic  1  
Mediterranean  0.5 1 0.8-1.1 
Arabic <0.01 0.7 0.6-0.9 
Chinese <0.001 0.7 0.6-0.9 
Indian 0.06 0.7 0.5-1.1 
Indigenous Australian <0.001 2.0 1.6-2.6 
Pacific Islander 0.6 1.1 0.8-1.7 
Albuminuria  <0.001 1.1 1.1-1.2 
BMI <0.001 1.01 1.0-1.1 
Cholesterol <0.001 1.1 1.1-1.2 
HDL <0.04 0.8 0.8-0.9 
No IHD <0.001 0.9 0.8-0.9 
Triglycerides <0.006 1.1 1.1-1.3 
Retinopathy <0.04 1.1 1.3-1.5 
Males <0.001 1.1 1.1-1.2 
Smoking <0.001 1.1 1.1-1.2 
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Supplementary Table 2: Impact of Need for Interpreter on Mortality 
Ethnicity 
n=4353 
HR of death when 
Interpreter needed  
n=1601 
HR of death when 
No Interpreter needed  
n=2752 
Mediterranean 
n=2130 
0.9 (0.8-1.1) 1.0 
Arabic 
n=471 
0.6* (0.4-0.9) 1.0 
Chinese 
n=1075 
0.9 (0.6-1.3) 1.0 
Indian 
n=463 
0.6 (0.2-1.5) 1.0 
Pacific Islander 
n=214 
0.3 (0.7-1.5) 1.0 
*p <0.05 versus Interpreter 
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Chapter 4:  Presented As Publication 
Comparison Of Complications And Mortality Of YT2DM And YT1DM : 
Long-Term Complications And Mortality In Young-Onset Diabetes 
Type 2 Diabetes Is More Hazardous And Lethal Than Type 1 Diabetes  
(1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
On publication, this paper was editorialised.  This is presented in Appendix 2  
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Chapter 5: Presented as publication 
Comparison of Complications of YT2DM vs. older onset T2DM: An 
Inverse Relationship Between Age Of Type 2 Diabetes Onset With 
Complications Risk And Mortality: The Impact Of Youth-Onset Type 2 
Diabetes (6) 
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Chapter 6: Presented as publication 
Data Collection On Retinopathy As A Public Health Tool: The Hubble 
Telescope Equivalent Of Looking Back In Time (4) 
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CHAPTER 7:  
 The Impact of Data Quality on an Electronic Database:  The Triple O 
(Outside Ophthalmologists And Optometrists) Retinopathy Study: 
Evidence of The Need For Standardised Reporting of Diabetic 
Retinopathy Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Publication arising: Letter to the Editor (Appendix 3)  
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7.1.1 Introduction  
The early detection and treatment of diabetic retinopathy remains an important 
component of modern diabetes care (240; 408).   Due to resource limitations, many 
hospital-based ophthalmology clinics can no longer perform routine eye examination 
and follow-up for the majority of patients.  As there is no nationwide retinopathy 
screening program in Australia, the task of organising regular eye examinations is left to 
the individual doctor or institution.  For more than two decades, treating 
endocrinologists at Royal Prince Alfred Hospital Diabetes Centre have documented 
retinopathy status by routinely examining fundi as part of diabetes complications 
assessment.  However, screening for diabetic retinopathy is now increasingly 
undertaken by outside ophthalmologists and optometrists (O-O&O).  The basis for this 
trend stems from the increasing availability of retinal photography in the community and 
also the emphasis of modern treatment guidelines on completing cycles of care at the 
general practice level.  This has resulted in the phenomenon of our staff having to 
frequently chase up eye results from O-O&O.  Our experience has highlighted two key 
issues in that retrieving eye information from O-O&O can be laborious, unrewarding and 
the information retrieved is often difficult to interpret and apply clinically.  The outcome 
is a communication barrier between health professionals.  This compromise care of 
people with diabetes because the setting of individualised glycaemic targets and urgent 
triaging of care cannot be made in a timely manner. 
Moreover and particularly relevant in the context of this thesis, a major consequence is 
that eye information entered into our database may be incomplete, inaccurate and 
unrepresentative.  The primary aim of this study is, therefore, to evaluate objectively the 
deficiencies of the current communication process on data quality.  The results 
pertaining to communications between health care providers are published in our 
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communication to the official Journal of the Australian and New Zealand College of 
Ophthalmologist shown in appendix 3.  Additional data on the representativeness of the 
data from O-O&O are also included in this Chapter. 
7.1.2 Methods 
  7.1.2.1 Communication Between Health Care Providers 
It is the standard practice at the Diabetes Centre for the treating physician to perform 
retinal assessment either by direct ophthalmoscopy with pupillary dilatation or by retinal 
photography.  The findings are graded clinically by the physician according to an 
adaptation of the Airlie House classification shown in Figure 16 (409).  These data are 
entered into the database, which currently contains approximately 15,000 records 
collected over two decades.  For patients who had a recent retinal assessment 
performed by an O-O&O, the majority preferred to have their report obtained from the 
relevant O-O&O, rather than having their examination repeated in-house.  The relevant 
O-O&O is, therefore, usually contacted for a report.  
For the purpose of the study examining the correspondence received from O-O&O, the 
retinopathy status described in the report is interpreted by one of the two 
endocrinologists involved in the study and coded according to the template in Figure 17.  
Where there is ambiguity in the interpretation of the report, a grade is assigned at the 
discretion of the assessor on the basis “beyond reasonable doubt”.  In addition, the 
suitability of each letter in conveying crucial clinical information pertinent to diabetic 
retinopathy care was determined by the endocrinologist.  Items examined included 
whether the report allowed coding for severity of retinopathy (if present), the presence 
or absence of macular pathology and whether the eye(s) affected could be determined 
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(Figure 18).  As the main aim of our study is to examine the utility and clarity of 
transmitted reports between professionals, rather than the prevalence or severity of 
retinopathy in our community, we did not attempt to cross check the accuracy of reports 
generated by one group of health professionals against the others, as the results would 
not impact on the central conclusion to be reached.   
Altogether, written reports from 683 consecutive patients who attended O-O&O over the 
preceding three years were available for analysis.  If more than one report from the O-
O&O was identified for an individual patient, only the first one was assessed.  To 
minimise bias, each individual O-O&O was limited to a total of 15 patients (mean 2.3 
per O-O&O) for the data analysis.  This resulted in 355 letters (266 from 
Ophthalmologists and 89 from Optometrists) being analysed.  The findings are shown in 
the published correspondence in the Result section.  
7.1.3 Representativeness of the O-O&O data 
In addition to the above, to study whether the retinopathy status of patients of the O-
O&O is representative of the total clinic population, the prevalence of their retinopathy 
was compared with 10,000 patients for whom eye data were generated in-house.  For 
this purpose, patients were divided into 5-year bands according to diabetes duration 
and the percentage with retinopathy calculated accordingly.  Results are shown in 
Figure 19. 
7.1.4 Results 
Results of the 355 O-O&O letters coded for individual items of interest are shown in the 
published correspondence.  A detailed breakdown of the results is shown in Figure 18.  
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For any duration of diabetes, more patients from ophthalmologists had retinopathy 
compared to the RPAH cohort (Figure 19).  By contrast, patients screened by 
optometrists had a very low prevalence of retinopathy in the first 15 years of diabetes 
compared to the other two groups.  However, the difference in prevalence between the 
groups diminished over time with the longer duration of diabetes. 
7.1.5 Discussion 
It is universally accepted that screening for retinopathy and delivery of appropriate 
monitoring and treatment are vital components of diabetes management.  Australia 
does not have a national screening program for diabetic retinopathy.  Although there 
are existing guidelines for the timing and frequency of eye examination for people with 
diabetes, their implementation is often variable and dependent on individual practices.  
A diabetic eye examination is increasingly performed by non-hospital based O-O&O 
and reports generated by them are often directed to a doctor who is the referrer but not 
the principal diabetes carer.  This often leaves the principal diabetes care provider in 
the situation of having to make a clinical decision in the absence of eye data.  There are 
several reasons contributing to this trend.  Firstly, due to high case volume of diabetes 
in the presence of limited resources, it is now very difficult for public hospital clinics to 
meet the demand for routine diabetes eye care even for its own patients, let alone those 
looked after at the primary care level in the community.  Secondly, patients commonly 
have more than one GP, and the O-O&O may have communicated with only the 
referring GP and not necessarily the other doctors or the diabetes specialist. Thirdly, 
optometrists do not require a referral, and a summary of relevant eye findings is not 
always communicated to the other healthcare providers.  Irrespective of the cause, the 
lack of eye information eventuates in the cumbersome process of retrieving information 
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on retinopathy status from multiple disparate sources.  It is a common experience that 
despite many attempts to contact the O-O&O, there is not always success in receiving a 
response. 
Moreover, patients are often unsure of the name of the O-O&O they had seen, or the 
nature of the eye examination performed and the findings.  This hurdle can be even 
more daunting when trying to source information from hospital eye clinics.   The lack of 
pivotal clinical eye information at an important point of diabetes care is an obstacle to 
efficient triaging of cases for urgent ophthalmic intervention and to the establishment of 
individualised glycaemic targets and monitoring schedules.  Obviously, the time taken 
by a clinician to seek out a report could be better utilised for more rewarding direct 
patient contact and clinical care. 
Our study highlights deficiencies in the methods by which findings on fundal 
examination are recorded for transmission.   Even when reports from O-O&O are 
available, a significant proportion omits vital information such as the severity of 
retinopathy, which is the predominant factor governing the need for urgent referral and 
treatment.  A related issue frequently encountered is the use of descriptive terms such 
as “severe” to describe retinopathy in correspondence.  It is often uncertain whether it 
was intended as a descriptive term rather than necessarily stipulating the grade of 
“severe retinopathy” which carries well-defined morphological features and prognostic 
implications (258).  This distinction can be critical as the latter term implies that a more 
rapid deterioration is imminent and mandates vigilant monitoring and prompt 
intervention.  Public ophthalmology clinic records display the same difficulties and have 
the additional (though not unique) problem of the extensive use of abbreviations and in-
house notations to record findings that are usually beyond the scope of a non-eye 
specialist to decipher or interpret. 
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Moreover, despite increased recognition of the medical significance of macular oedema 
and the advancing techniques for its detection (e.g. Optical Coherence Tomography) 
and treatment (e.g. anti-VEGF injections), its documentation in medical correspondence 
is ambiguous or even omitted in almost half of the reports analysed.  As we have only 
analysed the first report, if more than one is available, we cannot exclude the possibility 
that relevant information may have been included in subsequent correspondence.  
However, this simulates the usual clinical scenario where only one letter would often be 
retrieved from O-O&O.  
The information in the report from O-O&O, as well as its dissemination to appropriate 
clinicians, can have significant implications for a patient’s diabetes care.  Treating 
doctors rely on it when individualising a patient’s glycaemic target.  For example, 
detection of early retinopathy may trigger an intensification of glucose-lowering therapy 
and mandate closer follow-up of that individual patient.  Similarly, a report that clearly 
delineates the absence of significant retinopathy in an elderly patient might allow the 
treating doctor to relax the HbA1c target, lessening the risk of hypoglycaemia.  By O-
O&O facilitating smooth transmission of precise information to relevant clinicians, 
unnecessary repetition of eye examinations can be minimised, reducing the strain on 
individual patient as well as healthcare resources such as public ophthalmology clinics. 
Additionally, many patients are reluctant to have further eye appointments because of 
the costs involved.  If the treating doctor knows that a patient has vision-threatening 
retinopathy requiring intervention (rather than just monitoring) and conveys this 
message clearly, the patient may be more willing to do so.  Our clinical experience and 
the data presented clearly emphasise that these challenges, in varying combinations, 
often present significant barriers to efficient diabetes management in a health care 
system working under significant strain.  
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Apart from clinical care, our study also has important implications for data collection and 
research in a hospital clinic setting.  For example, if one relied purely on the subset of 
patients with outside ophthalmologist data to determine the prevalence of retinopathy, a 
higher prevalence of retinopathy than what is really the case would be found.  In 
contrast, if most of the data were obtained from optometrists, the opposite conclusion 
would be drawn.  These observations are obviously due to selection bias as patients 
with retinopathy or at higher risk of retinopathy are more likely to be referred to 
ophthalmologists while patients at low risk are more likely to present to an optometrist 
for a general eye assessment.  These confounding factors due to selection bias have 
the potential to distort the results of retinopathy surveys and limit their generalisability.  
This highlights the importance of well-conducted epidemiological survey such as the 
Blue Mountain Study (410).  In the absence of such, the distortion due to the 
representativeness of patient population in a survey of retinopathy prevalence must be 
taken into consideration.    
Resource constraints, an increasing burden of disease and sub-specialisation of health 
professionals, have led to fragmentation of diabetes care becoming inherent in our 
current medical system.  Although far from perfect, written correspondence remains the 
major vehicle for communication between health professionals and various studies 
have demonstrated that the content of letters is often not tailored to the needs of the 
recipients.  For example, the difficulties of inter-disciplinary communication have been 
documented in medical oncology where 80% of GPs surveyed wanted information on 
patient prognosis, but only 20% of specialists’ letters conveyed this information (411). 
To our knowledge, the current study is the first to investigate this aspect of 
communication in the diabetes setting on clinical care and data collection.  Moreover, it 
                                                                                                             212   
 
is likely that contemporary changes in technology and health care models in other fields 
of medicine have also led to the type of difficulties we have encountered.  
 
Figure 16: Modified Airlie House Retinopathy Grading Template 
Eye assessment Right Left  
Visual acuity 6/ 6/ 
Glaucoma No[  ] Yes[  ] No[  ] Yes[  ] 
Cataracts No[  ] Yes[  ] No[  ] Yes[  ] 
Cataract extraction No[  ] Yes[  ] No[  ] Yes[  ] 
Laser treatment No[  ] Yes[  ] No[  ] Yes[  ] 
Retinopathy   
Nil [   ] [   ] 
Minimal NPDR   [   ] [   ] 
Mild-Moderate NPDR [   ] [   ] 
Severe NPDR [   ] [   ] 
Proliferative * [   ] [   ] 
Advanced Proliferative* [   ] [   ] 
Not Performed [   ] [   ] 
Not Visualised [   ] [   ] 
Active Retinopathy [   ] [   ] 
Macular Oedema No[  ] Yes[  ] No[  ] Yes[  ] 
Report by outside Ophthalmologist No [   ]   Yes [   ] 
Report by outside Optometrist No [   ]   Yes [   ] 
Doctor Details 
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Figure 17:  Template for coding letters of correspondence from O-O&O 
If Retinopathy is present, does the report allow coding for severity of retinopathy? 
Can distinguish milder retinopathy from vision-threatening 
retinopathy (Severe NPDR or Proliferative Retinopathy) 
No[  ]       Yes[  ]       N/A [  ] 
Does it mention specifically  macular pathology No[  ]       Yes[  ]      N/A [  ] 
If retinopathy is present, does the report allow coding of both eyes? 
For any retinopathy No[  ]       Yes[  ]      N/A [  ] 
For severe NPDR and proliferative retinopathy (if present) No[  ]       Yes[  ]      N/A [  ] 
For macular pathology No[  ]        Yes[  ]     N/A [  ] 
 
Figure 18: Proportion of eye reports from O-O&O identifying key parameters relevant to the grading of 
diabetic retinopathy 
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Figure 19: The relationship between diabetes duration and prevalence of retinopathy according to service 
provider 
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Chapter 8 General Discussion and Conclusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Publication arising: Morbidity and Mortality in Young-Onset Type 2 Diabetes in 
Comparison to Type 1 Diabetes: Where Are We Now?  
Components of this chapter have been published (Appendix 1) 
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The overriding postulate examined in this thesis is that with appropriate planning, 
routinely collected clinical data within an electronic health record (eHR) over time can 
provide new valuable information with respect to diabetes and has utility in terms of 
health decision making.  This is relevant both in the context of public health delivery and 
for personalised and precision medicine.  This thesis illustrates this by describing a 
series of studies using a longstanding electronic health record.  We have chosen to 
examine diabetes subgroups stratified by ethnicity or by age of onset to be the focus of 
our investigations.  The choice of ethnicity and age of diabetes onset is made 
pragmatically with the knowledge that our eHR contains relevant records of both data 
fields, which can be linked to mortality and complications.  By making use of these 
resources, it has been possible to generate meaningful information, or at least 
observations, to facilitate further hypothesis testing.  
Given the two aspects for discussion are 1) the clinical results of each study and 2) the 
practical challenges and learnings arising from using the eHR for research, these are 
addressed separately.   
Prior to discussing the individual studies, it should be emphasised that the data arise 
from the clinical eHR described in detail in Chapter 2, which underscores the cohesive 
nature of studies in this thesis. Briefly, the database holds prospectively collected 
clinical data from patient encounters at the Royal Prince Alfred Diabetes Centre, 
Sydney Australia. With respect to the population studied, this single clinical facility is 
based in Metropolitan Sydney and is a secondary and tertiary referral centre for 
diabetes. The district population is predominantly white Australian but also other 
ethnicities from New Zealand, Europe and Asia are represented.  This multiethnic 
cohort also include a significant number of people who were born overseas. There are a 
small proportion of people of Australian Aboriginal and Torres Strait Islander descent. 
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Patients were seen at the Centre following referral mainly from their primary care 
general practitioner (GP).  With respect to data collection, as mentioned there is a 
standardised approach to this at the RPA Diabetes Centre which has been previously 
described (412). This approach is emphasised to clinical staff in regular team meetings 
and the centre participates in a National Benchmarking Audit, which provides feedback 
on data completeness and targets. This clinical model has been described in the 
publication by W Cheung et al (413). Briefly, this model of care consists largely of a 
one-visit review and structured complications screening and is underscored by a 
shared-care philosophy where the GP undertakes the major decisions regarding 
referral, timing and adjustment of diabetes medication. The Clinic makes 
recommendations regarding management of both metabolic abnormalities and diabetes 
complications. It is the prerogative of the GP to implement these recommendations and 
to refer the patients again when they judge necessary. 
With specific reference to the grading of retinopathy within the Diabetes Centre, this has 
been, until recently performed by a single clinician (DKY) who has published on his 
grading ability in alignment with ophthalmologists (414). Retinopathy grading is by 
modified ETDRS when performed in-house . It should be noted that in more recent 
years, retinopathy assessments are performed by various other professionals as 
outlined the study presented in Chapter 6. It should be recognised then that any 
retinopathy assessments within the database may lack the precision of earlier years.  
 
In the study presented in Chapter 3 on the influence of ethnicity on survival of patients 
with type 2 diabetes, we found that, in a population of 12,466 patients from 7 ethnic 
groups attending our Diabetes Centre, that the Anglo-Celtic population have a much 
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higher HR for death than most other ethnic groups over a very similar median follow-up 
period of about 10 years.  The Chinese had the lowest HR of 0.4 (95% CI 0.4-0.5), with 
the hazard for patients of Indian, Arabic, Mediterranean and Pacific Islander descent 
rising progressively.  This pattern is somewhat surprising as it would seem logical to 
surmise that migrants from arguably more disadvantaged countries, having grown up in 
a less public health conscious environment and less well-established health care 
system, would have worse survival outcomes.  The healthy migrant effect may be at 
play here, i.e. there may be a potential selection bias towards healthier migrants 
allowed into Australia.  This bias may be due to regulatory pressures or the self-
imposed exclusion from migration of less healthy individuals. 
In contrast and as commonly documented for similar comparisons in other countries, 
the Indigenous Australians had the highest HR for death, of 2.3 (95% CI 1.7-3.0), and 
the worse outcomes remain even after adjustment for risk factors.  Our data supports 
that much needs to be done for Australian Indigenous peoples, even in the urban 
context of metropolitan Sydney.  The existence of as yet unmeasured factors will also 
need to be addressed if we are to improve the relative health and diabetes related life 
expectancy for Aboriginal peoples.  
Interestingly, inability to speak English fluently as indicated by the need for interpreter 
services was found to be a favourable factor in determining survival, somewhat contrary 
to the common clinical impression (and frustration) that it is difficult to change the (often 
erroneous) health care beliefs of individuals in the presence of a language barrier. 
Alternatively, the lack of English fluency may signal a lack of acculturation towards a 
Westernised lifestyle which in and of itself may be beneficial.  Also counter intuitively, 
socioeconomic status as defined by postcode was found not to be an important factor in 
determining survival.  It is possible that the universal health care system of Australia, by 
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providing its citizens equal access to care has resulted in equity in survival as 
determined by the area of residency. 
The type of information provided by our study on diabetes mortality and its relationship 
with clinical factors in a multi-ethnic population living in the same city and in similar 
socio-demographic environments is relatively rare in the literature.  In support of our 
data, the comprehensive review on the Health Status of Migrants in Australia by 
Anikeeva et al. in 2010 (415), also found that many migrant groups have better health 
status according to several measures.  However, information on diabetes was quite 
scanty and mainly related to the prevalence of diabetes rather than long-term 
outcomes. 
The limitations with respect to the data collection are discussed later in this Chapter. 
Nevertheless, future studies of the potential factors over and above known risk factors 
for poor outcomes would be the next step to further identify intervention targets in our 
multiethnic population.  It is envisaged that similar analysis of detailed datasets so 
linked may help clinicians and administrators better plan strategies to overcome 
demonstrable inequity in the Australian universal healthcare setting. 
In the two subsequent studies presented in Chapter 4 and 5, on the impact of diabetes 
on mortality and complications, we focussed on comparing YT2DM with respectively (i) 
Type 1 diabetes and with (ii) Type 2 diabetes of an older age of onset.  YT2DM was 
selected for special attention given their increasing prevalence in many parts of the 
world and their well-documented difficulty in achieving good metabolic control, thus the 
higher potential for a detrimental impact of diabetes.  The standout feature of the 
YT2DM vs. Type 1 diabetes study was that, because of the availability of our eHR, we 
were able to compare patients with the same age of onset, i.e. 15-30 years of age.  This 
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revealed a higher mortality and prevalence of vascular complications for YT2DM than 
Type 1 diabetes, a finding which at the time was against what would generally be 
accepted as clinical dogma. This finding was also contrary to epidemiological 
information derived from examining the standard mortality rate (SMR) of Type 1 
diabetes and Type 2 diabetes of usual (older) age of onset.  This seeming contradiction 
may be explained by methodological differences.  In previous studies which measured 
the SMR of Type 1 and Type 2 diabetes, the death rate for each type of diabetes at any 
age group was compared with a background population without diabetes.  As type 1 
diabetes tends to present at an earlier age, part of the higher SMR associated with type 
1 diabetes can be attributed to the fact that at any age group studied, the type 1 
diabetic patients are likely to have on average a longer duration of diabetes than their 
counterparts with type 2 diabetes.  Thus, prior SMR comparisons of type 1 and type 2 
diabetes will have been affected by a lead-time bias.  By matching the age of diabetes 
onset, our study presented in Chapter 4 overcame this methodological issue.  Our 
finding of a 2 fold excess of all-cause mortality for YT2DM compared to type 1 and 
other results presented have been editorialised, have generated a high number of 
citations, and discussed in the diabetes literature and correspondence (10; 416-418). 
Some readers have been disturbed by the impression that our findings conveyed the 
notion that type 2 diabetes is a more serious disease than type 1 diabetes and 
diminished the importance of type 1 diabetes.  This is a legitimate concern, however, it 
would be important to note that this observation does not take anything away from the 
understanding of the potentially grave consequences of type 1 diabetes.  Rather, these 
data serve to highlight to clinicians, and they can no longer reassure the YT2DM that 
they have a milder form of diabetes.  Both types of diabetes are serious conditions 
especially when they affect young people in the most productive phase of their lives. 
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Both need support at an individual and community level, although the nature of help 
they need may be different.  
   The study presented in Chapter 5 compared the mortality of YT2DM with type 2 
diabetes of older age onset.  As age, itself is a significant determinant of mortality as 
well as the duration of diabetes, a simple comparison of mortality rates would again not 
distinguish the impact of diabetes versus ageing alone.  Therefore a Poisson regression 
model was used to include age of onset and age attained as factors in the calculation of 
the SMR, using the age matched Australian general population as background.  Such a 
method was previously described in the mortality study of patients attending the Steno 
Diabetes Centre (419).  The results again confirmed a higher SMR of patients with 
younger onset of type 2 diabetes, at any given age or at any given duration of diabetes.  
Thus, the impact of type 2 diabetes on mortality is higher in young onset type 2 
diabetes than for later onset disease.  In other words, the increased SMR attributable to 
type 2 diabetes became progressively less significant with a higher age of onset of 
diabetes.  Indeed diabetes which first appeared at an age older than 60 years had a 
negligible impact on SMR.  
In our opinion, these findings may have important public health implications.  Much of 
our efforts in increasing community awareness of diabetes and finding cases of 
undiagnosed diabetes tend to be directed towards the older population.  This has 
resulted in discovering many cases of diabetes in the older age groups, however, our 
studies suggest that their life expectancy is less impacted by diabetes as age becomes 
the main determinant of their overall survival.  This is not to say that older onset 
diabetes should be ignored as it should be noted that our patients were all treated 
which would have contributed to survival. However, our results argue for finding 
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practical ways of focussing our limited health resources on at-risk younger patients to 
prevent or delay the onset of diabetes.  
In this regard, it is pertinent to note that our studies have confirmed that individuals with 
YT2DM had severe cardiovascular risk factors even within a few years of onset of 
diabetes, suggesting a need to begin treating dyslipidaemia and hypertension at a very 
early age.  This is particularly problematic as the young age group is generally not 
considered as high risk and therefore not included in pivotal, event rate driven 
cardiovascular clinical trials.  The potential for pregnancy in young women further 
compounds this consideration as statins are contradicted in pregnancy.  Thus there is 
little objective evidence on how this group of young individuals with type 2 diabetes 
should be treated for their cardiovascular risk factors.  Therefore the treatment 
guidelines of various learned bodies have tended to only make general rather than 
specific recommendations of this facet of diabetes care.  Recently more specific 
guidance has been published by expert bodies with the two publications arising from 
this thesis cited in evidence of the need for early and aggressive intervention in young 
onset type 2 diabetes (420-422).  These results have also been discussed in a 
published review article presented in Appendix 1.  It is notable also that since the 
publication of these studies several larger data linkage studies have published similar 
findings for young onset type 2 diabetes confirming a higher impact of mortality than 
older onset diabetes (170) and in comparison type 1 diabetes (404).  
The future direction for studies of young onset type 2 diabetes should address the 
question as to how to prevent type 2 diabetes in young people. This may need to 
include in utero interventions such as aggressively managing weight gain and 
glycaemia thought to drive early onset type 2 diabetes risk in offspring.  Further studies 
should also address the challenge of achieving excellent glycaemic control in this 
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subgroup and interventions that halt the rapid beta cell decline.  Reasons for the greater 
prevalence of complications compared to type 1 diabetes should be further examined 
and may provide clues to effective intervention.  Overall however it should now be more 
widely recognised, particularly in primary care settings that YT2DM is not a benign 
condition and aggressive management of CVD risk factors are in order.  Currently, new 
guidelines for YT2DM have been published with this aim in mind (420; 421).  
In addition to the above studies, we have also tested a novel application for the use of 
the routinely collected eHR in the study of diabetes.  In previous sections of the thesis 
and indeed in the broader literature, the general tenor tends to be an examination of 
factors that affect diabetes complications and mortality.  In Chapter 6 we took a 
different approach by testing whether the prevalence of diabetic retinopathy, the best 
defined and the most specific of the diabetes complications in a population, can inform 
and compare the previous status of diabetes and overall treatment between 
populations.  For this purpose, we used two factors to our advantage.  First, our eHR 
includes comprehensive data on retinopathy status of individuals.  This is relatively 
uncommon in clinical databases because eye assessment is usually performed by 
another speciality, making difficult the routine collection of data.  Second, although the 
presence of retinopathy in individuals is quite unpredictable even when in possession of 
their relevant clinical data (such as HbA1c and duration of diabetes), the overall 
prevalence of retinopathy in a population is very dependent on the duration of diabetes 
and highly predictable.  By exploiting these two factors in combination, we were able to 
show that the rate of change in retinopathy prevalence in a defined population (e.g. in 
young-onset type 2 diabetes) can be compared to another population (e.g. in older 
onset type 2 diabetes) and any difference noted could be used to explore factors that 
account for the difference.  For example, in the study shown in Chapter 6 the impact of 
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age of diabetes onset on retinopathy was found to be explainable by previous 
glycaemic control measured by calculation of updated HbA1c. 
Similarly, the difference in retinopathy development in 7 ethnic groups could also be 
shown to correlate with updated HbA1c.  By contrast, other factors such as 
socioeconomic status and fluency in English communication were found to be 
unimportant contributors in this regard.  In essence, retinopathy has the advantage that 
it takes many years to develop and therefore acts as an integrator of the overall 
glycaemic control for the many years beforehand, making it superior to a single 
measurement of HbA1c which is only an integrator of glycaemic control for 3 months.   
The eHR and Research: Advantages and Challenges   
In addition to the clinical findings described above, aspects of using the eHR specifically 
for diabetes research deserve a separate mention.  The work and findings of this thesis 
are substantially based on extracting and analysing data from over 20,000 individuals 
which have been stored over a period of 2-3 decades on an ongoing basis in the RPAH 
Diabetes Centre eHR.  The systematically collected data serves as an individual 
repository of information on demographic profile, disease progression and other risk 
factors.  The results described in this thesis showed that prospective collection of such 
edata could generate information, which improves the understanding of diabetes, helps 
in the development of strategies for patient care and can shape future research.  
The advantages of research using such an eHR have been many fold.  The studies 
herein have been cost effective as the data are already collected for other reasons.  As 
the data are collected prospectively in real time, they are not affected by recall bias. 
Further, the large sample size provided by the systematic approach to clinical care in 
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our studies have allowed for increased power to provide high-resolution comparisons 
between subgroups.  Furthermore, validity is provided by coded data for many 
outcomes in our dataset.   
Our use of an eHR in studying diabetes is not unique, and there have been other 
national and international diabetes systems described in the literature that have 
advanced significantly the knowledge of the disease and its complications 
(45; 423; 424).  However for many years, these systems have worked in silos, but now 
with the digital revolution extending across all facets of government and health care, 
technology has enabled (amongst other things) the linkage of data between disparate 
systems.  The ability now to link datasets with granular clinical details to large 
administration databases with hard binary outcomes (i.e. death vs not dead or dialysis 
or no dialysis etc.) has enormous potential capacity.  The studies presented in Chapter 
3, 4 and 5 relied on the ability to link our electronic medical records with the Australia 
National Death Index (425), a national registry of mortality.  This data linkage offered a 
unique, opportunity to study the relationship between high-resolution clinical data that 
has been collected over many years with an accurate record of individual mortality in 
Australia. By high-resolution one means the detail provided by many clinical factors that 
could be utilised in adjusted modelling for the risk of death as in Chapter 3.   The high 
impact nature of our findings should encourage future studies of linkage between other 
eHR with clinical data and administrative databases such as the NDI or another 
example might be the Australia and New Zealand Dialysis and Transplant Registry 
(ANZDATA) for renal outcomes. That this methodology can provide new knowledge has 
been underscored and evidenced by the studies in Chapters 4 and 5. 
The study presented in Chapter 6 widens our concept of using a clinical eHR for the 
study of diabetes and its management.  Instead of, or in addition to, asking how 
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different types of diabetes or different approaches to diabetes management impact on 
outcomes, we can now use retinopathy development as a surrogate to compare 
retrospectively the overall glycaemic management delivered.  Thus, the routinely 
collected retinopathy data can be used creatively to compare group outcomes, infer 
past quality care and predict for health needs into the future.  
It is pertinent to bear in mind that relying on a single hospital eHR obviously has many 
inherent limitations which we must acknowledge in reaching any conclusion.  The 
suitability of an eHR for the study of the type described in Chapter 6 is naturally heavily 
dependent on the quality of eye data collected.  The study described in Chapter 7 and 
the publication arising illustrated how changes over time in technology (e.g. increased 
availability of retinal camera in the community) and model of diabetes care delivery (e.g. 
limitation in the resources of a public hospital eye clinic) can have great impact on the 
quality and suitability of eye data collected over time.  There must be continued 
vigilance over such factors if the eHR is to be used for clinical or research purposes. 
Therefore users must be ever ready to modify work practice to ensure the quality of 
data collected.  Nevertheless, overall it would be reasonable to surmise that assuming 
data quality is maintained, the electronic health record can be used to inform public 
health measures and identify gaps in patient care specifically looking at diabetic 
retinopathy data. 
The need to keep the datasets up to date, in appropriate formats and in an accurate 
manner is essential to the utility of such datasets.  For example, the standardised 
methodology applied to complications assessment and data dictionary as described in 
Chapter 2 provided robustness to the data quality and to the conclusions derived.  
However, despite standardisation, there are some limitations of the routine data 
collections that still persist in self reported data.  For example in the study presented in 
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Chapter 3 ethnicity is self-reported, and this can be ambiguous.  In our experience, a 
Vietnamese of Chinese descent may nominate either ethnicity when questioned.  
Offspring of inter-racial marriages also pose a problem in coding.  We attempted to 
minimise this type of data issue by grouping all the ambiguous cases as “others” and 
did not include them in the analysis. 
Nevertheless, this in and of itself may have introduced some bias.  Furthermore, the 
date of arrival to Australia of an individual who nominated a non-Anglo-Celtic ethnicity is 
not collected, and some patients may have been born in Australia, a trend likely to be 
increasing over the decades since the inception of the data collection.  Thus, we were 
unable to differentiate ethnicity and migrant status completely.  
Selection bias arising from data availability is minimised by a standardised approach to 
complications screening and the requirements for all data fields to be completed for 
each assessment as part of clinical care.  Missing data has been less of an issue than it 
could have been if these processes were not in place.  However, we cannot discount 
the effect of referral bias.  Our patients are not selected on a population basis but 
dependent on referrals from primary care doctors who are themselves very 
heterogeneous in their practice and philosophy of referrals.   
In addition, the problem of individuals joining the dataset at different disease time points 
has been challenging for our studies on mortality.  For example, patients are referred to 
our Centre at variable times after the diagnosis of diabetes and therefore, by definition, 
patients referred must have survived that period of time.  This creates the possibility of 
incurring “immortal time bias” in the analysis of this dataset (426).  What is meant by 
this is that, as not all patients were seen from the time of diagnosis, some people had to 
have survived (Immortal Time) to have been seen at the diabetes Centre.  Therefore, 
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the dataset may be enriched with those who are “survivors’ which potentially could have 
influenced the outcome. The impact of this on this dataset is unknown and should be 
acknowledged. It is also the policy of our clinic to not follow up every patient and only 
those perceived to have more problems are reviewed on an ongoing basis.  It is 
therefore likely that our patient base would represent a more complex group of patients.  
In Australia, patients can also switch between the public and the private systems, 
depending on their socio-economic status and philosophical belief.  These types of 
patient selection problems cannot be completely overcome at a technical level by better 
data collection and retrieval.  Furthermore, unmeasured confounding such as 
unavailability of data on diet and physical activity may impact results.  Therefore, any 
conclusions made based on a single hospital eHR must take these factors into 
consideration.   
 
The eHR and Research: Future directions   
Overall, the findings outlined confirm a positive role for the routinely collected data 
within the eHR as a meaningful research tool for diabetes care.  Following on from this 
evidence, there are enormous potential research advantages for the use of the routinely 
collected eHR on a national basis.  This is partially relevant with the advent of the ”My 
health record” in Australia being rolled out by the Australian Government with plans to 
be activated widely in 2019.  However, if this research potential is to be realised, there 
are broader real world systematic challenges to be overcome, and these are discussed 
below. 
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By necessity, the eHR needs to cover a wide territory with many health-related fields, 
and the diabetes aspect may not be comprehensive enough for targeted research 
questions such as the ones we have posed.  It is not a simple matter that can be 
addressed by adding more diabetes fields to the eHR because every major disease 
would demand the same depth of data.  This would likely make the eHR instruments 
unwieldy and in turn, lead to unenthusiastic usage and poor data quality.  One way to 
address this issue is for stakeholders of each major disease to develop a minimum 
dataset that should be collected at each patient encounter.  A tiered structure of 
required information could then be progressively activated at different levels of diabetes 
severity and care.  As a start, existing datasets such as that collected by the ANDA or 
our own can be further developed to form the basis of a national diabetes dataset.  This 
ambition of a national tiered and shared eHR for clinical use and research would need 
enthusiastic input from learned societies and governments.  Whatever the ultimate 
format adopted, in any broadly applicable eHR there will be more users under the 
umbrella of more institutions, magnifying the difficulties of maintaining data quality.   An 
important strategy to help address this issue is to develop a national data dictionary and 
data standard.  This would, in turn, allow for the comparison of national information 
about diabetes in a meaningful way. 
There are also many other issues of developing a national eHR with research capability 
in diabetes.  A transition to a specific eHR format would often necessitate the loss of 
legacy data already collected by different software systems over many years.  This 
would require specific IT solutions to integrate existing systems.  Other relevant issues 
requiring attention is in the designing of data access for research balancing the principle 
of “open data” vs privacy protection.  In addition to ethical issues, considerations of 
privacy and safety are paramount.  For example, questions to be addressed are 
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whether the use of data are appropriate, are there disclosure risks held in the data 
itself, are there settings on unauthorised use and are the statistical analysis set up for 
non-disclosure. 
In summary, the novel studies within this thesis supports the notion that the routinely 
collected data held in the eHR can provide useful evidence for health decision making 
beyond that of the randomised controlled trial.  However, the future utility of routinely 
collected clinical data depends on resolution of the privacy and access issues 
mentioned above and analytic processes adapted to account for the aforementioned 
data challenges.  It will be then that existing data sources such ours can become better 
known, accessed and the promise of future opportunities provided by such data fully 
realised.  
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Morbidity and Mortality in Young-Onset Type 2 Diabetes in 
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Appendix 2 – Commentary on publication presented in Chapter 4 
The Changing Face of Young-Onset Diabetes: Type 1 Optimism 
Mellowed by Type 2 Concerns 
                                                                                                             301   
 
  
                                                                                                             302   
 
 
 
                                                                                                             303   
 
  
                                                                                                             304   
 
Appendix 3 – Letter to the Editor 
Communication in the multidisciplinary care of diabetic eye disease 
(5) 
  
                                                                                                             305   
 
  
                                                                                                             306   
 
Appendix 4 - Statement of Contributions by co-authors 
 
Further signatures in the next page 
                                                                                                             307   
 
 
                                                                                                             308   
 
 
Further signatures in the next page 
  
                                                                                                             309   
 
 
  
                                                                                                             310   
 
  
                                                                                                             311   
 
 
  
                                                                                                             312   
 
  
                                                                                                             313   
 
 
 
 
 
 
 
  
                                                                                                             314   
 
Appendix 5 - Data Forms 
                                                                                                             315   
 
  
                                                                                                             316   
 
                                                                                                             317   
 
 
  
                                                                                                             318   
 
                                                                                                             319   
 
                                                                                                             320   
 
                                                                                                             321   
 
                                                                                                             322   
 
                                                                                                             323   
 
  
                                                                                                             324   
 
This page left intentionally blank 
 
